<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001941.pub3" GROUP_ID="NEUROMUSC" ID="179299072216451670" MERGED_FROM="" MODIFIED="2014-11-18 08:54:01 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;I don't understand the logic of this comment. DMD is not as rapidly progressive as ALS. Surely the point is that non-randomised natural history studies have shown marked improvement in survival in DMD (and similar childhood onset neuromuscular disease conditions such as SMA, congenital myopathy and congenital muscular dystrophy) and thus randomised controlled trials would not be ethical. You might wish to look at a recently pblished paper in Arch Dis Child on effects of home ventilation, sorry I don't have reference to hand but is was published in last few months. Also you should quote Michelle Eagles DMD survival papers in your discussion (both in Neuromuscular Disorders I think 2008 and 2010.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;The above above not is marked as modified by Angela A Gunn but has nothing to do with me - Angela&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;You also need to search the following trials registries&lt;/p&gt;&lt;p&gt;ClinicalTrials.gov and&lt;/p&gt;&lt;p&gt;&lt;a protected=&quot;true&quot; href=&quot;http://www.who.int/ictrp/en/&quot;&gt;http://www.who.int/ictrp/en/&lt;/a&gt; (WHO international Clinical trials Registry)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 08:53:15 +0000" NOTES_MODIFIED_BY="Ruth  Brassington" REVIEW_NO="004" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-11-18 08:54:01 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE>Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</TITLE>
<CONTACT MODIFIED="2014-11-18 08:54:01 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>djillali.annane@rpc.ap-hop-paris.fr</EMAIL_1><ADDRESS><DEPARTMENT>Critical Care Department</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris</ORGANISATION><ADDRESS_1>104. Boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 86</PHONE_1><PHONE_2>+33 1 47 10 77 87</PHONE_2><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-11-18 08:54:01 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>djillali.annane@rpc.ap-hop-paris.fr</EMAIL_1><ADDRESS><DEPARTMENT>Critical Care Department</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris</ORGANISATION><ADDRESS_1>104. Boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 86</PHONE_1><PHONE_2>+33 1 47 10 77 87</PHONE_2><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON><PERSON ID="3019E60E82E26AA200D5E26B61F83D22" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Orlikowski</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor of Medicine</POSITION><EMAIL_1>david.orlikowski@rpc.aphp.fr</EMAIL_1><ADDRESS><DEPARTMENT>Intensive Care Medicine and Home Respiratory Unit</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré (AP-HP)</ORGANISATION><ADDRESS_1>104 boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 76</PHONE_1><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON><PERSON ID="15371" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Sylvie</FIRST_NAME><LAST_NAME>Chevret</LAST_NAME><POSITION>Professor of Medicine</POSITION><EMAIL_1>sylvie.chevret@paris7.jussieu.fr</EMAIL_1><ADDRESS><DEPARTMENT>Departement de Biostatistique et Informatique Médicale</DEPARTMENT><ORGANISATION>Hôpital Saint Louis</ORGANISATION><ADDRESS_1>1 Avenue Claude Vellefaux</ADDRESS_1><CITY>75475 Paris</CITY><ZIP>Cedex 10</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 42 49 97 42</PHONE_1><PHONE_2>+33 1 42 49 97 45</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-07-01 10:30:12 +0100" MODIFIED_BY="Ruth  Brassington">
<UP_TO_DATE>
<DATE DAY="10" MONTH="6" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="6" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-07-29 10:18:00 +0100" MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-07-29 10:18:00 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="31" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>The review has been updated, with inclusion of new trials</P>
<P>We have re-arranged the outcomes to move up mortality at one year (or more) to be the primary outcome</P>
<P>We have excluded trials that have investigated short-course and short-term effects (from a few minutes to a few nights) as this review aims to summarise the effects of long-term mechanical ventilation</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-02-04 10:59:51 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>We have included two new trials</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-09-25 19:15:45 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-09-25 19:15:45 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="20" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-06-20 21:22:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>The searches for MEDLINE, EMBASE and the Cochrane Neuromuscular Disease Group Trials Register were updated in June 2006. Four new trials were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Assistance Publique Hôpitaux de Paris</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Versailles SQY</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Association Française de lutte contre la Myopathie</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-18 08:53:15 +0000" MODIFIED_BY="Ruth  Brassington">
<SUMMARY MODIFIED="2014-07-29 10:18:34 +0100" MODIFIED_BY="Ruth  Brassington">
<TITLE MODIFIED="2014-07-01 10:12:19 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;I don't understand the logic of this comment. DMD is not as rapidly progressive as ALS. Surely the point is that non-randomised natural history studies have shown marked improvement in survival in DMD (and similar childhood onset neuromuscular disease conditions such as SMA, congenital myopathy and congenital muscular dystrophy) and thus randomised controlled trials would not be ethical. You might wish to look at a recently pblished paper in Arch Dis Child on effects of home ventilation, sorry I don't have reference to hand but is was published in last few months. Also you should quote Michelle Eagles DMD survival papers in your discussion (both in Neuromuscular Disorders I think 2008 and 2010&lt;/p&gt;" NOTES_MODIFIED="2014-07-01 10:12:19 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">Mechanical ventilation at night for people with nerve, muscle or chest wall disease who have persistent breathing problems</TITLE>
<SUMMARY_BODY MODIFIED="2014-07-29 10:18:34 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the effect of mechanical ventilation at night in people with chronic (i.e. persistent) difficulties with breathing spontaneously due to diseases of the nerves, muscles or chest wall.</P>
<P>
<B>Background</B>
</P>
<P>Weakness of muscles of breathing or changes in the control of breathing are major complications of diseases of the nerves or muscles and of the chest wall. These problems can lead to hypoventilation, which is a state in which not enough air enters the lungs. People may then need devices to help them breathe (mechanical ventilation). Mechanical ventilation is widely offered to people with nerve and muscle diseases or chest wall deformities who develop chronic hypoventilation. We wanted to discover whether mechanical ventilation at night improved survival and symptoms of hypoventilation in this group and to compare different types of ventilation.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review includes 10 clinical trials involving 173 participants with persistent, stable hypoventilation. Three trials included only participants with motor neuron diseases, in three all participants had chest wall deformation only, and one trial included only participants with Duchenne muscular dystrophy. The other three trials had mixed populations.</P>
<P>The trials were comparisons of mechanical ventilation and standard care (five trials), different methods of ventilation (four trials) or both (one trial).</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>We found that mechanical ventilation at night may relieve the symptoms of chronic hypoventilation and prolong survival. However, the quality of the studies was very low. The benefit of long-term mechanical ventilation should be confirmed in further trials.</P>
<P>The evidence is current to June 2014.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-07-29 10:18:20 +0100" MODIFIED_BY="Ruth  Brassington">
<ABS_BACKGROUND MODIFIED="2014-07-01 10:10:57 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Chronic alveolar hypoventilation is a common complication of many neuromuscular and chest wall disorders. Long-term nocturnal mechanical ventilation is commonly used to treat it. This is a 2014 update of a review first published in 2000 and previously updated in 2007.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-07-29 10:18:01 +0100" MODIFIED_BY="Ruth  Brassington">
<P>To examine the effects on mortality of nocturnal mechanical ventilation in people with neuromuscular or chest wall disorders. Subsidiary endpoints were to examine the effects of respiratory assistance on improvement of chronic hypoventilation, sleep quality, hospital admissions and quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-07-01 10:11:07 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE and EMBASE on 10 June 2014. We contacted authors of identified trials and other experts in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-07-29 10:18:05 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We searched for quasi-randomised or randomised controlled trials of participants of all ages with neuromuscular or chest wall disorder-related stable chronic hypoventilation of all degrees of severity, receiving any type and any mode of long-term nocturnal mechanical ventilation. The primary outcome measure was one-year mortality and secondary outcomes were unplanned hospital admission, short-term and long-term reversal of hypoventilation-related clinical symptoms and daytime hypercapnia, improvement of lung function and sleep breathing disorders.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-02-04 11:00:27 +0000" MODIFIED_BY="[Empty name]">
<P>We used standard Cochrane methodology to select studies, extract data and assess the risk of bias in included studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-29 10:18:20 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The 10 eligible trials included a total of 173 participants. Roughly half of the trials were at low risk of selection, attrition or reporting bias, and almost all were at high risk of performance and detection bias. Four trials reported mortality data in the long term. The pooled risk ratio (RR) of dying was 0.62 (95% confidence interval (CI) 0.42 to 0.91, P value = 0.01) in favour of nocturnal mechanical ventilation compared to spontaneous breathing. There was considerable and significant heterogeneity between the trials, possibly related to differences between the study populations. Information on unplanned hospitalisation was available from two studies. The corresponding pooled RR was 0.25 (95% CI 0.08 to 0.82, P value = 0.02) in favour of nocturnal mechanical ventilation. For most of the outcome measures there was no significant long-term difference between nocturnal mechanical ventilation and no ventilation. Most of the secondary outcomes were not assessed in the eligible trials. Three out of the 10 trials, accounting for 39 participants, two with a cross-over design and one with two parallel groups, compared volume- and pressure-cycled non-invasive mechanical ventilation in the short term. From the only trial (16 participants) on parallel groups, there was no difference in mortality (one death in each arm) between volume- and pressure-cycled mechanical ventilation. Data from the two cross-over trials suggested that compared with pressure-cycled ventilation, volume-cycled ventilation was associated with less sleep time spent with an arterial oxygen saturation below 90% (mean difference (MD) 6.83 minutes, 95% CI 4.68 to 8.98, P value = 0.00001) and a lower apnoea-hypopnoea (per sleep hour) index (MD -0.65, 95% CI -0.84 to -0.46, P value = 0.00001). We found no study that compared invasive and non-invasive mechanical ventilation or intermittent positive pressure versus negative pressure ventilation.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Current evidence about the therapeutic benefit of mechanical ventilation is of very low quality, but is consistent, suggesting alleviation of the symptoms of chronic hypoventilation in the short term. In four small studies, survival was prolonged and unplanned hospitalisation was reduced, mainly in participants with motor neuron diseases. With the exception of motor neuron disease and Duchenne muscular dystrophy, for which the natural history supports the survival benefit of mechanical ventilation against no ventilation, further larger randomised trials should assess the long-term benefit of different types and modes of nocturnal mechanical ventilation on quality of life, morbidity and mortality, and its cost-benefit ratio in neuromuscular and chest wall diseases.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-07-29 11:49:36 +0100" MODIFIED_BY="Ruth  Brassington">
<BACKGROUND MODIFIED="2014-07-29 10:18:49 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Long-term mechanical ventilation in people with neuromuscular conditions was first introduced between 1950 and 1960 in France and Sweden, as a consequence of the poliomyelitis epidemics. During the following decades, the concept of home mechanical ventilation expanded rapidly. Long-term mechanical ventilation was implemented in many other countries, and for many other conditions including neuromuscular or chest wall disorders, spinal cord injury and chronic obstructive pulmonary disease. Long-term mechanical ventilation can be delivered via a canula directly inserted into the trachea (invasive mechanical ventilation) or more frequently via face or nasal mask, or via a mouth piece (non-invasive mechanical ventilation). At the beginning of the 1990s, 26,000 people in France and 11,419 in the USA were receiving long-term respiratory assistance. About 10% presented with neuromuscular or chest wall disorders (<LINK REF="REF-Chailleux-1996" TYPE="REFERENCE">Chailleux 1996</LINK>; <LINK REF="REF-Milligan-1991" TYPE="REFERENCE">Milligan 1991</LINK>). A European survey conducted between July 2001 and June 2002 reported the use of home mechanical ventilation in 483 centres in 16 countries (<LINK REF="REF-Lloyd_x002d_Owen-2005" TYPE="REFERENCE">Lloyd-Owen 2005</LINK>). That study identified 27,118 participants with long-term mechanical ventilation for lung or neuromuscular diseases related chronic respiratory failure. Then, the estimated prevalence was 6.6 per 100,000 people. In 2010, the estimated number of ventilator users in the USA was about 11,000, with three-quarters receiving invasive mechanical ventilation (<LINK REF="REF-King-2012" TYPE="REFERENCE">King 2012</LINK>). The estimated prevalence of children receiving home mechanical ventilation ranged from 4.7 to 6.4 per 100,000 children, that is a total of 3500 to 4800 children. Prolonged mechanical ventilation is a life-sustaining technology, which can be delivered at home, and is the fastest growing sector of the home health care economy (<LINK REF="REF-Arras-1995" TYPE="REFERENCE">Arras 1995</LINK>; <LINK REF="REF-Lewarski-2007" TYPE="REFERENCE">Lewarski 2007</LINK>). In 1990, the cost in the USA was estimated to be USD 789 per day for each ventilator-assisted patient by the American Association for Respiratory Care and the Gallup Organization (<LINK REF="REF-Milligan-1991" TYPE="REFERENCE">Milligan 1991</LINK>). In the USA, a Medicare rough estimate of total payment for home mechanical ventilation was over USD 35 million for 2005 (<LINK REF="REF-Lewarski-2007" TYPE="REFERENCE">Lewarski 2007</LINK>). The average payment for home mechanical ventilation by Medicare, Medicaid or other private insurances varies from USD 500 to 1000 per month (<LINK REF="REF-Lewarski-2007" TYPE="REFERENCE">Lewarski 2007</LINK>).</P>
<P>Chronic alveolar hypoventilation is a state characterised by reduced arterial oxygen tension (PaO<SUB>2</SUB>) and increased carbon dioxide tension (PaCO<SUB>2</SUB>), which the patient may correct at least partially by voluntary hyperventilation (<LINK REF="REF-Newsom_x002d_Davis-1980" TYPE="REFERENCE">Newsom-Davis 1980</LINK>). In most cases, chronic alveolar hypoventilation leads to daytime fatigue, hypersomnia and changes in psychological function. The mechanisms underlying hypercapnia in people with neuromuscular or chest wall disorders are multiple and not yet fully understood. They may involve impairment of lung mechanics or airway function and cough, ventilation-perfusion mismatch, blunted central ventilatory drive or respiratory-muscle fatigue. Abnormalities may occur while awake or during sleep (<LINK REF="REF-Loh-1979" TYPE="REFERENCE">Loh 1979</LINK>; <LINK REF="REF-Newsom_x002d_Davis-1980" TYPE="REFERENCE">Newsom-Davis 1980</LINK>; <LINK REF="REF-Rapha_x00eb_l-1987" TYPE="REFERENCE">Raphaël 1987</LINK>; <LINK REF="REF-Skatrud-1980" TYPE="REFERENCE">Skatrud 1980</LINK>; <LINK REF="REF-Smith-1987" TYPE="REFERENCE">Smith 1987</LINK>). Numerous observational and uncontrolled studies suggest that nocturnal mechanical ventilation at least partially improves lung mechanics, respiratory muscle strength, or respiratory drive, or reduces ventilation-perfusion mismatch, by day as well as night (<LINK REF="REF-Annane-1999" TYPE="REFERENCE">Annane 1999</LINK>; <LINK REF="REF-Bach-1987" TYPE="REFERENCE">Bach 1987</LINK>; <LINK REF="REF-Barb_x00e9_-1996" TYPE="REFERENCE">Barbé 1996</LINK>; <LINK REF="REF-Carroll-1988" TYPE="REFERENCE">Carroll 1988</LINK>; <LINK REF="STD-Ellis-1987" TYPE="STUDY">Ellis 1987</LINK>; <LINK REF="REF-Heckmatt-1990" TYPE="REFERENCE">Heckmatt 1990</LINK>; <LINK REF="REF-Hoeppner-1984" TYPE="REFERENCE">Hoeppner 1984</LINK>). A multicentre randomised trial of preventive nocturnal non-invasive positive pressure ventilatory assistance in 70 participants with moderate pulmonary insufficiency due to Duchenne muscular dystrophy (DMD) showed that survival was significantly worse in participants receiving preventive nocturnal ventilatory assistance, although daytime blood gases were improved (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). Several other randomised trials, performed on parallel groups (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>), or based on a cross-over design and small samples (<LINK REF="STD-Ambrosino-1997" TYPE="STUDY">Ambrosino 1997</LINK>; <LINK REF="STD-Ellis-1987" TYPE="STUDY">Ellis 1987</LINK>; <LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Restrick-1993" TYPE="STUDY">Restrick 1993</LINK>; <LINK REF="STD-Willson-2004" TYPE="STUDY">Willson 2004</LINK>), suggested that nocturnal ventilation had beneficial effects on arterial blood gases or sleep parameters. Several reviews emphasise that nocturnal ventilatory assistance may be effective in reducing daytime hypoventilation, improving quality of life and prolonging survival in people with chronic alveolar hypoventilation (<LINK REF="REF-Claman-1996" TYPE="REFERENCE">Claman 1996</LINK>; <LINK REF="REF-Orlikowski-2005" TYPE="REFERENCE">Orlikowski 2005</LINK>; <LINK REF="REF-Simonds-2003" TYPE="REFERENCE">Simonds 2003</LINK>). A recent observational study highlighted that ventilator users deserve close monitoring (<LINK REF="REF-Chatwin-2010" TYPE="REFERENCE">Chatwin 2010</LINK>). In that study, 1211 patients requiring home mechanical ventilation had access to online support. There were about 500 patient calls each month, and close to 200 home emergency visits, identifying a ventilator dysfunction in about one-quarter of cases. A Consensus Conference of the American College of Chest Physicians recommended the implementation of long-term ventilation in patients with chronic hypercapnia during the day and in those with symptomatic nocturnal hypercapnia, particularly when secondary to neuromuscular or skeletal disorders (<LINK REF="REF-Make-1998" TYPE="REFERENCE">Make 1998</LINK>). Another recent experts' consensus recommended the use of non-invasive bilevel positive ventilation either part time (&lt; 23 hours) or full time (&gt; 23 hours) in patients with end-stage chronic respiratory failure related to neuromuscular or chest wall disorders (<LINK REF="REF-Bach-2013" TYPE="REFERENCE">Bach 2013</LINK>).</P>
<P>The determination of the size of any beneficial effect of nocturnal mechanical ventilation on daytime hypoventilation in patients with neuromuscular or chest wall disorders and the comparative effects of different modes of ventilation requires a systematic review.</P>
<P>The primary aim of the present review was to search systematically for, and combine all evidence from, randomised trials relating to the effects of nocturnal mechanical ventilation in people with neuromuscular or chest wall disorders in order to supply the best evidence currently available on which to base recommendations for clinical practice and further research. This is a 2014 update of a review first published in 2000 and previously updated in 2007.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-07-29 10:18:51 +0100" MODIFIED_BY="Ruth  Brassington">
<P>To examine the effects on mortality of nocturnal mechanical ventilation in people with neuromuscular or chest wall disorders. Subsidiary endpoints were to examine the effects of respiratory assistance on improvement of chronic hypoventilation, sleep quality, hospital admissions and quality of life.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-29 11:45:25 +0100" MODIFIED_BY="Ruth  Brassington">
<SELECTION_CRITERIA MODIFIED="2014-07-29 11:44:58 +0100" MODIFIED_BY="Ruth  Brassington">
<CRIT_STUDIES MODIFIED="2014-07-29 10:18:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We examined all randomised and quasi-randomised trials with or without blinding (although blinding seems unlikely to be feasible).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-07-29 10:18:57 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Participants with stable chronic hypoventilation, defined by an arterial CO<SUB>2</SUB> tension above 6 kPa during the day, or symptoms of nocturnal hypercapnia (i.e. any of the following: diurnal hypersomnia, headaches, nightmares, enuresis), including children and adults of all degrees of severity, whether living in institutions or in the community. We excluded studies reporting results for people with chronic obstructive pulmonary disease. We included data from studies of mixed populations if separate data were available from the participants with neuromuscular or chest wall disorders, or when contact with the authors resulted in the provision of the data.</P>
<P>We considered chronic hypoventilation due to one of the following medical conditions, according to the classification of the Consensus Conference of the American College of Chest Physicians.</P>
<OL>
<LI>Central nervous system disorders: Arnold-Chiari malformation, central nervous system trauma, cerebrovascular disorders, disorders of congenital and acquired central control of breathing, myelomeningocele, spinal cord traumatic injuries.</LI>
<LI>Neuromuscular disorders: amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), polio and postpolio syndrome, congenital childhood hypotonia, Guillain-Barré syndrome, infantile botulism, muscular dystrophy, myotonic dystrophy, phrenic nerve paralysis, myasthenia gravis.</LI>
<LI>Skeletal disorders: kyphoscoliosis, thoracic wall deformities, thoracoplasty.</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-07-29 10:18:59 +0100" MODIFIED_BY="Ruth  Brassington">
<OL>
<LI>Long-term treatment (at least four weeks) with nocturnal mechanical ventilation (for at least three hours per night) versus no ventilation.</LI>
<LI>Type of ventilation: invasive techniques, i.e. tracheostomy (intermittent positive pressure) versus non-invasive techniques using negative pressure or positive pressure. For negative pressure, we considered the four available types of body enclosures, (i) body tanks (iron lungs), (ii) chest shells (rigid domes that fit over the chest and abdomen), (iii) body wraps (nylon or plastic jackets that surround the chest and abdomen), and (iv) abdominal pneumobelts (inflatable rubber bladders held firmly against the abdomen by nylon corsets). For non-invasive positive pressure ventilation, nasal, mouthpiece and oronasal interfaces were all considered.</LI>
<LI>Mode of ventilation: volume-cycled, pressure-cycled mechanical ventilation or bilevel positive airway pressure (BiPAP).</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-07-29 11:44:58 +0100" MODIFIED_BY="Ruth  Brassington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-07-29 11:44:58 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Mortality at one year.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-07-29 10:19:05 +0100" MODIFIED_BY="Ruth  Brassington">
<OL>
<LI>Admission to hospital (other than routine visits).</LI>
<LI>Reversal of daytime hypoventilation-related clinical symptoms, i.e. diurnal hypersomnia, headaches, nightmares, enuresis.</LI>
<LI>Reversal of daytime hypercapnia, i.e. arterial CO<SUB>2</SUB> tension (on room air) below 6 kPa.</LI>
<LI>Lung function measurements, i.e. forced vital capacity (FVC), respiratory muscle strength, ventilation-perfusion mismatch.</LI>
<LI>Sleep studies, i.e. apnoea-hypopnoea index or mean oxygen saturation or the time spent with an arterial oxygen saturation below 90%.</LI>
<LI>Quality of life as assessed in individual studies.</LI>
</OL>
<P>We recorded outcomes for short-term effects (within one month) and the long-term effects (12 months or more) following implementation of mechanical ventilation.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-07-29 10:19:11 +0100" MODIFIED_BY="Ruth  Brassington">
<P>On 10 June 2014, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL (2014, Issue 5 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to May 2014) and EMBASE (January 1980 to May 2014).</P>
<P>We checked all references in the identified trials and contacted authors to identify any additional published or unpublished data.</P>
<P>The detailed search strategies are in the appendices: Neuromuscular Disease Group Specialized Register <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, CENTRAL <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, MEDLINE <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and EMBASE <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-29 11:45:25 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY_SELECTION MODIFIED="2014-07-29 10:19:13 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Two review authors (DA, DO) checked titles and abstracts identified from the database searches. We obtained the full text of all studies of possible relevance for independent assessment by both review authors. The review authors decided which trials fitted the inclusion criteria, and graded their risk of bias. Any disagreement was resolved by discussion between the review authors. We contacted the authors of one large trial in DMD to clarify whether the study had included people with chronic hypoventilation (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-07-29 10:19:23 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Two review authors independently performed data extraction and the review authors systematically contacted authors of trials to provide missing data where possible. The review authors resolved any disagreement by discussion. One review author entered data into the Cochrane authoring software Review Manager (currently RevMan 5, <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), and the other review authors checked this.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-07-29 10:19:27 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We assessed the risk of bias in included studies using the Cochrane 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We documented the risk of bias using the following criteria: baseline comparison of experimental groups, explicit diagnostic criteria, completeness of follow-up. The review authors resolved any disagreement by discussion<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-07-01 10:13:56 +0100" MODIFIED_BY="Ruth  Brassington">
<P>For each outcome measure we computed 2 x 2 tables, summarising the number of people who experienced the event or outcome in each comparison group and the total number in each group. These tables were organised so that a beneficial effect of treatment was associated with a risk ratio (RR) &lt; 1. We performed intention-to-treat analyses. We performed all statistical calculations using RevMan.</P>
</EFFECT_MEASURES>
<BIAS_ASSESSMENT MODIFIED="2014-07-29 11:45:25 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We would have sought evidence of publication bias using the funnel plot method but there were too few studies included in any meta-analysis (the Cochrane Handbook recommends at least 10, "because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry" (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-07-29 10:19:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We calculated a weighted treatment effect (using a fixed-effect model) across trials. We expressed the results as risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous outcomes and mean difference (MD and 95% CI) for continuous outcomes. We considered methods based on random-effects only when there was heterogeneity.</P>
<P>We included a 'Summary of findings' table for each comparison for which data were available and included the following outcomes:</P>
<OL>
<LI>the number of deaths at one year;</LI>
<LI>admission to hospital (other than routine visits);</LI>
<LI>the number of participants with improvement in symptoms of hypoventilation in the long term</LI>
<LI>the number of participants with improvement in daytime hypercapnia in the long term</LI>
</OL>
<P>We used the GRADE criteria (study limitations (risk of bias), consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the evidence for each outcome. We followed the methods and recommendations described in Section 8.5 and Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and used GRADEpro software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-07-01 10:14:23 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We carried out a subgroup analysis to consider people with skeletal disorders and those with primary central nervous system or neuromuscular dysfunction separately.</P>
<P>When we found significant heterogeneity, we performed a graphic analysis to identify the trials and the factors responsible (related to participants' selection or treatment).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-07-29 10:19:44 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We performed sensitivity analyses on the basis of risk of bias to test for heterogeneity in the results.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-07-29 11:49:36 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY_DESCRIPTION MODIFIED="2014-07-29 10:20:58 +0100" MODIFIED_BY="Ruth  Brassington">
<SEARCH_RESULTS MODIFIED="2014-07-18 11:33:00 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Our search results are detailed in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. In June 2014, the updated search revealed 26 possible randomised trials. We excluded 16 trials (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). There remained 10 trials that fulfilled the selection criteria (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-07-29 10:20:56 +0100" MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="4">Source of information</HEADING>
<P>In addition to the extracted data from the publications, we obtained unpublished information from one trial (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial centres and design</HEADING>
<P>There was only one multicentre trial, involving 17 hospitals in France (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). This trial was performed on two parallel groups. Four were small, single-centre, cross-over studies (<LINK REF="STD-Jaye-2009" TYPE="STUDY">Jaye 2009</LINK>; <LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>; <LINK REF="STD-Willson-2004" TYPE="STUDY">Willson 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Age of participants</HEADING>
<P>Two trials enrolled both children and adults (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). All remaining trials enrolled only adults.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial populations</HEADING>
<P>Three trials included only participants with motor neuron diseases (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>). Three trials included only participants with chest wall deformities (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). One trial included only participants with DMD (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). All remaining trials enrolled a mixed population of congenital or acquired neuromuscular diseases or chest wall deformation. All trials included only participants with stable chronic hypoventilation. One trial included both asymptomatic and symptomatic chronic hypoventilation (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). Contact with the primary trial author resulted in provision of individual data showing that 19 of the 70 participants had symptoms of nocturnal hypoventilation or daytime hypercapnia, 10 in the ventilation group and nine in the control group. Individual data from these 19 participants were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control intervention</HEADING>
<P>None of the studies used sham mechanical ventilation. The control arm was spontaneous ventilation in all except four trials (<LINK REF="STD-Jaye-2009" TYPE="STUDY">Jaye 2009</LINK>; <LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>; <LINK REF="STD-Willson-2004" TYPE="STUDY">Willson 2004</LINK>). In the first trial, the authors compared two different modalities for bilevel positive airway pressure (<LINK REF="STD-Jaye-2009" TYPE="STUDY">Jaye 2009</LINK>). In two trials, the authors compared volume-targeted to pressure-targeted non-invasive ventilation (<LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). In the last trial, the authors compared two different interfaces (nasal versus full face mask) to deliver bilevel positive airway pressure (<LINK REF="STD-Willson-2004" TYPE="STUDY">Willson 2004</LINK>). In all trials, co-interventions included, as needed, oxygen, physiotherapy, antibiotics and other palliative care measures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nocturnal mechanical ventilation</HEADING>
<P>The experimental treatments were volume-cycle positive intermittent ventilation in two studies (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>), and BiPAP in all remaining trials. One study had three arms (one control arm and two experimental arms) (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>).</P>
<P>Three trials compared volume-cycle versus BiPAP (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Mortality at one year was reported in four trials (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>).</P>
<P>Unplanned hospital admission was reported in two trials (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>).</P>
<P>Four trials reported short-term effects of interventions on arterial blood gas, pulmonary function tests and sleep studies (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Jaye-2009" TYPE="STUDY">Jaye 2009</LINK>; <LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). One study reported only arterial blood gas at hospital discharge and at three months (<LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>). We extrapolated short-term (within one month) values from the three-month values. One study reported only short-term effects on sleep studies (<LINK REF="STD-Willson-2004" TYPE="STUDY">Willson 2004</LINK>).</P>
<P>Long-term effects of intervention on clinical symptoms of nocturnal hypoventilation were reported in three studies (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). Five trials reported long-term effects of interventions on arterial blood gas, pulmonary function, sleep studies and quality of life (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Qualitative analysis of included trials</HEADING>
<P>Four were cross-over trials. A first study compared one-month effects of volume-cycle nocturnal intermittent positive ventilation to pressure-cycle ventilation (i.e. BiPAP) in people with kyphoscoliosis-related chronic hypoventilation (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>). This study showed that, compared to baseline, both modes of nocturnal ventilation improved daytime arterial blood gas and nocturnal mean arterial oxygen saturation. Another study compared the short-term effects of nocturnal BiPAP delivered through a nasal mask or through a full face mask in people with symptomatic chronic hypoventilation (<LINK REF="STD-Willson-2004" TYPE="STUDY">Willson 2004</LINK>). This study showed that nocturnal BiPAP was equally effective on nocturnal mean oxygen saturation and nocturnal transcutaneous CO<SUB>2</SUB> tension. This study did not assess daytime or long-term effects of ventilation. Another study compared a one-month treatment with two different modes of pressure support ventilation with or without automatic titration in 20 participants with neuromuscular disorders (<LINK REF="STD-Jaye-2009" TYPE="STUDY">Jaye 2009</LINK>). This study showed comparable effects of the two modes of ventilation on nocturnal oxygenation and sleep quality. However, there was a small but significant increase in nocturnal arterial CO<SUB>2</SUB> tension with automatic pressure support titration compared with standard pressure support ventilation (mean transcutaneous CO<SUB>2</SUB> tension: MD -0.80, 95% CI -1.18 to -0.42). The last cross-over trial compared a one-month treatment with volume-cycled or pressure-cycled nocturnal non-invasive ventilation in 13 participants with chest wall deformities (<LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). This trial found comparable effects of the two modes of ventilation on daytime arterial gas exchange, sleep studies, pulmonary function, psychometric tests and health status.</P>
<P>Six studies were conducted on parallel groups, one in DMD (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>), three in motor neuron disease (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>), one in people with chest wall deformities (<LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>), and one in people with various congenital neuromuscular and chest wall diseases (<LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). The first was a multicentre study and included 70 participants (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). Contact with the primary author resulted in provision of individual data showing that 19 of the 70 participants had symptoms of nocturnal hypoventilation or daytime hypercapnia, 10 in the ventilation group and nine in the control group. Individual data from these 19 participants were available. This study compared nocturnal intermittent positive ventilation versus supportive treatment, i.e. physiotherapy and antibiotics if needed. This study showed that nocturnal mechanical ventilation improved daytime arterial blood gases in the short term. At one year, nocturnal mechanical ventilation improved symptoms related to nocturnal hypoventilation, tended to improve daytime arterial blood gases and had no significant effect on FVC. At one year, one of the 10 participants in the experimental group died, and none of the nine participants in the control group. This study provided no data on sleep studies. The second study included 20 participants in a single centre, 10 in the experimental group, who received nocturnal BiPAP, and 10 in the control group, who received oxygen, bronchodilators and other palliative measures (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>). This study provided no data on short-term effects of nocturnal ventilation. This study showed at one year a significant difference in survival rate in favour of nocturnal ventilation and no significant difference for daytime arterial blood gases and FVC between nocturnal ventilation and supportive treatment. This study provided no data on symptoms related to nocturnal hypoventilation or on sleep studies. The third study included 13 participants with ALS, an FVC of 70% or more, and nocturnal oxygen desaturation of at least one minute or at least two clinical signs of chronic hypoventilation (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>). Participants were followed up every three months on the basis of ALS functional rating scale-respiratory, pulmonary symptom scale, Short Form (SF) 36, pulmonary function testing and nocturnal oxymetry. In this small-sized study, nocturnal positive pressure ventilation improved the vitality subscale of SF-36, the mean pulmonary symptom score (before treatment of 72.7 versus after treatment of 80.8, P value = 0.04). The fourth study included 41 participants with ALS and either orthopnoea with maximum inspiratory pressure less than 60% of that predicted or symptomatic hypercapnia (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>). Twenty-two participants were randomly assigned to nocturnal BiPAP and 19 to standard care, that is physiotherapy and assisted cough techniques as needed. In both groups participants received pneumococcal and annual influenza vaccines and had access to palliative care, including hospice facilities, whenever needed. This study showed that nocturnal ventilation improved survival and prolonged quality of life on several scales including the generic SF-36, and two specific scales, namely the symptoms domain of the sleep apnoea quality of life index and the chronic respiratory disease questionnaire. This study provided no data on short-term effects of nocturnal ventilation, and no data on arterial blood gas, lung function or sleep studies. The fifth study involved 16 participants with chest wall deformities and compared the effects of volume-cycled (nine participants) with pressure-cycled non-invasive ventilation (seven participants) on the time to achieve normalisation of daytime arterial CO<SUB>2</SUB> tension (<LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>). Four participants were lost to follow-up in the volume-cycled non-invasive ventilation arm and one was lost to follow-up in the pressure-cycled non-invasive ventilation arm. Per protocol analysis showed a significant drop of PaCO<SUB>2</SUB> at hospital discharge in the pressure-cycled non-invasive ventilation arm (5.3 ± 1.2 versus 7.6 ± 1.2 kPa) but not in the volume-cycled non-invasive ventilation arm (6.4 ± 0.9 versus 7.2 ± 0.7 kPa). At three months, PaCO<SUB>2</SUB> dropped significantly from baseline in both arms, 5.6 ± 1.3 versus 7.6± 1.2 kPa and 5.3 ± 1.3 versus 7.2 ± 0.7 kPa. This study provided no information on mortality, unplanned hospitalisation, clinical symptoms, pulmonary function tests or sleep studies.</P>
<P>In the last study, 26 participants with chronic nocturnal hypoventilation and normal daytime CO<SUB>2</SUB> tension were randomly assigned to nocturnal bilevel airway positive pressure (n = 12) or to standard care (n = 14), that is physiotherapy and antibiotics if needed (<LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). Participants were followed up for 24 months. This study showed that nocturnal BiPAP reduced time spent with nocturnal hypercapnia and improved mean nocturnal oxygen saturation. There was no significant difference between groups in daytime arterial CO<SUB>2</SUB> tension variations over time. There were more participants in the control group that met the criteria for mandatory ventilation than in the experimental group. Finally, compared with controls, a gain in SF-36 general health score was seen in the experimental group by 18 months. In addition, in this study, participants with daytime hypercapnia at the time of randomisation were not included but were similarly followed up. These participants had significant reductions in daytime mean arterial CO<SUB>2</SUB> tension with no significant changes in lung function.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-07-29 10:20:58 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Five of the 10 excluded studies were non-randomised studies (<LINK REF="STD-Aboussouan-1997" TYPE="STUDY">Aboussouan 1997</LINK>; <LINK REF="STD-Bach-1998" TYPE="STUDY">Bach 1998</LINK>; <LINK REF="STD-Fanfulla-2005" TYPE="STUDY">Fanfulla 2005</LINK>; <LINK REF="STD-Masa-1997" TYPE="STUDY">Masa 1997</LINK>; <LINK REF="STD-Padman-1998" TYPE="STUDY">Padman 1998</LINK>). One study included participants in an unstable condition (i.e. acute respiratory failure) (<LINK REF="STD-Celikel-1998" TYPE="STUDY">Celikel 1998</LINK>). Four studies assessed the effects of a very short course of mechanical ventilation during the daytime and provided no data on nocturnal mechanical ventilation (<LINK REF="STD-Ambrosino-1997" TYPE="STUDY">Ambrosino 1997</LINK>; <LINK REF="STD-Elliott-1994" TYPE="STUDY">Elliott 1994</LINK>; <LINK REF="STD-Hart-2002" TYPE="STUDY">Hart 2002</LINK>; <LINK REF="STD-Meecham-Jones-1993" TYPE="STUDY">Meecham Jones 1993</LINK>). Five trials compared a short course (one to three nights) of different modes of non-invasive ventilation with a control night on spontaneous breathing (<LINK REF="STD-Ellis-1987" TYPE="STUDY">Ellis 1987</LINK>; <LINK REF="STD-Restrick-1993" TYPE="STUDY">Restrick 1993</LINK>), or without such a control night (<LINK REF="STD-Crescimanno-2011" TYPE="STUDY">Crescimanno 2011</LINK>; <LINK REF="STD-Highcock-2002" TYPE="STUDY">Highcock 2002</LINK>; <LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>). Another trial compared initiation of non-invasive nocturnal ventilation at home versus at hospital in people with neuromuscular or chest wall diseases and chronic hypoventilation (<LINK REF="STD-Chatwin-2008" TYPE="STUDY">Chatwin 2008</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-29 10:21:23 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The detailed risk of bias in the included trials is reported in the 'Risk of bias' tables (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.<BR/>
</P>
<ALLOCATION MODIFIED="2014-07-29 10:21:05 +0100" MODIFIED_BY="Ruth  Brassington">
<P>In four trials, we considered allocation concealment adequate (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Jaye-2009" TYPE="STUDY">Jaye 2009</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>). In one trial, participants were alternately assigned to nocturnal BiPAP or supportive treatment and we considered the randomisation concealment inadequate (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>). In the remaining trials allocation concealment was unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-07-29 10:21:07 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Observer blinding was intended in only one study (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>). In one trial, participants were blinded to the intervention they received, i.e. volume-cycled or pressure-cycled non-invasive ventilation (<LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). In the remaining trials, participant blinding was felt not to be feasible and none of trials used sham mechanical ventilation.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-07-29 10:21:18 +0100" MODIFIED_BY="Ruth  Brassington">
<P>In all trials the baseline clinical features were similar in each group. In one trial, two of 12 participants in the experimental group and two of 14 in the control group were lost to follow-up (<LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). In a second trial, one participant in the experimental arm was lost to follow-up (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>). In a third trial that compared volume-cycled non-invasive ventilation to pressure-cycled non-invasive ventilation, five participants were lost to follow-up, four in the volume-cycled non-invasive ventilation arm and one in the pressure-cycled non-invasive ventilation arm (<LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>). Two participants did not tolerate volume-cycled non-invasive ventilation and were switched to pressure-cycled non-invasive ventilation after two days following randomisation. One participant in each arm died and one participant in the volume-cycled non-invasive ventilation arm did not want to return for measurements in hospital at three months. In all other trials, follow-up was complete and adherence to treatment was good.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-07-29 10:21:23 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We assessed the trials as at low risk of bias from selective reporting with the exception of three trials. <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> was at high risk of bias because the investigators reported only preliminary results. Two trials did not provide information allowing us to assess reporting bias and we considered them at unclear risk (<LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Explicit definition</HEADING>
<P>All trials used explicit and internationally accepted diagnostic criteria for DMD, other congenital neuromuscular disease, motor neuron diseases and chest wall disease. All trials used explicit criteria to define chronic nocturnal hypoventilation.</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-07-29 11:49:36 +0100" MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="3">Nocturnal ventilation versus no ventilation</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure: mortality at one year</HEADING>
<P>Four studies reported the one-year mortality rate (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). In <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>, one out of 10 participants died in the treatment group compared to none of the control group. In <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>, three out of 10 participants died in the treatment group compared to nine out of 10 in the control group. In <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>, 13 out of 22 participants died in the treatment group compared to 16 out of 19 in the control group. In <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>, after 24 months of follow-up there were no reported deaths. In the pooled analysis, 17 deaths occurred among 51 participants in the nocturnal ventilation group versus 25 deaths among 48 participants in the control group, resulting in a risk ratio (RR) of dying of 0.62 (95% confidence interval (CI) 0.42 to 0.91, P value = 0.01) in favour of the experimental arm (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was some heterogeneity across the studies (I<SUP>2 </SUP>= 30%) that may be explained by differences in the rate of disease progression, which was faster for participants with hypercapnic amyotrophic lateral sclerosis (ALS) (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>) than in participants with Duchenne muscular dystrophy (DMD) (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>) or other slowly progressive diseases (<LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). It was also the case that observed mortality rates were higher in the two studies conducted in ALS participants than in the two other trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Admission to hospital (other than routine visits)</HEADING>
<P>Two studies, accounting for 38 participants, reported this outcome in the long term (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). Two of 19 participants in the nocturnal ventilation group had unplanned hospital admission versus 10 of 19 in the control group, resulting in a RR of 0.25 (95% CI 0.08 to 0.82, P value = 0.02) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was no heterogeneity across the studies (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reversal of daytime hypoventilation-related clinical symptoms</HEADING>
<P>None of the trials provided data for this outcome in the short term.</P>
<P>Three trials, accounting for 51 participants, reported this outcome in the long term (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). In <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>, four out of 10 participants in the treatment group did not have improved clinical symptoms at one year compared to seven out of nine participants in the control group. The estimated risk of "no improvement of hypoventilation related clinical symptoms" in this study was not significant (RR 0.51, 95% CI 0.22 to 1.19). <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> reported failure to improve hypoventilation-related clinical symptoms at three months in three out of six participants in the experimental arm and all seven controls. In this study, the pulmonary symptom score improved from baseline in the experimental arm (80.8 versus 72.7, P value = 0.04) (RR 0.53, 95% CI 0.25 to 1.14). In <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>, at 24 months there was an absence of improvement in clinical symptoms in none of the nine treated participants and nine of 10 participants in the control arm (RR 0.06, 95% CI 0.00 to 0.87).</P>
<P>Combining these three trials, seven of 25 participants in the nocturnal ventilation group did not experience improvement in hypoventilation-related symptoms versus 23 of 26 participants in the control group. The RR was 0.43 (95% CI 0.18 to 1.03, P value = 0.06) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reversal of daytime hypercapnia</HEADING>
<P>One study provided data on this outcome in the short term (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). Three out of seven participants in the treatment group did not have improved daytime hypercapnia compared to nine out of nine in the control group (RR 0.33, 95% CI 0.14 to 0.80, P value = 0.01) (see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Three studies, accounting for 58 participants, reported the proportion of participants who did not experience an improvement in daytime hypercapnia (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). There were 14 of 29 such participants in the experimental arm versus 24 of 29 in the control arm. The pooled RR was 0.59 (95% CI 0.41 to 0.86, P value = 0.006) in favour of nocturnal ventilation (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). There was significant heterogeneity across the studies (I² = 94%). This heterogeneity may be explained by differences in the speed of disease progression: slow in two trials (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>) versus rapid in one trial (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>).</P>
<P>However, at one year, from 60 participants in these three studies (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>; <LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>), the mean difference (MD) of the arterial CO<SUB>2</SUB> tension was -0.26 kPa (95% CI -0.61 to 0.09 kPa), which means that it was lower in the treated group but not significantly (see <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lung function measurements</HEADING>
<P>None of the studies assessed this outcome in the short term. Two studies reported one-year values for forced vital capacity (FVC) (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>), for 13 participants in the treated group and 15 participants in the control group. The MD of the FVC in these two trials was 159 mL (95% CI -84 to 401 mL), non-significantly more in the treated than the control group (see <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). At 24 months of follow-up, one study showed no significant difference in changes in sniff nasal inspiratory pressure (SNIP), which was 1.62 (6.1) in the control group versus -4.1 (14.1) cmH<SUB>2</SUB>O in the treated group (see <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), or changes in cough peak flow, which was 43.3 (52.2) L/min in the control group versus -0.9 (34.4) L/min in the treated group (<LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). The other subcategory outcome, namely ventilation-perfusion mismatch, was not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sleep studies</HEADING>
<P>One study assessed this outcome in the long term, at 24 months, in 14 treated and 12 control participants (<LINK REF="STD-Ward-2005" TYPE="STUDY">Ward 2005</LINK>). This study showed that mean nocturnal oxygen saturation increased from 93.5 (1.9)% to 96.6 (1.2)% in the treated group versus 95.2 (2.1)% to 93.6 (1.7)% in the control group, and the MD of nocturnal oxygen saturation in this study was 3.00% (95% CI 1.85% to 4.15%) (see <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). There was no significant difference between the two groups for the minimum overnight oxygen saturation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>In a small-sized study, nocturnal positive pressure ventilation improved the vitality subscale of SF-36, the mean pulmonary symptom score (before treatment of 72.7 versus after treatment of 80.8, P value = 0.04) (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>). In a second trial of 41 participants with ALS, nocturnal ventilation improved survival and prolonged quality of life on several scales including the generic SF-36, and two specific scales, namely the symptoms domain of the sleep apnoea quality of life index and the chronic respiratory disease questionnaire (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Invasive ventilation versus non-invasive ventilation</HEADING>
<P>We found no study that compared invasive to non-invasive ventilation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intermittent positive pressure ventilation versus negative pressure ventilation</HEADING>
<P>We found no study that compared invasive ventilation versus non-invasive ventilation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Volume-cycled versus pressure-cycled ventilation</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: mortality at one year</HEADING>
<P>We found only one study of volume-cycled versus pressure-cycled ventilation, which provided mortality data after three months following randomisation (<LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>). In this small (16 participants), single-centre trial only two deaths were reported, one in each group (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Admission to hospital (other than routine visits)</HEADING>
<P>This outcome was not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reversal of daytime hypoventilation-related clinical symptoms</HEADING>
<P>This outcome was not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reversal of daytime hypercapnia</HEADING>
<P>One study reported in the short term, i.e. at one month, that six of 10 participants in the pressure-cycled non-invasive ventilation group and six of 10 participants in the volume-cycled non-invasive ventilation group did not improve daytime hypercapnia (RR 1.00, 95% CI 0.49 to 2.05, P value = 1.00) (see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>).</P>
<P>Three studies, accounting for 39 participants, reported daytime arterial oxygen tension after one month of intervention (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Struik-2011" TYPE="STUDY">Struik 2011</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). The MD in arterial CO<SUB>2</SUB> tension was 0.45 kPa (95% CI -0.21 to 1.10, P value = 0.18) in favour of volume-cycled ventilation with significant heterogeneity across the studies (I<SUP>2 </SUP>= 93%) (see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lung function measurements</HEADING>
<P>This outcome was not available in the long term.</P>
<P>One trial, which was a cross-over study with 13 participants, reported in the short term (at one month) (<LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). The trial found no significant difference between pressure- and volume-cycled non-invasive ventilation for FVC with a mean difference of 40.00% (95% CI -7.04 to 87.04, P value = 0.10) (see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), maximal inspiratory pressure (mean difference -2.20 cmH<SUB>2</SUB>O (95% CI -4.92 to 0.52, P value = 0.11) and sniff nasal inspiratory pressure (SNIP) (mean difference -1.70 cm H<SUB>2</SUB>O (95% CI -4.70 to 1.30, P value = 0.06) (see <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sleep studies</HEADING>
<P>One study, which was a cross-over study with 13 participants, provided treatment effects on mean nocturnal SaO<SUB>2</SUB> in the short term (<LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). There was no difference between pressure- and volume-cycled non-invasive ventilation, with a mean difference of 1.20 (95% CI -0.70 to 3.10, P value = 0.22) (see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
<P>Two studies, accounting for 23 participants, reported treatment effects on the time spent with nocturnal SaO<SUB>2</SUB> below 90%, in the short term (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). The MD was 6.83 minutes (95% CI 4.68 to 8.98 minutes, P value &lt; 0.00001) in favour of the volume-cycled non-invasive ventilation. However, there was strong heterogeneity across the studies (I<SUP>2 </SUP>= 99%) (see <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
<P>Two studies, accounting for 23 participants, reported the apnea-hypopnoea index per hour of sleep in the short term (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). The MD was -0.65 (95% CI -0.84 to -0.46, P value &lt; 0.00001) in favour of the volume-cycled non-invasive ventilation. There was no heterogeneity across the studies (I<SUP>2 </SUP>= 0%) (see <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>In one study, which was a cross-over study with 13 participants, there were no differences between volume-cycled and pressure-cycled ventilated patients in any of the components of the SF-36 scale.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-07-29 10:22:22 +0100" MODIFIED_BY="Ruth  Brassington">
<P>A huge number of reports of uncontrolled trials claim beneficial effects of nocturnal mechanical ventilation for chronic hypoventilation related to neuromuscular or chest wall disorders (<LINK REF="REF-Claman-1996" TYPE="REFERENCE">Claman 1996</LINK>; <LINK REF="REF-Make-1998" TYPE="REFERENCE">Make 1998</LINK>). By contrast, we found a limited number of randomised studies. Only one study was a multicentre trial (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>). This trial enrolled 70 participants with Duchenne muscular dystrophy (DMD) during a five-year period. The study was designed to assess whether implementation of nocturnal mechanical ventilation early in the course of the disease prevents respiratory failure and prolongs survival. At randomisation, only 19 out of the 70 participants met the criteria currently proposed for long-term mechanical ventilation, namely symptoms of nocturnal hypoventilation or daytime hypercapnia (<LINK REF="REF-Make-1998" TYPE="REFERENCE">Make 1998</LINK>). Three studies were based on a cross-over design and the population size was very small (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>; <LINK REF="STD-Willson-2004" TYPE="STUDY">Willson 2004</LINK>). The allocation concealment was adequate in only four of the 10 studies. Thus, the overall methodological quality of these trials was weak.</P>
<P>This systematic review suggests that, in people with chronic hypoventilation related to neuromuscular or chest wall diseases, nocturnal mechanical ventilation improves hypoventilation-related clinical symptoms, nocturnal mean oxygen saturation, daytime hypercapnia and quality of life, and reduces the risk of unplanned hospitalisation and mortality, compared to no ventilation. However, taking into account the small number of participants, the lack of observer blinding and the presence of significant heterogeneity across the studies, any conclusions must be drawn very cautiously. Data on the effects of nocturnal mechanical ventilation on lung function measurements and on sleep studies are too scarce to allow any definite conclusion. A large, Italian, single-centre, retrospective cohort study of patients with DMD showed a progressive increase in crude survival (<LINK REF="REF-Passamano-2012" TYPE="REFERENCE">Passamano 2012</LINK>). The survival rate in DMD at the age of 20 years was 23.3% in the 1960s, 54% in patients born in the 1970s and 59.8% in those born in the 1980s (P value &lt; 0.001). In this observational study, the crude mean age for respiratory-related death was 17.7 years in patients who did not receive mechanical ventilation and 27.9 years in mechanically ventilated patients (P value &lt; 0.001). Similar findings in patients with DMD were found in other, single-centre, retrospective observational studies from the United Kingdom (<LINK REF="REF-Eagle-2002" TYPE="REFERENCE">Eagle 2002</LINK>), the United States of America (<LINK REF="REF-Bach-2011" TYPE="REFERENCE">Bach 2011</LINK>), Canada (<LINK REF="REF-McKim-2013" TYPE="REFERENCE">McKim 2013</LINK>), Belgium (<LINK REF="REF-Toussaint-2006" TYPE="REFERENCE">Toussaint 2006</LINK>), and Germany (<LINK REF="REF-Wollinsky-2012" TYPE="REFERENCE">Wollinsky 2012</LINK>). An observational study of 144 children (47% with neuromuscular disorders, including DMD, spinal muscular atrophy (SMA) type 1 and type 2, and congenital myopathy) showed 94% and 91% survival rates at 5 and 10 years, respectively, with long-term mechanical ventilation (<LINK REF="REF-McDougall-2013" TYPE="REFERENCE">McDougall 2013</LINK>).</P>
<P>It seems likely that hypoventilation-related symptoms may reflect different degrees of respiratory failure more in rapidly progressive diseases than in less rapidly progressive neuromuscular disorders. Subsequently, the effects of nocturnal mechanical ventilation should be different. So, it seems likely that the criteria for nocturnal mechanical ventilation should differ in rapidly progressive and less rapidly progressive neuromuscular disorders (<LINK REF="REF-Rapha_x00eb_l-1999" TYPE="REFERENCE">Raphaël 1999</LINK>). Similarly, correcting nocturnal hypoventilation in people with diurnal hypercapnia may yield a more rapid, clinically evident benefit than in people with normal daytime hypercapnia.</P>
<P>Data from two small cross-over studies showed that volume-cycled and pressure-cycled ventilation improved symptoms related to chronic hypoventilation and daytime hypercapnia significantly and similarly, at least in the short term (<LINK REF="STD-Laserna-2003" TYPE="STUDY">Laserna 2003</LINK>; <LINK REF="STD-Tuggey-2005" TYPE="STUDY">Tuggey 2005</LINK>). Volume-cycled non-invasive ventilation may be associated with less nocturnal desaturation and apneas. However, taking into account the small number of participants, any conclusion should be drawn very cautiously.</P>
<P>There were no available data from randomised trials to decide on comparisons between invasive ventilation and non-invasive ventilation, or between intermittent positive ventilation and negative pressure ventilation. Observational studies have suggested that, in DMD with nocturnal mechanical ventilation and diurnal hypercapnia, daytime non-invasive ventilation may prolonged survival and may be safe even when patients required 24-hour continuous respiratory support, thus preventing tracheostomy (<LINK REF="REF-Bach-2011" TYPE="REFERENCE">Bach 2011</LINK>; <LINK REF="REF-McKim-2013" TYPE="REFERENCE">McKim 2013</LINK>; <LINK REF="REF-Toussaint-2006" TYPE="REFERENCE">Toussaint 2006</LINK>). Likewise, an observational study of 144 children requiring long-term respiratory support, including patients with DMD (n = 18), SMA type 1 (n = 6) and type 2 (n = 14), and other congenital myopathies (n = 18), showed that five-year survival was 94% overall and was significantly higher for patients on non-invasive ventilation (97%) than invasively ventilated patients (84%) (<LINK REF="REF-McDougall-2013" TYPE="REFERENCE">McDougall 2013</LINK>). Another study of 194 infants with SMA type 1, found that in comparison with invasive mechanical ventilation, non-invasive ventilation with mechanical cough assist was associated with lower survival rates at 24 months of life (68% versus 95%, P value &lt; 0.001) and at 48 months of life (45% versus 89%, P value &lt; 0.001) (<LINK REF="REF-Gregoretti-2013" TYPE="REFERENCE">Gregoretti 2013</LINK>).</P>
<P>The lack of assessment of adverse events associated with long-term mechanical ventilation is a limitation of the current review. Unpublished information was available for only one trial. Subsequently, there were missing data for several outcomes of interest.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-07-29 10:22:29 +0100" MODIFIED_BY="Ruth  Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2014-07-29 10:22:24 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Current evidence about the therapeutic benefit of mechanical ventilation is of very low quality, but directionally consistent, suggesting alleviation of the symptoms of chronic hypoventilation, improvement in survival and reduced risk of unplanned hospitalisation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-07-29 10:22:29 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Large randomised trials are needed to confirm the possible long-term beneficial effects of nocturnal mechanical ventilation on hypoventilation-related symptoms, quality of life, unplanned hospital admission rate and mortality, and to evaluate its cost-effectiveness in people with chest wall disorders and in people with neuromuscular diseases other than motor neuron disease or Duchenne muscular dystrophy, because natural history studies have shown substantial improvements in survival. Future trials should be stratified according to the type of disease and whether the course is rapidly progressive or not. The comparisons between invasive and non-invasive ventilation, and between volume-cycled and pressure-cycled ventilation, also require well-designed, multicentre, randomised trials. Finally, particular attention may be given to new modes of ventilation, such as auto-titrating pressure support devices, which are increasingly used.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-07-01 10:20:15 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We acknowledge the work of JC Chevrolet and the late JC Raphael on earlier versions of this review.</P>
<P>The authors thank Miss S. Loiseau from the Association Française de lutte contre la Myopathie for her technical assistance in searching for articles.</P>
<P>The Cochrane Neuromuscular Disease Group (CNMDG) Trials Search Co-ordinator, Angela Gunn, provided searches.</P>
<P>The editorial base of the CNMDG receives funding from the MRC Centre for Neuromuscular Diseases and the Motor Neuron Disease Association.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-11-18 08:53:15 +0000" MODIFIED_BY="Ruth  Brassington">
<P>D Annane: my group was the co-ordinating centre of a publicly funded multicentre trial of non-invasive ventilation in DMD that has been included in this review (<LINK REF="STD-Rapha_x00eb_l-1994" TYPE="STUDY">Raphaël 1994</LINK>), and we are co-ordinating an ongoing, publicly funded, multicentre trial of non-invasive ventilation in adults with myotonic dystrophy type 1.</P>
<P>S Chevret: none known.</P>
<P>D Orlikowski declares the following:</P>
<UL>
<LI>grants from AFM for a randomised study of non-invasive ventilation in myotonic dystrophy type 1 and from Phillips for a study of Average Volume Assured Pressure Support (AVAPS) in myotonic dystrophy type 1;</LI>
<LI>fees from IP Santé à domicile;</LI>
<LI>he has acted as a medical referee for Foyer ADEP Evry.</LI>
</UL>
<P>All the activities mentioned are in the field of care and research conducted in neuromuscular diseases and home ventilation.</P>
<P>Outside this work, he received funding from Covidien and from Genzyme to attend the AAN conference 2012.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-07-29 10:22:29 +0100" MODIFIED_BY="Ruth  Brassington">
<P>All authors contributed to the design of the protocol for this review. All authors contributed to the search for published and unpublished trials. D Annane and S Chevret were responsible for data extraction and entry onto the computer, and for data analyses. All authors contributed to the interpretation of data and D Annane and S Chevret wrote the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-07-29 10:22:37 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Change in authorship: JC Raphael (deceased) and JC Chevrolet are no longer authors of the review for this update.</P>
<P>We included 'Summary of findings' tables.</P>
<P>We have re-arranged the outcomes to move up mortality at one year (or more) to be the primary outcome.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDIES MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<INCLUDED_STUDIES MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Bourke-2006" MODIFIED="2013-06-11 15:06:10 +0100" MODIFIED_BY="Angela A Gunn" NAME="Bourke 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-06-11 15:06:10 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ</AU>
<TI>Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>2</NO>
<PG>140-7</PG>
<IDENTIFIERS MODIFIED="2013-06-11 15:06:10 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-11 15:06:10 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="16426990"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-2001" MODIFIED="2014-03-06 16:59:15 +0000" MODIFIED_BY="Ruth Brassington" NAME="Jackson 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-03-06 16:59:15 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wrench M et al</AU>
<TI>A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>75-8</PG>
<IDENTIFIERS MODIFIED="2013-06-04 09:38:07 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-04 09:38:07 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11676995"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaye-2009" MODIFIED="2014-02-04 11:47:53 +0000" MODIFIED_BY="[Empty name]" NAME="Jaye 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-02-04 11:47:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaye J, Chatwin M, Dayer M, Morrell MJ, Simonds AK</AU>
<TI>Autotitrating versus standard noninvasive ventilation: a randomised crossover trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>3</NO>
<PG>566-71</PG>
<IDENTIFIERS MODIFIED="2013-06-11 16:14:01 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-11 16:14:01 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="19251798 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laserna-2003" MODIFIED="2013-06-11 14:57:04 +0100" MODIFIED_BY="Angela A Gunn" NAME="Laserna 2003" NOTES="&lt;p&gt;[Erratum appears in Arch Bronconeumol. 2003 Apr;39(4):191 Note: Belaustegui A [corrected to Beiztegui A]]&lt;/p&gt;" NOTES_MODIFIED="2013-06-11 14:57:04 +0100" NOTES_MODIFIED_BY="Angela A Gunn" YEAR="2003">
<REFERENCE MODIFIED="2013-06-11 14:55:50 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laserna E, Barrot E, Beiztegui A, Quintana E, Hernandez A, Castillo J</AU>
<TI>Non-invasive ventilation in kyphoscoliosis. A comparison of a volumetric ventilator and a BiPAP support pressure device</TI>
<TO>Ventilacion no invasiva en cifoescoliosis. Estudio comparativo entre respirador volumetrico y soporte de presion (BiPAP)</TO>
<SO>Archivos de Bronconeumologia</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>1</NO>
<PG>13-8</PG>
<IDENTIFIERS MODIFIED="2013-06-11 14:55:50 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-11 14:55:50 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12550014"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-1995" MODIFIED="2013-06-11 14:49:50 +0100" MODIFIED_BY="Angela A Gunn" NAME="Pinto 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-06-11 14:49:50 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. Journal of Neurological Sciences 1995; 129 (Suppl.):19-26.&lt;/p&gt;" NOTES_MODIFIED="2013-06-11 14:49:50 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML</AU>
<TI>Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1995</YR>
<VL>129</VL>
<NO>Suppl</NO>
<PG>19-26</PG>
<IDENTIFIERS MODIFIED="2013-06-11 14:49:50 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-11 14:49:50 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="7595610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rapha_x00eb_l-1994" MODIFIED="2013-06-11 14:47:54 +0100" MODIFIED_BY="Angela A Gunn" NAME="Raphaël 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-06-11 14:47:54 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;Raphael JC, Chevret S, Chastang C, Bouvet F, and the French Multicenter Cooperative Study Group on Home Mechanical Assistance in Duchenne de Boulogne Muscular Dystrophy. Randomised trial of preventive nasal ventilation in Duchenne Muscular Dystrophy. Lancet 1994;343:1600-1604.&lt;/p&gt;" NOTES_MODIFIED="2013-06-11 14:47:54 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raphaël JC, Chevret S, Chastang C, Bouvet F, and the French Multicenter Cooperative Group on Home Mechanical Ventilation Assistance in Duchenne de Boulogne Muscular Dystrophy</AU>
<TI>Randomised trial of preventive nasal ventilation in Duchenne muscular dystrophy</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8913</NO>
<PG>1600-4</PG>
<IDENTIFIERS MODIFIED="2013-06-11 14:47:54 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-11 14:47:54 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="7911921 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Struik-2011" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Struik 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Struik FM, Duiverman ML, Meijer PM, Nieuwenhuis JA, Kerstjens HA, Wijkstra PJ</AU>
<TI>Volume-targeted versus pressure-targeted noninvasive ventilation in patients with chest-wall deformity: a pilot study</TI>
<SO>Respiratory Care</SO>
<YR>2011</YR>
<VL>56</VL>
<NO>10</NO>
<PG>1522&#8211;5</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:19:02 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-06 15:19:02 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="21513604"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuggey-2005" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Tuggey 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuggey JM, Elliott MW</AU>
<TI>Randomised crossover study of pressure and volume non-invasive ventilation in chest wall deformity</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>10</NO>
<PG>859&#8211;64</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:19:58 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-06 15:19:58 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="12550014"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-2005" MODIFIED="2013-06-11 15:05:03 +0100" MODIFIED_BY="Angela A Gunn" NAME="Ward 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-06-11 15:05:03 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward S, Chatwin M, Heather S, Simonds AK</AU>
<TI>Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>12</NO>
<PG>1019-24</PG>
<IDENTIFIERS MODIFIED="2013-06-11 15:05:03 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-11 15:05:03 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="16299118"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willson-2004" MODIFIED="2014-03-06 16:59:38 +0000" MODIFIED_BY="Ruth Brassington" NAME="Willson 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-03-06 16:59:38 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willson GN, Piper AJ, Norman M, Chaseling WG, Milross MA, Collins ER et al</AU>
<TI>Nasal versus full face mask for noninvasive ventilation in chronic respiratory failure</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>605-9</PG>
<IDENTIFIERS MODIFIED="2013-06-11 15:03:50 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2013-06-11 15:03:50 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="15083762"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Aboussouan-1997" MODIFIED="2014-03-06 15:20:50 +0000" MODIFIED_BY="Ruth Brassington" NAME="Aboussouan 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-03-06 15:20:50 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H</AU>
<TI>Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>127</VL>
<NO>6</NO>
<PG>450-3</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:20:50 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ambrosino-1997" MODIFIED="2014-03-06 15:20:56 +0000" MODIFIED_BY="Ruth Brassington" NAME="Ambrosino 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-03-06 15:20:56 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Ambrosino N, Vitacca M, Polese G, Pagani M, Foglio K, Rossi A. Short term effects of nasal proportional assist ventilation in patients with chronic hypercapnic respiratory insufficiency. European Respiratory Journal 1997;10:2829-2834.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:20:56 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ambrosino N, Vitacca M, Polese G, Pagani M, Foglio K, Rossi A</AU>
<TI>Short term effects of nasal proportional assist ventilation in patients with chronic hypercapnic respiratory insufficiency</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>12</NO>
<PG>2829-34</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:20:56 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bach-1998" MODIFIED="2014-03-06 15:21:04 +0000" MODIFIED_BY="Ruth Brassington" NAME="Bach 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-06 15:21:04 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Bach JR, Rajaraman R, Ballanger F, Tzeng AC, Ishikawa Y, Kulessa R, Bansal T. Neuromuscular ventilatory insufficiency: effect of home mechanical ventilator use versus oxygen therapy on pneumonia and hospitalization rates. American Journal of Physical Medicine and Rehabilitation 1998; 77:8-19.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:04 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bach JR, Rajaraman R, Ballanger F, Tzeng AC, Ishikawa Y, Kulessa R et al</AU>
<TI>Neuromuscular ventilatory insufficiency: effect of home mechanical ventilator use versus oxygen therapy on pneumonia and hospitalization rates</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>1998</YR>
<VL>77</VL>
<NO>1</NO>
<PG>8-19</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:04 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celikel-1998" MODIFIED="2014-03-06 15:21:11 +0000" MODIFIED_BY="Ruth Brassington" NAME="Celikel 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-06 15:21:11 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Celikel T, Sungur M, Ceyhan B, Karakurt S. Comparison of nonivasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure. Chest 1998; 114: 1636-1642.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:11 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celikel T, Sungur M, Ceyhan B, Karakurt S</AU>
<TI>Comparison of noninvasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>1636-42</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:11 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chatwin-2008" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Chatwin 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chatwin M, Nickol AH, Morrell MJ, Polkey MI, Simonds AK</AU>
<TI>Randomised trial of inpatient versus outpatient initiation of home mechanical ventilation in patients with nocturnal hypoventilation</TI>
<SO>Respiratory Medicine</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>11</NO>
<PG>1528-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crescimanno-2011" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Crescimanno 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crescimanno G, Maronne O, Vianello A</AU>
<TI>Efficacy and comfort of volume-guaranteed pressure support inpatients with chronic ventilatory failure of neuromuscular origin</TI>
<SO>Respirology</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>4</NO>
<PG>672&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elliott-1994" MODIFIED="2014-03-06 15:21:20 +0000" MODIFIED_BY="Ruth Brassington" NAME="Elliott 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-03-06 15:21:20 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Elliott MW, Aquilina R, Green M, Moxham J, Simonds AK. A comparison of different modes of noninvasive ventilatory support: effects on ventilation and inspiratory muscle effort. Anaesthesia 1994; 49: 279-283.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:20 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elliott MW, Aquilina R, Green M, Moxham J, Simonds AK</AU>
<TI>A comparison of different modes of noninvasive ventilatory support: effects on ventilation and inspiratory muscle effort</TI>
<SO>Anaesthesia</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>4</NO>
<PG>279-83</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:20 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-1987" MODIFIED="2014-03-06 15:21:27 +0000" MODIFIED_BY="Ruth Brassington" NAME="Ellis 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-03-06 15:21:27 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Ellis ER, Bye PT, Bruderer JW, Sullivan CE. Treatment of respiratory failure during sleep in patients with neuromuscular disease: positive pressure ventilation through a nose mask. American Review Respiratory Disease 1987;135:148-152.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:27 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis ER, Bye PT, Bruderer JW, Sullivan CE</AU>
<TI>Treatment of respiratory failure during sleep in patients with neuromuscular disease: positive pressure ventilation through a nose mask</TI>
<SO>American Review Respiratory Disease</SO>
<YR>1987</YR>
<VL>135</VL>
<NO>1</NO>
<PG>148-52</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:27 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fanfulla-2005" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Fanfulla 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fanfulla F, Delmastro M, Berardinelli A, Lupo ND, Nava S</AU>
<TI>Effects of different ventilator settings on sleep and inspiratory effort in patients with neuromuscular disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>172</VL>
<NO>5</NO>
<PG>619-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hart-2002" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hart 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hart N, Hunt A, Polkey MI, Fauroux B, Lofaso F, Simonds AK</AU>
<TI>Comparison of proportional assist ventilation and pressure support ventilation in chronic respiratory failure due to neuromuscular and chest wall deformity</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>979&#8211;81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Highcock-2002" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Highcock 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Highcock MP, Morrish E, Jamieson S, Shneerson JM, Smith IE</AU>
<TI>An overnight comparison of two ventilators used in the treatment of chronic respiratory failure</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>942&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masa-1997" MODIFIED="2014-03-06 15:21:40 +0000" MODIFIED_BY="Ruth Brassington" NAME="Masa 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-03-06 15:21:40 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Masa JF, Celli BR, Riesco JA, Sanchez de Cos J, Disdier C, Sojo A. Noninvasive positive pressure ventilation and not oxygen may prevent overt ventilatory failure in patients with chest wall diseases. Chest 1997;112:207-213.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:40 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masa JF, Celli BR, Riesco JA, Sanchez de Cos J, Disdier C, Sojo A</AU>
<TI>Noninvasive positive pressure ventilation and not oxygen may prevent overt ventilatory failure in patients with chest wall diseases</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<NO>1</NO>
<PG>207-13</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:40 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meecham-Jones-1993" MODIFIED="2014-03-06 15:21:47 +0000" MODIFIED_BY="Ruth Brassington" NAME="Meecham Jones 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-03-06 15:21:47 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Meecham Jones DJ, Wedzicha JA. Comparison of pressure and volume preset nasal ventilator systems in stable chronic respiratory failure. European Respiratory Journal 1993; 6: 1060-1064.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:47 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meecham Jones DJ, Wedzicha JA</AU>
<TI>Comparison of pressure and volume preset nasal ventilator systems in stable chronic respiratory failure</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>7</NO>
<PG>1060-4</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:47 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orlikowski-2009" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Orlikowski 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orlikowski D, Mroue G, Prigent H, Moulin C, Bohic M, Ruquet M et al</AU>
<TI>Automatic air-leak compensation in neuromuscular patients: a feasibility study</TI>
<SO>Respiratory Medicine</SO>
<YR>2009</YR>
<VL>103</VL>
<NO>2</NO>
<PG>173-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padman-1998" MODIFIED="2014-03-06 15:21:59 +0000" MODIFIED_BY="Ruth Brassington" NAME="Padman 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-06 15:21:59 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Padman R, Lawless ST, Kettrick RG. Nonivasive ventilation via bilevel positive airway pressure support in pediatric practice. Critical Care Medicine 1998; 26: 169-173.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:59 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padman R, Lawless ST, Kettrick RG</AU>
<TI>Noninvasive ventilation via bilevel positive airway pressure support in pediatric practice</TI>
<SO>Critical Care Medicine</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>1</NO>
<PG>169-73</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:59 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Restrick-1993" MODIFIED="2014-03-06 15:21:53 +0000" MODIFIED_BY="Ruth Brassington" NAME="Restrick 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-03-06 15:21:53 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Restrick LJ, Fox NC, Braid G, Ward EM, Paul EA, Wedzicha JA. Comparison of nasal pressure support ventilation with nasal intermittent positive pressure ventilation in patients with nocturnal hypoventilation. European Respiratory Journal 1993;6:364-70.&lt;/p&gt;" NOTES_MODIFIED="2014-03-06 15:21:53 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Restrick LJ, Fox NC, Braid G, Ward EM, Paul EA, Wedzicha JA</AU>
<TI>Comparison of nasal pressure support ventilation with nasal intermittent positive pressure ventilation in patients with nocturnal hypoventilation</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>3</NO>
<PG>364-70</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:21:53 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Annane-1999" MODIFIED="2014-07-01 10:36:17 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Annane 1999" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Quera-Salva MA, Lofaso F, Vercken JB, Lesieur O, Fromageot C et al</AU>
<TI>Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>1</NO>
<PG>157-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arras-1995" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Arras 1995" TYPE="BOOK">
<AU>Arras JD</AU>
<SO>Bringing the Hospital Home: Ethical and Social Implications of High-tech Home Care</SO>
<YR>1995</YR>
<PB>The Johns Hopkins University Press</PB>
<CY>Baltimore</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="080184990xISBN 080184990x"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bach-1987" MODIFIED="2014-03-06 15:28:09 +0000" MODIFIED_BY="Ruth Brassington" NAME="Bach 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bach JR, Alba A, Mosher R, Delaubier A</AU>
<TI>Intermittent positive pressure ventilation via nasal access in the management of respiratory insufficiency</TI>
<SO>Chest</SO>
<YR>1987</YR>
<VL>92</VL>
<NO>1</NO>
<PG>169-70</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:28:09 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Bach-2011" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Bach 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bach JR, Martinez D</AU>
<TI>Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival</TI>
<SO>Respiratory Care</SO>
<YR>2011</YR>
<VL>56</VL>
<NO>6</NO>
<PG>744&#8211;50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bach-2013" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Bach 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bach JR, Gonçalves MR, Hon A, Ishikawa Y, De Vito EL, Prado F et al</AU>
<TI>Changing trends in the management of end-stage neuromuscular respiratory muscle failure: recommendations of an international consensus</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2013</YR>
<VL>92</VL>
<NO>3</NO>
<PG>267-77</PG>
<IDENTIFIERS MODIFIED="2013-06-11 16:14:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-31 10:33:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23051760"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barb_x00e9_-1996" MODIFIED="2014-03-06 15:28:35 +0000" MODIFIED_BY="Ruth Brassington" NAME="Barbé 1996" TYPE="JOURNAL_ARTICLE">
<AU>Barbé F, Quera-Salva MA, de Lattre J, Gajdos P, Agusti AGN</AU>
<TI>Long term effects of nasal intermittent positive-pressure ventilation on pulmonary function and sleep architecture in patients with neuromuscular diseases</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>5</NO>
<PG>1179-83</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:28:35 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Carroll-1988" MODIFIED="2014-03-06 15:29:00 +0000" MODIFIED_BY="Ruth Brassington" NAME="Carroll 1988" TYPE="JOURNAL_ARTICLE">
<AU>Carroll N, Branthwaite MA</AU>
<TI>Control of nocturnal hypoventilation by nasal intermittent positive pressure ventilation</TI>
<SO>Thorax</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>5</NO>
<PG>349-53</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:00 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Chailleux-1996" MODIFIED="2014-03-06 15:29:10 +0000" MODIFIED_BY="Ruth Brassington" NAME="Chailleux 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chailleux E, Fauroux B, Binet F, Dautzenberg B, Polu JM for the Observatory Group of ANTADIR</AU>
<TI>Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>109</VL>
<NO>3</NO>
<PG>741-9</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:10 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Chatwin-2010" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Chatwin 2010" TYPE="JOURNAL_ARTICLE">
<AU>Chatwin M, Heather S, Hanak A, Polkey MI, Simonds AK</AU>
<TI>Analysis of home support and ventilator malfunction in 1,211 ventilator-dependent patients</TI>
<SO>European Respiratory Journal</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>2</NO>
<PG>310-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Claman-1996" MODIFIED="2014-03-06 15:28:43 +0000" MODIFIED_BY="Ruth Brassington" NAME="Claman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Claman DM, Piper A, Sanders MH, Stiller RA, Votteri BA</AU>
<TI>Nocturnal non-invasive positive pressure ventilatory assistance</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>6</NO>
<PG>1581-8</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:28:43 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Eagle-2002" MODIFIED="2014-02-04 11:47:53 +0000" MODIFIED_BY="[Empty name]" NAME="Eagle 2002" TYPE="JOURNAL_ARTICLE">
<AU>Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K</AU>
<TI>Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>10</NO>
<PG>926-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Jan Brozek, Andrew Oxman, Holger Schünemann</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gregoretti-2013" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Gregoretti 2013" TYPE="JOURNAL_ARTICLE">
<AU>Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Ravà L, Bignamini E et al</AU>
<TI>Survival of patients with spinal muscular atrophy type 1</TI>
<SO>Pediatrics</SO>
<YR>2013</YR>
<VL>131</VL>
<NO>5</NO>
<PG>e1509-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heckmatt-1990" MODIFIED="2014-03-06 15:29:20 +0000" MODIFIED_BY="Ruth Brassington" NAME="Heckmatt 1990" TYPE="JOURNAL_ARTICLE">
<AU>Heckmatt JZ, Loh L, Dubowitz V</AU>
<TI>Night time nasal ventilation in neuromuscular disease</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<NO>8689</NO>
<PG>579-82</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:20 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoeppner-1984" MODIFIED="2014-07-01 10:35:47 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hoeppner 1984" TYPE="JOURNAL_ARTICLE">
<AU>Hoeppner VH, Cockcroft DW, Dosman JA, Cotton DJ</AU>
<TI>Nighttime ventilation improves respiratory failure in secondary kyphoscoliosis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1984</YR>
<VL>129</VL>
<NO>2</NO>
<PG>240-3</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:33:47 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-King-2012" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="King 2012" TYPE="JOURNAL_ARTICLE">
<AU>King AC</AU>
<TI>Long-term home mechanical ventilation in the United States</TI>
<SO>Respiratory Care</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>6</NO>
<PG>921-30</PG>
<IDENTIFIERS MODIFIED="2013-05-31 08:29:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-31 08:29:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22663967"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lewarski-2007" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Lewarski 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lewarski JS, Gay PC</AU>
<TI>Current issues in home mechanical ventilation</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>2</NO>
<PG>671&#8211;6</PG>
<IDENTIFIERS MODIFIED="2013-05-31 10:10:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-31 10:10:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17699139"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lloyd_x002d_Owen-2005" MODIFIED="2014-07-01 10:35:38 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Lloyd-Owen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd-Owen SJ, Donaldson GC, Ambrosino N, Escarabill J, Farre R, Fauroux B et al</AU>
<TI>Patterns of home mechanical ventilation use in Europe: results of the European Survey</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1025-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loh-1979" MODIFIED="2014-03-06 15:29:26 +0000" MODIFIED_BY="Ruth Brassington" NAME="Loh 1979" TYPE="JOURNAL_ARTICLE">
<AU>Loh L, Hughes JM, Davis J</AU>
<TI>Gas exchange problems in bilateral diaphragm paralysis</TI>
<SO>Bulletin Européen de Physiopathologie Respiratoire</SO>
<YR>1979</YR>
<VL>15</VL>
<NO>Suppl</NO>
<PG>137-41</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:26 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Make-1998" MODIFIED="2014-03-06 15:37:43 +0000" MODIFIED_BY="Ruth Brassington" NAME="Make 1998" TYPE="JOURNAL_ARTICLE">
<AU>Make BJ, Hill NS, Goldberg AI, Bach JR, Criner GJ, Dunne PE et al</AU>
<TI>Mechanical ventilation beyond the intensive care unit: report of a consensus conference of the American College of Chest Physicians</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>113</VL>
<NO>5 Suppl</NO>
<PG>289S-344S</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:37:43 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-McDougall-2013" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="McDougall 2013" TYPE="JOURNAL_ARTICLE">
<AU>McDougall CM, Adderley RJ, Wensley DF, Seear MD</AU>
<TI>Long-term ventilation in children: longitudinal trends and outcomes</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2013</YR>
<VL>98</VL>
<NO>9</NO>
<PG>660-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKim-2013" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="McKim 2013" TYPE="JOURNAL_ARTICLE">
<AU>McKim DA, Griller N, LeBlanc C, Woolnough A, King J</AU>
<TI>Twenty-four hour noninvasive ventilation in Duchenne muscular dystrophy: a safe alternative to tracheostomy</TI>
<SO>Canadian Respiratory Journal</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>1</NO>
<PG>e5-e9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milligan-1991" MODIFIED="2008-06-20 21:51:34 +0100" MODIFIED_BY="[Empty name]" NAME="Milligan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Milligan S</AU>
<TI>American Association for Respiratory Care and Gallup estimate numbers and costs of caring for chronic ventilator patients</TI>
<SO>American Association for Respiratory Care Times</SO>
<YR>1991</YR>
<VL>15</VL>
<PG>30-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newsom_x002d_Davis-1980" MODIFIED="2014-03-06 15:29:35 +0000" MODIFIED_BY="Ruth Brassington" NAME="Newsom-Davis 1980" TYPE="JOURNAL_ARTICLE">
<AU>Newsom-Davis J</AU>
<TI>The respiratory system in muscular dystrophy</TI>
<SO>British Medical Bulletin</SO>
<YR>1980</YR>
<VL>36</VL>
<NO>2</NO>
<PG>135-8</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:35 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Orlikowski-2005" MODIFIED="2014-03-06 15:41:36 +0000" MODIFIED_BY="Ruth Brassington" NAME="Orlikowski 2005" TYPE="JOURNAL_ARTICLE">
<AU>Orlikowski D, Prigent H, Gonzalez J, Sharshar T, Raphaël JC</AU>
<TI>Long term domiciliary mechanical ventilation in patients with neuromuscular diseases (indications, establishment and follow up)</TI>
<TO>Ventilation mécanique à domicile et au long cours des patients neuromusculaires (indications, mise en place et surveillance)</TO>
<SO>Revue des Maladies Respiratoires</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>6 Pt 1</NO>
<PG>1021-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Passamano-2012" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Passamano 2012" TYPE="JOURNAL_ARTICLE">
<AU>Passamano L, Taglia A, Palladino A, Viggiano E, D'Ambrosio P, Scutifero M et al</AU>
<TI>Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients</TI>
<SO>Acta Myologica</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>2</NO>
<PG>121-5</PG>
<IDENTIFIERS MODIFIED="2013-10-27 08:48:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-27 08:48:01 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23097603"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-1987" MODIFIED="2014-02-04 11:47:53 +0000" MODIFIED_BY="[Empty name]" NAME="Raphaël 1987" TYPE="BOOK_SECTION">
<AU>Raphaël JC, Gajdos P, de Lattre J</AU>
<TI>Chronic respiratory insufficiency related to neuromuscular diseases, therapeutic perspectives</TI>
<TO>Handicape respiratoire chronique d&#8217;origine neuromusculaire: physiopathologie, perspectives thérapeutiques</TO>
<SO>Fonction diaphragmatique - Travail respiratoire. Monographie de la Société de Réanimation de Langue Française</SO>
<YR>1987</YR>
<PG>203-28</PG>
<PB>Expansion Scientifique Française</PB>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-1999" MODIFIED="2014-03-06 15:29:42 +0000" MODIFIED_BY="Ruth Brassington" NAME="Raphaël 1999" TYPE="JOURNAL_ARTICLE">
<AU>Raphaël JC, Chevret S, Annane D</AU>
<TI>Is early noninvasive mechanical ventilation of first choice in stable restrictive patients with chronic respiratory failure?</TI>
<SO>Monaldi Archives of Chest Disease</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>1</NO>
<PG>90-7</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:42 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simonds-2003" MODIFIED="2014-07-17 12:42:23 +0100" MODIFIED_BY="[Empty name]" NAME="Simonds 2003" TYPE="JOURNAL_ARTICLE">
<AU>Simonds AK</AU>
<TI>Home ventilation</TI>
<SO>European Respiratory Journal. Supplement</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl 47</NO>
<PG>38S-46S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skatrud-1980" MODIFIED="2014-07-17 12:42:44 +0100" MODIFIED_BY="[Empty name]" NAME="Skatrud 1980" TYPE="JOURNAL_ARTICLE">
<AU>Skatrud J, Iber C, McHugh W, Rasmussen H, Nichols D</AU>
<TI>Determinants of hypoventilation during wakefulness and sleep in diaphragmatic paralysis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1980</YR>
<VL>121</VL>
<NO>3</NO>
<PG>587-93</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:58 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1987" MODIFIED="2014-07-01 10:35:15 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Smith 1987" TYPE="JOURNAL_ARTICLE">
<AU>Smith PE, Calverley PM, Edwards RH, Evans GA, Campbell EJ</AU>
<TI>Practical problems in the respiratory care of patients with muscular dystrophy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>316</VL>
<NO>19</NO>
<PG>1197-205</PG>
<IDENTIFIERS MODIFIED="2014-03-06 15:29:51 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Toussaint-2006" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Toussaint 2006" TYPE="JOURNAL_ARTICLE">
<AU>Toussaint M, Steens M, Wasteels G, Soudon P</AU>
<TI>Diurnal ventilation via mouthpiece: survival in end-stage Duchenne patients</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>3</NO>
<PG>549&#8211;55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wollinsky-2012" MODIFIED="2014-07-17 12:43:17 +0100" MODIFIED_BY="[Empty name]" NAME="Wollinsky 2012" TYPE="JOURNAL_ARTICLE">
<AU>Wollinsky KH, Kutter B, Geiger PM</AU>
<TI>Long-term ventilation of patients with Duchenne muscular dystrophy:experiences at the Neuromuscular Centre Ulm</TI>
<SO>Acta Myologica</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>3</NO>
<PG>170-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Annane-2000" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Annane 2000" TYPE="COCHRANE_REVIEW">
<AU>Annane D, Chevrolet JC, Chevret S, Raphaël JC</AU>
<TI>Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-03-06 17:46:01 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-06 17:46:01 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001941"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2007" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Annane 2007" TYPE="COCHRANE_REVIEW">
<AU>Annane D, Orlikowski D, Chevret S, Chevrolet JC, Raphaël JC</AU>
<TI>Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-03-06 17:47:22 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-06 17:47:22 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001941.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-07-29 10:23:05 +0100" MODIFIED_BY="Ruth  Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-07-29 10:23:00 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:38 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Bourke-2006">
<CHAR_METHODS MODIFIED="2014-07-01 10:20:30 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, open, parallel-group study with a follow-up period of at least 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 10:20:32 +0100" MODIFIED_BY="Ruth  Brassington">
<P>41 participants with ALS with or without bulbar features, meeting definite diagnostic criteria, who had orthopnoea with inspiratory maximal pressure less than 60% of predicted or symptomatic daytime hypercapnia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 10:22:38 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control: standard care<BR/>Experimental: non-invasive nasal nocturnal ventilation with bilevel airway pressure</P>
<P>At least 1 year follow-up period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 10:22:38 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Survival time</P>
<P>Quality of life SF-36 mental component summary</P>
<P>Sleep apnoea quality of life index symptoms domain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:38 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:40 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Jackson-2001">
<CHAR_METHODS MODIFIED="2014-07-01 10:20:36 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, single-blind study, randomisation stratified according to bulbar versus limb onset</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 10:22:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>13 adults with ALS of less than 3 years duration, with an FVC &#8805; 70% and nocturnal oxygen desaturation for &#8805; 1 minute or at least 2 clinical symptoms of chronic hypoventilation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-04 11:31:33 +0000" MODIFIED_BY="[Empty name]">
<P>Control: no respiratory support until FVC fell below 50%</P>
<P>Experimental: nocturnal positive pressure ventilation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 10:22:40 +0100" MODIFIED_BY="Ruth  Brassington">
<P>No clear primary outcome</P>
<UL>
<LI>ALS functional rating scale-respiratory version (ALSFRS-R)</LI>
<LI>Short Form 36</LI>
<LI>Modified Calgary Sleep Apnea Quality of Life Index (SAQLI)</LI>
<LI>FVC% (sitting and supine, maximal inspiratory force (MIP), maximal expiratory force (MEP))</LI>
<LI>Daytime and nocturnal oximetry, and peak cough expiratory flow (PCEF)</LI>
<LI>Symptoms of hypoventilation, assessed using a pulmonary symptom scale consisting of 14 questions, which were answered on a scale from 1 to 7</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:40 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:42 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Jaye-2009">
<CHAR_METHODS MODIFIED="2014-07-01 10:20:44 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, randomised, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 10:22:41 +0100" MODIFIED_BY="Ruth  Brassington">
<P>25 adults meeting the following criteria:</P>
<OL>
<LI>with neuromuscular disease or chest wall deformation related chronic hypoventilation</LI>
<LI>on nocturnal non-invasive mechanical ventilation for &#8805; 6 months</LI>
<LI>stable respiratory condition for &#8805; 3 months</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 10:20:47 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control: 1-month treatment with conventional nocturnal positive pressure support ventilation</P>
<P>Experimental: 1-month treatment with auto-titrated nocturnal positive pressure ventilation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 10:22:42 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Primary outcome: mean overnight oxygen saturation</P>
<P>Secondary outcomes:</P>
<UL>
<LI>sleep studies: overnight mean and maximum transcutaneous CO<SUB>2</SUB>, minimum SaO<SUB>2</SUB>, SaO<SUB>2</SUB> desaturation index, total sleep time, sleep latency, sleep efficiency, percentage of sleep stages, arousals, arousal index and heart rate variability</LI>
<LI>pulmonary function</LI>
<LI>non-invasive assessment of respiratory muscles strength</LI>
<LI>subjective assessment of tolerance to the ventilator on a visual analogical scale</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:42 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:43 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Laserna-2003">
<CHAR_METHODS MODIFIED="2014-07-01 10:20:53 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, open, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-17 12:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>10 participants with kyphoscoliosis and chronic hypercapnic respiratory failure<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 10:20:56 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control: spontaneous ventilation<BR/>Experimental 1: nocturnal ventilation with bilevel airway pressure<BR/>Experimental 2: nocturnal volume-cycle ventilation<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 10:20:56 +0100" MODIFIED_BY="Ruth  Brassington">
<P>1-month improvement in sleep parameters, clinical symptoms and arterial blood gas</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:43 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Pinto-1995">
<CHAR_METHODS MODIFIED="2014-07-01 10:31:12 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, open, parallel-group study with a 3-year follow-up period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 10:22:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>20 participants having ALS with bulbar features (definite diagnostic criteria) and with chronic hypercapnic respiratory failure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 10:21:03 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control: oxygen, bronchodilators and other palliative measures<BR/>Experimental group: non-invasive nasal nocturnal ventilation with bilevel airway pressure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 10:21:05 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Mortality at 1 and 3 years</P>
<P>Survival time </P>
<P>Bulbar and spinal Norris scores </P>
<P>Quality of life </P>
<P>Modified Barthel score </P>
<P>Arterial blood gases </P>
<P>Respiratory function tests</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:46 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Rapha_x00eb_l-1994">
<CHAR_METHODS MODIFIED="2014-07-01 10:21:08 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Multicentre (17 centres in France), open, parallel-group study </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 10:21:10 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Children and adults with Duchenne muscular dystrophy<BR/>19 of the 70 included participants presenting with symptoms of nocturnal hypoventilation or daytime PaCO<SUB>2</SUB> &#8805; 6 kPa and were evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 10:21:11 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control group: combination of antibiotic and physiotherapy, if needed<BR/>Experimental group: nocturnal intermittent positive ventilation through a nose mask or a mouthpiece</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 10:22:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Short-term (24 hours): arterial blood gases</P>
<P>Long-term (6 months to 1 year):</P>
<UL>
<LI>Symptoms of nocturnal hypoventilation</LI>
<LI>Death</LI>
<LI>Number of unplanned hospitalisations</LI>
<LI>Arterial blood gases</LI>
<LI>Forced vital capacity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Individual data were available from the co-ordinating centre. 5-year inclusion period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:48 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Struik-2011">
<CHAR_METHODS MODIFIED="2014-07-01 10:21:16 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, open-label trial with 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 10:21:17 +0100" MODIFIED_BY="Ruth  Brassington">
<P>16 adults with chest wall deformities and daytime PaCO<SUB>2</SUB> &gt; 45 mm Hg, and one of the following symptoms of nocturnal hypoventilation: daytime sleepiness, fatigue, morning headaches and/or dyspnea, or weight loss. All the participants were NIV-naïve<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 10:22:47 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control treatment: volume-targeted NIV during the night-time</P>
<P>Experimental treatment: pressure-targeted NIV during the night-time</P>
<P>In both arms NIV was titrated to decrease PaCO<SUB>2</SUB> to 45 mmHg, maintain SaO<SUB>2</SUB> above 90%, and improve symptoms while maintaining patient comfort<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 10:22:48 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The number of days needed to successfully establish the patient on NIV, defined as adequate patient adjustment to NIV and effective ventilation (PaCO<SUB>2</SUB> &lt; 45 mm Hg). NIV adjustment was considered adequate when the patient could sleep with the NIV for at least 6 hours per night<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:48 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:54 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Tuggey-2005">
<CHAR_METHODS MODIFIED="2014-07-01 10:21:22 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, single-blinded, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 10:22:49 +0100" MODIFIED_BY="Ruth  Brassington">
<P>13 adults with chronic respiratory failure related to chest wall deformities and with stable clinical status on long-term night-time mechanical ventilation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 10:22:51 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control treatment: 4-week course of night-time ventilation with volume-targeted NIV</P>
<P>Experimental treatment: 1-week course of night-time ventilation with pressure-targeted NIV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 10:22:54 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Primary outcome: daytime arterial blood gas tensions during spontaneous breathing</P>
<P>Secondary outcomes:</P>
<OL>
<LI>Resting minute ventilation and occlusion pressure at 100 ms (P0.1), hypercapnic ventilatory responses</LI>
<LI>Spirometry, maximal (plateau) inspiratory and expiratory mouth pressures, and sniff nasal inspiratory pressures</LI>
<LI>Psychometric measures included a battery of tests sensitive to changes due to chronic hypoxia and sleep deprivation</LI>
<LI>Health status assessed by validated disease specific (MRF-28) and generic (SF-36v2) questionnaires together with the Hospital Anxiety and Depression Scale</LI>
<LI>Physical activity at home measured using a pedometer</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:54 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:55 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Ward-2005">
<CHAR_METHODS MODIFIED="2014-07-01 10:21:29 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, open, parallel-group study with a 2-year follow-up period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 10:21:30 +0100" MODIFIED_BY="Ruth  Brassington">
<P>n = 26 adults and children with congenital neuromuscular and chest wall disease<BR/>Chronic respiratory failure with diurnal normocapnia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 10:21:32 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control: spontaneous ventilation<BR/>Experimental: nocturnal ventilation with bilevel airway pressure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 10:22:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Peak transcutaneous arterial CO<SUB>2</SUB> tension<BR/>Number of participants who developed criteria for mandatory mechanical ventilation<BR/>Changes in pulmonary function and respiratory muscles strength</P>
<P>SF-36 quality of life domain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 10:22:55 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Willson-2004">
<CHAR_METHODS MODIFIED="2014-07-01 10:21:38 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre, cross-over, open study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 10:21:40 +0100" MODIFIED_BY="Ruth  Brassington">
<P>16 participants with neuromuscular diseases (n = 3), chest wall diseases (n = 5) or non-neuromuscular and non-chest wall diseases (n = 8)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 10:22:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Control: nocturnal ventilation with bilevel airway pressure using nasal mask<BR/>Experimental: nocturnal ventilation with bilevel airway pressure using full face mask</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 10:21:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Short-term (1-night treatment) effects on sleep parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 10:22:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALS: amyotrophic lateral sclerosis<BR/>CO<SUB>2</SUB>: carbon dioxide<BR/>FVC: forced vital capacity<BR/>NIV: non-invasive ventilation<BR/>PaCO<SUB>2</SUB>: carbon dioxide tension<BR/>SaO<SUB>2</SUB>: oxygen saturation<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-07-29 10:23:05 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:01 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Aboussouan-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:01 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Non-randomised, open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:02 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Ambrosino-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:02 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Mechanical ventilation was implemented for 1-hour run during the daytime. No data are available for the effects of nocturnal ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:02 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Bach-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:02 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Non-randomised, open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 10:21:46 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Celikel-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 10:21:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Participants in an unstable condition, i.e. acute respiratory failure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 10:21:47 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Chatwin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 10:21:47 +0100" MODIFIED_BY="Ruth  Brassington">
<P>This trial compared initiation of NIV at home versus in hospital</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:03 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Crescimanno-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:03 +0100" MODIFIED_BY="Ruth  Brassington">
<P>This trial compared the very short-term (over 3 nights) effect on gas exchange, sleep and respiratory function of 3 different modes of ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:03 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Elliott-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:03 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Mixed population, i.e. COPD and only 4 participants with chest wall disorders. Mechanical ventilation was implemented for 5-minute courses during daytime. No data were available for night-time ventilation effects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 10:21:50 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Ellis-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 10:21:50 +0100" MODIFIED_BY="Ruth  Brassington">
<P>This trial compared short-term (24-hour) effects of 1 night on positive- or negative-pressure ventilation or spontaneous breathing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:03 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Fanfulla-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:03 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Non-randomised, open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:04 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Hart-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>This trial compared a very short course (i.e. 40 minutes) of proportional assisted ventilation and pressure support ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 10:21:51 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Highcock-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 10:21:51 +0100" MODIFIED_BY="Ruth  Brassington">
<P>This trial compared the short-term (overnight) effects on sleep and gas exchange of 2 different ventilators for pressure support ventilation in participants with chronic respiratory failure due to chest wall deformities</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:04 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Masa-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Non-randomised, open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 10:21:53 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Meecham-Jones-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 10:21:53 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Mixed population, i.e. COPD and only 3 participants with neuromuscular or chest wall disorders. Mechanical ventilation was implemented for a 2-hour course during daytime. No data were available for the effects of nocturnal ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 10:21:53 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Orlikowski-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 10:21:53 +0100" MODIFIED_BY="Ruth  Brassington">
<P>This trial compared overnight effects on air leaks of 2 modes of ventilation with or without automatic air leak compensation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 10:21:55 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Padman-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 10:21:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Non-randomised, open study. Participants were in an unstable condition, i.e. acute respiratory failure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 10:23:04 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Restrick-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 10:23:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>This trial compared the short-term effects (24-hour) of 1 overnight session of volume-cycled or pressure-cycled NIV or spontaneous breathing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>COPD: chronic obstructive pulmonary disease<BR/>NIV: non-invasive ventilation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-07-29 10:22:49 +0100" MODIFIED_BY="Ruth  Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-07-01 10:21:43 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:31:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>Computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:32:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:50 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Jaye-2009">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:56 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Laserna-2003">
<DESCRIPTION>
<P>Information was not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:06 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Pinto-1995">
<DESCRIPTION>
<P>Participants were alternately assigned to experimental or control arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:32:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1994">
<DESCRIPTION>
<P>Computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:33:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Struik-2011">
<DESCRIPTION>
<P>The method for generating the sequence of randomisation was not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:34:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuggey-2005">
<DESCRIPTION>
<P>Method for generating the random sequence generation was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:33 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Ward-2005">
<DESCRIPTION>
<P>Information was not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:43 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Willson-2004">
<DESCRIPTION>
<P>Information was not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-07-29 10:22:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:34 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>Computer-generated list; centralised randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>No information was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:32:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaye-2009">
<DESCRIPTION>
<P>Centralised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:57 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Laserna-2003">
<DESCRIPTION>
<P>Information was not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:06 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Pinto-1995">
<DESCRIPTION>
<P>Participants were alternately assigned to experimental or control arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-29 10:22:47 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1994">
<DESCRIPTION>
<P>Computer-generated list, centralised randomisation, stratified for centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:33:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Struik-2011">
<DESCRIPTION>
<P>Sealed envelope </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:34:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuggey-2005">
<DESCRIPTION>
<P>Method for allocation concealment was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:33 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Ward-2005">
<DESCRIPTION>
<P>Information was not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:43 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Willson-2004">
<DESCRIPTION>
<P>Information was not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-03-05 16:22:41 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-07-01 10:21:27 +0100" MODIFIED_BY="Ruth  Brassington" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-02-04 11:31:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>No party was blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 10:20:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Participants and personnel were not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 10:20:50 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Jaye-2009">
<DESCRIPTION>
<P>Participants and personnel were not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-02-04 11:32:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Laserna-2003">
<DESCRIPTION>
<P>No party was blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-02-04 11:32:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pinto-1995">
<DESCRIPTION>
<P>No party was blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-02-04 11:32:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapha_x00eb_l-1994">
<DESCRIPTION>
<P>No party was blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 10:21:18 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Struik-2011">
<DESCRIPTION>
<P>Neither the participants nor the personnel were blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 10:21:27 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Tuggey-2005">
<DESCRIPTION>
<P>Participants were blinded to treatment received in an appropriate manner, i.e. use of same ventilator and ventilator setting masked to the participant. Personnel were not blinded to experimental treatments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-02-04 11:34:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ward-2005">
<DESCRIPTION>
<P>No party was blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-02-04 11:34:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Willson-2004">
<DESCRIPTION>
<P>No party was blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-07-01 10:21:44 +0100" MODIFIED_BY="Ruth  Brassington" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:20:35 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:20:43 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>The outcomes were assessed by a blinded clinical evaluator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:20:51 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Jaye-2009">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:20:57 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Laserna-2003">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:21:07 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Pinto-1995">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:21:14 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Rapha_x00eb_l-1994">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:21:20 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Struik-2011">
<DESCRIPTION>
<P>The outcome assessors were not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:21:27 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Tuggey-2005">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:21:34 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Ward-2005">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 10:21:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Willson-2004">
<DESCRIPTION>
<P>The outcome assessor was not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-07-29 10:22:49 +0100" MODIFIED_BY="Ruth  Brassington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-06 14:50:52 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 10:20:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>One participant out of 7 in the experimental arm was lost to follow-up at 3 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 10:20:51 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Jaye-2009">
<DESCRIPTION>
<P>5 out of 25 randomised participants were dropped from the analysis for incomplete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-04 11:32:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laserna-2003">
<DESCRIPTION>
<P>No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-04 11:32:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pinto-1995">
<DESCRIPTION>
<P>No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-04 11:32:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1994">
<DESCRIPTION>
<P>No loss to follow-up</P>
<P>Only a subgroup of participants had symptoms of chronic hypoventilation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-29 10:22:49 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Struik-2011">
<DESCRIPTION>
<P>2 participants did not tolerate volume NIV and switched to pressure NIV after 2 days. 3 participants dropped out: 2 died (1 from cancer, the other from pneumothorax), and 1 did not want to return for measurements in hospital at 3 months<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 10:21:28 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Tuggey-2005">
<DESCRIPTION>
<P>All participants completed treatments sessions and none was lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 10:21:36 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Ward-2005">
<DESCRIPTION>
<P>There were 2/12 and 2/14 participants lost to follow-up in the control and experimental arms, respectively</P>
<P>Half way through the follow-up period (12 months), 70% of control participants received the experimental treatment NIV, as they worsened to meet criteria for mechanical ventilation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 10:21:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Willson-2004">
<DESCRIPTION>
<P>No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-07-01 10:21:45 +0100" MODIFIED_BY="Ruth  Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:35 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>Outcomes presented in the results section matched those reported in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Only preliminary data were published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:52 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Jaye-2009">
<DESCRIPTION>
<P>Outcomes presented in the results section matched those reported in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:20:58 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Laserna-2003">
<DESCRIPTION>
<P>Outcomes presented in the results section matched those reported in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:07 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Pinto-1995">
<DESCRIPTION>
<P>Outcomes presented in the results section matched those reported in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:14 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-1994">
<DESCRIPTION>
<P>Outcomes presented in the results section matched those reported in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:33:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Struik-2011">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:34:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuggey-2005">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:37 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Ward-2005">
<DESCRIPTION>
<P>Outcomes presented in the results section matched those reported in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 10:21:45 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Willson-2004">
<DESCRIPTION>
<P>Outcomes presented in the results section matched those reported in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-07-29 11:54:46 +0100" MODIFIED_BY="Ruth  Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-07-29 11:54:40 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-03-06 16:53:07 +0000" MODIFIED_BY="Ruth Brassington">Nocturnal ventilation versus no ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</TITLE>
<TABLE COLS="7" ROWS="23">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Nocturnal ventilation versus no ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> patients with neuromuscular and chest wall disorders and chronic hypoventilation<BR/>
<B>Settings: </B>ambulatory patients<BR/>
<B>Intervention:</B> nocturnal ventilation versus no ventilation<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No ventilation</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Nocturnal ventilation </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality at 1 year (or more)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.62 </B>
<BR/>(0.42 to 0.91)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>99<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>521 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>323 per 1000</B>
<BR/>(219 to 474)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>421 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>261 per 1000</B>
<BR/>(177 to 383)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Unplanned admission to hospital</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.25 </B>
<BR/>(0.08 to 0.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>38<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>526 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>132 per 1000</B>
<BR/>(42 to 432)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>517 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>129 per 1000</B>
<BR/>(41 to 424)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>No improvement of hypoventilation symptoms: long-term</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.43 </B>
<BR/>(0.18 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>51<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>885 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>380 per 1000</B>
<BR/>(159 to 911)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>900 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>387 per 1000</B>
<BR/>(162 to 927)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>No improvement of daytime hypercapnia: long-term</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.59 </B>
<BR/>(0.41 to 0.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>58<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>828 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>488 per 1000</B>
<BR/>(339 to 712)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>778 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>459 per 1000</B>
<BR/>(319 to 669)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in a footnote<SUP>3</SUP>. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Small unblinded trials.<BR/>
<SUP>2</SUP>There was strong heterogeneity across the trials, possibly related to populations with very different severity of illness.<BR/>
<SUP>3</SUP>Assumed control risk is based on actual control group risk as reported in included trials.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-07-29 11:54:46 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-05-31 15:43:13 +0100" MODIFIED_BY="Grade Profiler">Volume-cycled ventilation versus pressure-cycled ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Volume-cycled ventilation versus pressure-cycled ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> patients with neuromuscular and chest wall disorders and chronic hypoventilation<BR/>
<B>Settings:</B> ambulatory patients<BR/>
<B>Intervention:</B> volume-cycled ventilation versus pressure-cycled ventilation<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Volume-cycled ventilation</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Pressure-cycled ventilation</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Mortality at 1 year (or more)</B>
</P>
<P>Not measured - data reported for mortality at 3 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>111 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>143 per 1000</B>
<BR/>(11 to 1000)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.29 </B>
<BR/>(0.1 to 17.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Unplanned admission to hospital </B>- not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>No improvement of hypoventilation symptoms: long-term</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>No improvement of daytime hypercapnia: long-term</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes<SUP>2</SUP>. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Only one small sized and unblinded study with few events (one death in each group).<BR/>
<SUP>2</SUP>Assumed control risk is based on actual control group risk as reported in included trials.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-08-08 19:58:53 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2014-07-17 12:48:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Nocturnal ventilation versus no ventilation</NAME>
<DICH_OUTCOME CHI2="2.8424568743689353" CI_END="0.907462572306402" CI_START="0.41985679826182604" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6172554820744866" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" I2="29.638334427007706" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.04217127811113506" LOG_CI_START="-0.3768988103864697" LOG_EFFECT_SIZE="-0.20953504424880237" METHOD="MH" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="0.2414175961187136" P_Q="1.0" P_Z="0.014134634397350479" Q="0.0" RANDOM="NO" SCALE="103.31" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="48" WEIGHT="99.99999999999999" Z="2.453823487031524">
<NAME>Mortality at one year</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.045240561831161" CI_START="0.47107746014845764" EFFECT_SIZE="0.7017045454545454" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.019216254707836694" LOG_CI_START="-0.32690767514476726" LOG_EFFECT_SIZE="-0.1538457102184653" MODIFIED="2013-08-05 13:01:30 +0100" MODIFIED_BY="[Empty name]" ORDER="23658" O_E="0.0" SE="0.2033149097365047" STUDY_ID="STD-Bourke-2006" TOTAL_1="22" TOTAL_2="19" VAR="0.04133695252116305" WEIGHT="64.32300730943264"/>
<DICH_DATA CI_END="0.8784641683094214" CI_START="0.1264833730497411" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.05627594825276191" LOG_CI_START="-0.8979665611865629" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-08-05 13:01:30 +0100" MODIFIED_BY="[Empty name]" ORDER="23659" O_E="0.0" SE="0.4944132324730442" STUDY_ID="STD-Pinto-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.24444444444444444" WEIGHT="33.714758092586145"/>
<DICH_DATA CI_END="59.57376743870334" CI_START="0.12485388869486465" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7750550657040625" LOG_CI_START="-0.9035979265811878" LOG_EFFECT_SIZE="0.43572856956143735" MODIFIED="2013-08-05 13:01:30 +0100" MODIFIED_BY="[Empty name]" ORDER="23660" O_E="0.0" SE="1.573454027214515" STUDY_ID="STD-Rapha_x00eb_l-1994" TOTAL_1="10" TOTAL_2="9" VAR="2.4757575757575756" WEIGHT="1.9622345979812041"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-05 13:01:30 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.0" STUDY_ID="STD-Ward-2005" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3356737256602046" CI_END="0.818236022300479" CI_START="0.07679334262614256" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25066926259430516" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.08712140488903378" LOG_CI_START="-1.1146764282243646" LOG_EFFECT_SIZE="-0.6008989165566991" METHOD="MH" MODIFIED="2014-07-01 10:27:22 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" P_CHI2="0.5623373028882037" P_Q="1.0" P_Z="0.02188743492887702" Q="0.0" RANDOM="NO" SCALE="427.58" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="2.2923156581483184">
<NAME>Unplanned admission to hospital</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.21559756982024" CI_START="0.007612506378517477" EFFECT_SIZE="0.12987012987012986" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.34549088011869794" LOG_CI_START="-2.118472330463662" LOG_EFFECT_SIZE="-0.886490725172482" MODIFIED="2013-08-05 13:02:26 +0100" MODIFIED_BY="[Empty name]" ORDER="23657" O_E="0.0" SE="1.4473441867106782" STUDY_ID="STD-Rapha_x00eb_l-1994" TOTAL_1="10" TOTAL_2="9" VAR="2.0948051948051947" WEIGHT="35.604770017035776"/>
<DICH_DATA CI_END="1.1507784305812003" CI_START="0.08757641826072993" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.060991713170190684" LOG_CI_START="-1.0576128207493916" LOG_EFFECT_SIZE="-0.49831055378960054" MODIFIED="2013-08-05 13:02:26 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.6570738404061082" STUDY_ID="STD-Ward-2005" TOTAL_1="9" TOTAL_2="10" VAR="0.43174603174603166" WEIGHT="64.39522998296422"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.829270384902061" CI_END="1.0272233355881133" CI_START="0.17918744381722024" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4290285814877986" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" I2="47.77072917374695" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.011664876770372893" LOG_CI_START="-0.7466924258789558" LOG_EFFECT_SIZE="-0.3675137745542914" METHOD="MH" MODIFIED="2014-07-17 12:44:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14739572100658838" P_Q="1.0" P_Z="0.05747662894905742" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2705849359950655" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.8996685584284903">
<NAME>No improvement of hypoventilation symptoms: long-term</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1428080547619013" CI_START="0.24889957964437615" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.05797329272428513" LOG_CI_START="-0.6039758368517605" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2013-08-05 13:09:20 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.38883219541400654" STUDY_ID="STD-Jackson-2001" TOTAL_1="6" TOTAL_2="7" VAR="0.15119047619047615" WEIGHT="47.04805692830943"/>
<DICH_DATA CI_END="1.1860035707139571" CI_START="0.22300927454977915" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.07408599656537164" LOG_CI_START="-0.6516770750593109" LOG_EFFECT_SIZE="-0.2887955392469696" MODIFIED="2013-08-05 13:09:20 +0100" MODIFIED_BY="[Empty name]" ORDER="23661" O_E="0.0" SE="0.4263168208574835" STUDY_ID="STD-Rapha_x00eb_l-1994" TOTAL_1="10" TOTAL_2="9" VAR="0.1817460317460317" WEIGHT="43.86989841213917"/>
<DICH_DATA CI_END="0.8716921005220171" CI_START="0.0038451656863809818" EFFECT_SIZE="0.05789473684210526" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.05963688967481747" LOG_CI_START="-2.4150849419143903" LOG_EFFECT_SIZE="-1.237360915794604" MODIFIED="2013-08-05 13:09:20 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="1.383601845541428" STUDY_ID="STD-Ward-2005" TOTAL_1="9" TOTAL_2="10" VAR="1.9143540669856458" WEIGHT="9.082044659551403"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8047957983175638" CI_START="0.13938556744591157" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3349282296650718" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.09431429964930604" LOG_CI_START="-0.8557821925442884" LOG_EFFECT_SIZE="-0.47504824609679713" METHOD="MH" MODIFIED="2014-07-17 12:44:44 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.014465925887674456" Q="0.0" RANDOM="NO" SCALE="88.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0" Z="2.4454805303184393">
<NAME>No improvement of daytime hypercapnia: short-term</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8047957983175638" CI_START="0.13938556744591163" EFFECT_SIZE="0.3349282296650718" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.09431429964930604" LOG_CI_START="-0.8557821925442882" LOG_EFFECT_SIZE="-0.47504824609679713" ORDER="23651" O_E="0.0" SE="0.4472900096133733" STUDY_ID="STD-Rapha_x00eb_l-1994" TOTAL_1="10" TOTAL_2="9" VAR="0.2000683526999316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.285148310131305" CI_END="0.8611824712617091" CI_START="0.40673229219346907" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5918367346938775" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" I2="94.16657037062022" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.06490481850459864" LOG_CI_START="-0.3906913457545165" LOG_EFFECT_SIZE="-0.22779808212955757" METHOD="MH" MODIFIED="2014-07-17 12:44:49 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="3.5898666483902275E-8" P_Q="1.0" P_Z="0.006126898810929499" Q="0.0" RANDOM="NO" SCALE="9.28" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="2.740911605461995">
<NAME>No improvement of daytime hypercapnia: long-term</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2000599982148181" CI_START="0.8332916699894815" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.07920295958282342" LOG_CI_START="-0.07920295958282345" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-05 13:13:46 +0100" MODIFIED_BY="[Empty name]" ORDER="23662" O_E="0.0" SE="0.093048421039847" STUDY_ID="STD-Pinto-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.008658008658008642" WEIGHT="42.85714285714286"/>
<DICH_DATA CI_END="0.9321305287707723" CI_START="0.07093689879119124" EFFECT_SIZE="0.2571428571428571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-0.030523267951159557" LOG_CI_START="-1.1491278018707418" LOG_EFFECT_SIZE="-0.5898255349109508" MODIFIED="2013-08-08 15:05:23 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.6570738404061082" STUDY_ID="STD-Rapha_x00eb_l-1994" TOTAL_1="10" TOTAL_2="9" VAR="0.4317460317460317" WEIGHT="30.075187969924812"/>
<DICH_DATA CI_END="1.1507784305812003" CI_START="0.08757641826072993" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.060991713170190684" LOG_CI_START="-1.0576128207493916" LOG_EFFECT_SIZE="-0.49831055378960054" MODIFIED="2013-08-05 13:13:46 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.6570738404061082" STUDY_ID="STD-Ward-2005" TOTAL_1="9" TOTAL_2="10" VAR="0.43174603174603166" WEIGHT="27.067669172932334"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.556781312197242" CI_END="0.0874914733225447" CI_START="-0.6089210713010728" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.26071479898926403" ESTIMABLE="YES" I2="69.49722882659663" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2014-07-17 12:44:55 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.03768893780931781" P_Q="1.0" P_Z="0.14224093890887166" Q="0.0" RANDOM="NO" SCALE="4.51" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="1.467496874375597">
<NAME>Daytime PaCO<SUB>2</SUB>: long-term</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6629527288344758" CI_START="-0.42295272883447554" EFFECT_SIZE="0.1200000000000001" ESTIMABLE="YES" MEAN_1="6.14" MEAN_2="6.02" MODIFIED="2013-08-05 13:14:35 +0100" MODIFIED_BY="[Empty name]" ORDER="23663" SD_1="0.46" SD_2="0.61" SE="0.277021788725312" STUDY_ID="STD-Pinto-1995" TOTAL_1="7" TOTAL_2="8" WEIGHT="41.12909366812974"/>
<CONT_DATA CI_END="0.4232251196331701" CI_START="-0.76322511963317" EFFECT_SIZE="-0.16999999999999993" ESTIMABLE="YES" MEAN_1="5.33" MEAN_2="5.5" MODIFIED="2013-08-05 13:14:35 +0100" MODIFIED_BY="[Empty name]" ORDER="23664" SD_1="0.49" SD_2="0.78" SE="0.30267143902258103" STUDY_ID="STD-Rapha_x00eb_l-1994" TOTAL_1="10" TOTAL_2="9" WEIGHT="34.453560910144624"/>
<CONT_DATA CI_END="-0.3253274302501413" CI_START="-1.7346725697498573" EFFECT_SIZE="-1.0299999999999994" ESTIMABLE="YES" MEAN_1="6.86" MEAN_2="7.89" MODIFIED="2013-08-05 13:14:35 +0100" MODIFIED_BY="[Empty name]" ORDER="23665" SD_1="0.67" SD_2="1.08" SE="0.3595334278120544" STUDY_ID="STD-Ward-2005" TOTAL_1="14" TOTAL_2="12" WEIGHT="24.417345421725635"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.796205671835222" CI_END="401.43195048283195" CI_START="-84.43367676374055" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="158.4991368595457" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2014-07-17 12:48:06 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.37223028821414683" P_Q="1.0" P_Z="0.20098184858152512" Q="0.0" RANDOM="NO" SCALE="813.88" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.2787593211146882">
<NAME>Forced vital capacity: long-term</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ventilation</GRAPH_LABEL_2>
<CONT_DATA CI_END="909.0065660987578" CI_START="-159.00656609875784" EFFECT_SIZE="375.0" ESTIMABLE="YES" MEAN_1="1787.0" MEAN_2="1412.0" MODIFIED="2013-08-05 13:15:24 +0100" MODIFIED_BY="[Empty name]" ORDER="23666" SD_1="301.0" SD_2="514.0" SE="272.4573361097109" STUDY_ID="STD-Pinto-1995" TOTAL_1="3" TOTAL_2="6" WEIGHT="20.695654527306115"/>
<CONT_DATA CI_END="374.7958050431248" CI_START="-170.7958050431248" EFFECT_SIZE="102.0" ESTIMABLE="YES" MEAN_1="1198.0" MEAN_2="1096.0" MODIFIED="2013-08-05 13:15:24 +0100" MODIFIED_BY="[Empty name]" ORDER="23667" SD_1="251.0" SD_2="343.0" SE="139.18409072559663" STUDY_ID="STD-Rapha_x00eb_l-1994" TOTAL_1="10" TOTAL_2="9" WEIGHT="79.30434547269388"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.43249548990062" CI_START="-13.872495489900619" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.72" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2014-07-17 12:45:07 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.16908153091593128" Q="0.0" RANDOM="NO" SCALE="23.53" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.375161017317628">
<NAME>Respiratory muscle strength: long-term</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" MODIFIED="2014-03-05 19:44:09 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Mean improvement in maximal inspiratory pressure</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" MODIFIED="2013-08-05 13:15:43 +0100" MODIFIED_BY="[Empty name]" ORDER="23668" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Ward-2005" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.43249548990062" CI_START="-13.872495489900619" DF="0" EFFECT_SIZE="-5.72" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2014-03-05 19:44:17 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Z="0.16908153091593128" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="1.375161017317628">
<NAME>Mean improvement in SNIP</NAME>
<CONT_DATA CI_END="2.43249548990062" CI_START="-13.872495489900619" EFFECT_SIZE="-5.72" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="1.62" MODIFIED="2013-08-05 13:15:43 +0100" MODIFIED_BY="[Empty name]" ORDER="23669" SD_1="14.1" SD_2="6.1" SE="4.159512906464845" STUDY_ID="STD-Ward-2005" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.738163841233547E-31" CI_END="4.149031249074832" CI_START="1.8509687509251673" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2014-07-17 12:45:13 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="3.10005713910608E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="99.99999999999999" Z="5.117260264552845">
<NAME>Mean nocturnal SaO<SUB>2</SUB>: long-term</NAME>
<GROUP_LABEL_1>Ventilation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ventilation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.149031249074833" CI_START="1.8509687509251678" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="96.55" MEAN_2="93.55" MODIFIED="2013-08-05 13:16:04 +0100" MODIFIED_BY="[Empty name]" ORDER="23670" SD_1="1.2" SD_2="1.7" SE="0.5862512057049232" STUDY_ID="STD-Ward-2005" TOTAL_1="14" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="2">
<NAME>Volume-cycled ventilation versus pressure-cycled ventilation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.1356610089125" CI_START="0.09646906668088354" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.233900862018655" LOG_CI_START="-1.0156119231685188" LOG_EFFECT_SIZE="0.10914446942506807" METHOD="MH" MODIFIED="2014-07-17 12:46:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8491589854651994" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="9" WEIGHT="100.0" Z="0.19019161001751508">
<NAME>Mortality at one year (here 3-month data)</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.1356610089125" CI_START="0.09646906668088354" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.233900862018655" LOG_CI_START="-1.0156119231685188" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-08-07 13:17:03 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.3213749452868198" STUDY_ID="STD-Struik-2011" TOTAL_1="7" TOTAL_2="9" VAR="1.746031746031746" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.045572410139742" CI_START="0.4888607193972105" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.31081485746799004" LOG_CI_START="-0.31081485746799004" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-07-17 12:46:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>No improvement of daytime hypercapnia: short-term</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.045572410139742" CI_START="0.4888607193972105" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.31081485746799004" LOG_CI_START="-0.31081485746799004" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-05 13:25:37 +0100" MODIFIED_BY="[Empty name]" ORDER="23675" O_E="0.0" SE="0.3651483716701107" STUDY_ID="STD-Laserna-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.1333333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="30.55627707350103" CI_END="1.1005545670210182" CI_START="-0.20718435132085244" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.44668510785008286" ESTIMABLE="YES" I2="93.45470001077311" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.041611580345630894" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.34999852634245204" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="3" P_CHI2="2.3162849560609544E-7" P_Q="1.0" P_Z="0.1805928204469512" Q="0.0" RANDOM="NO" SCALE="4.01" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="5" WEIGHT="100.0" Z="1.3389319711102787">
<NAME>Daytime PaCO<SUB>2</SUB>: short-term</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="3.238697238229314" CI_START="0.7613027617706858" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-07 14:03:26 +0100" MODIFIED_BY="[Empty name]" ORDER="66" SE="0.632" STUDY_ID="STD-Laserna-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="27.864532892725208"/>
<IV_DATA CI_END="-0.9122199885802698" CI_START="-3.0877800114197305" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-07 14:02:39 +0100" MODIFIED_BY="[Empty name]" ORDER="64" SE="0.555" STUDY_ID="STD-Struik-2011" TOTAL_1="8" TOTAL_2="5" WEIGHT="36.132661914272774"/>
<IV_DATA CI_END="2.78973997540427" CI_START="0.6102600245957297" EFFECT_SIZE="1.7" ESTIMABLE="YES" ESTIMATE="1.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-07 14:03:06 +0100" MODIFIED_BY="[Empty name]" ORDER="65" SE="0.556" STUDY_ID="STD-Tuggey-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="36.00280519300202"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="8.765121169122353E-32" CI_END="87.0391356289613" CI_START="-7.039135628961297" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="40.00000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.939714569469955" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="1.6020599913279625" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.09558070454332195" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.666666666666667">
<NAME>Forced vital capacity: short-term</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="87.0391356289613" CI_START="-7.039135628961304" EFFECT_SIZE="40.0" ESTIMABLE="YES" ESTIMATE="40.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-08 18:13:52 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SE="24.0" STUDY_ID="STD-Tuggey-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.05850690381465019" CI_END="0.04253431849151368" CI_START="-3.990369563050371" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-1.9739176222794288" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-1.3712605213108509" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="5" P_CHI2="0.8088715972825307" P_Q="0.8088715972825307" P_Z="0.05503229025646355" Q="0.05850690381465019" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="1.9186212028626244">
<NAME>Respiratory muscles strength</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.5243499385106749" CI_START="-4.924349938510675" DF="0" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-0.28037877858836285" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-03-05 19:44:54 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Z="0.11348214802192796" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="54.78352445588579" Z="1.5827338129496404">
<NAME>Maximal inspiratory pressure</NAME>
<IV_DATA CI_END="0.5243499385106749" CI_START="-4.924349938510675" EFFECT_SIZE="-2.2" ESTIMABLE="YES" ESTIMATE="-2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-08 18:15:23 +0100" MODIFIED_BY="[Empty name]" ORDER="73" SE="1.39" STUDY_ID="STD-Tuggey-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="54.78352445588579"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.2987448963462833" CI_START="-4.698744896346283" DF="0" EFFECT_SIZE="-1.7" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.11352385392962132" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-03-05 19:44:47 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Z="0.2665205436096857" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="45.216475544114196" Z="1.1111111111111112">
<NAME>Sniff nasal inspiratory pressure</NAME>
<IV_DATA CI_END="1.2987448963462833" CI_START="-4.698744896346283" EFFECT_SIZE="-1.7" ESTIMABLE="YES" ESTIMATE="-1.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-08 18:16:23 +0100" MODIFIED_BY="[Empty name]" ORDER="74" SE="1.53" STUDY_ID="STD-Tuggey-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="45.216475544114196"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="3.1011650650038525" CI_START="-0.7011650650038526" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.4915248829456352" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.21604500853597963" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.2371134020618557">
<NAME>Mean nocturnal SaO<SUB>2</SUB>: short-term</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="3.1011650650038525" CI_START="-0.7011650650038526" EFFECT_SIZE="1.2" ESTIMABLE="YES" ESTIMATE="1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-08 18:25:35 +0100" MODIFIED_BY="[Empty name]" ORDER="68" SE="0.97" STUDY_ID="STD-Tuggey-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="198.64547086793664" CI_END="8.983864914233159" CI_START="4.675993342413726" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="6.8299291283234425" ESTIMABLE="YES" I2="99.49659058641976" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.9534632130392213" LOG_CI_START="0.6698738841504013" LOG_DATA="NO" LOG_EFFECT_SIZE="0.8344161971899157" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="7" P_CHI2="-1.3322676295501878E-15" P_Q="1.0" P_Z="5.136955693488158E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="6.214862669557825">
<NAME>Time spent with nocturnal SaO<SUB>2</SUB> below 90%: short-term</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.47935444044316844" CI_START="-4.479354440443169" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-07 14:16:31 +0100" MODIFIED_BY="[Empty name]" ORDER="70" SE="1.265" STUDY_ID="STD-Laserna-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="75.47241908799045"/>
<IV_DATA CI_END="38.34916008169438" CI_START="29.65083991830562" EFFECT_SIZE="34.0" ESTIMABLE="YES" ESTIMATE="34.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-07 14:17:57 +0100" MODIFIED_BY="[Empty name]" ORDER="69" SE="2.219" STUDY_ID="STD-Tuggey-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="24.52758091200956"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.8298755186721987" CI_END="-0.46321005253043046" CI_START="-0.8363750097102335" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-0.649792531120332" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="8" P_CHI2="0.36230859401131554" P_Q="1.0" P_Z="8.745209711421359E-12" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="6.825774681759978">
<NAME>Apnoea-hypopnoea index (/hour): short-term</NAME>
<GROUP_LABEL_1>Pressure</GROUP_LABEL_1>
<GROUP_LABEL_2>Volume</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pressure-cycled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours volume-cycled</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-0.12760684293738966" CI_START="-0.8723931570626103" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-08 17:47:25 +0100" MODIFIED_BY="[Empty name]" ORDER="71" SE="0.19" STUDY_ID="STD-Laserna-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="25.10373443983402"/>
<IV_DATA CI_END="-0.48440396170059397" CI_START="-0.915596038299406" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-08 17:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="71" SE="0.11" STUDY_ID="STD-Tuggey-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="74.89626556016597"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-07-29 10:22:50 +0100" MODIFIED_BY="Ruth  Brassington">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-07-17 12:50:35 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAPkCAYAAACDZrgPAABmc0lEQVR42u2dD4RVXd/+H5IkSSQZ
I4kkvUkiSZIxJMntMYaMW/J6xEiSJJIkIzGSJImRZCSRJMkYkmTkFhnJSCIjGUkkGUnW773W++7z
W2fN3mvtff7N+fP5cMyc2X/XXt/1vfZea8+6/mUc/vWvf/HpoE+zQZ0Qf9Ca/MttxNBhld9EdU78
EX/Q4kJChdKYSShA3UMV9UhFEgT/6shjA/EHCAkgJED8AUICCAnxR/wRAwgJ0JBJIkAMICRAQyaJ
ADEACAkgJED8AUICCEkr8ObNG4IGIYE8QpL2n6gLFiwoW+fOnTtmzZo1ZtGiRWbbtm1mcnKytOzH
jx/m4MGDdtmKFSvM8ePHzbdv3whyypjr2IqV/fv3m8WLF5slS5aYAwcOmC9fvjS03O5y93fF9Hxd
v3aMR4Skg55IHj58aM6cOVP6/s8//5jt27ebjx8/mj9//pjR0VGzYcOG0vLDhw+bixcv2mX6XLly
xfT19RHklDHXsc+fP2/OnTtXip/bt2+XxV+jhYQnOMoEVQqJGvLmzZvtU0bCwMCAGR4eztxGd23a
zt3H0qVLg8H08uVLs3LlSrN169ayhLJs2TJ7V6qnGpdfv37Zpx7dta5fv95MTEyULT916pTdTst3
795tPn36FDyezvHIkSP2PLu6uuwTl3t9Hj9+bBYuXGifzDZt2mSePXtGQ67TsXt7e83bt29L33//
/m327t2buZ8PHz6UnmBUR4qHBw8elMVfqG5jy5Pf0+aL8ssQi7ubN2+a1atX2zjSuT558iR3ORAS
aFkhuX79+py7QTWEUF+xLyRK+n6XgB9MR48etdt8/vy5dFw1Ov1NiUSNW085CWfPnjX37t2zvz96
9KjsiejSpUvm6tWrpTta7UuiEzre5cuXzYULF+zf1I2yc+fOsiB3G/3Y2JhZu3YtDblOx1ZCd+Mn
+VsWutHRU3FS36p73SQkxOo2tjzrd/97nriTUCTionhSXOUtB0ICLSskCm51Ybko+JVMdceku6f+
/v6yMRA1HnVnqTHMzs6aY8eOzRlj8YPJvXMTW7ZsmZNM3OQt4fCXJ2zcuNGKlytkGqsJHU9PJu42
r169KgtyNehEuGjI9T22m1xDfwvhxlusbmPL8wpJJXEXu/5uORASaEkhmZqasgPpaZU/ODhovn//
XrrzUndXgkRFA6Rq/OvWrbOiE3siSUscoQH/UGJJEy13/azj+V167noqg75L4NR/T0Ou37Fj9ZeG
uir1lKo4VEL3nyZDdRtbnldIKok7/2+hciAk0JJCoqcK9fmmdT24d15qeCGhUH+3+p6LBFPoCSaW
WNKWxRpkbJukkasbbc+ePebkyZM05Dp2beX5W8KtW7fsE+rIyIgZHx+33ZUhofCPXSReQkJSSdy5
f4uVAyGBlhQSvWmlxOnjD3xKSNTFlcX9+/fLnljyBJMGtPXEk4WedLK6trSt38XgCl3a8fQWmruN
xC/r+uhV53ZpAM0oJBLqnz9/lr6re1QD11lIZNxYUVesu+9Y3caW5xWSSuLO/VusHAgJtKSQaEwi
GYx20ViBPu7rvW4XmO6qJB5Cb6IoMajfuUgwaeAyGQDVR9/dZKLHf3U3iadPn84ZbE/GaPS5du2a
FZ7Q8TTIOTQ0VBpw7enpKVtP+9ebW8IfJKUh1/bYelvPrXvdoYe6E/XyR/J2k0RAsejuO1a3seXu
77ph0jhHIhj+YHvRuHP/FisHQgItKSRKlll3/WowGoDWHZfeRHn37l1pmURDA5jJGElskDrrPPS2
mO7SkmO4oqa7VA3y6xjqS/aFKnkNUx8N/r9//z56PL3SrMFRvXKscR93PXVr6TjJa5uJqNCQa39s
1bOSuepdn3379gX/ofX58+f2pkf1IsFXvPn7DtVtbLn7u94cTM4rrQxF4879W6wcCAm0pJBARwQB
SQSIAUBIACEB4g8QEkBIgPgDhARoyCQRIAYQEqAhk0SAGACEBBASIP4AIQGEBIg/QEiAhkwSAWIA
IWkIzWJd2qkWqghJe9FqcUwMtLGQVOoeVwkh69LETEoz7tbiuKHt59NCdT4bHUJS//PtxPaEkCAk
Da380L58B7l6His0GR9CgpDU83zbsT0hJAhJIRtSEbLEDdmLhqxL89iaho6b57zdc0w7luYTy7JF
zbIHjlmtxhqSyqRzXr58uXXI8+daCp1TuwhJu1kvd1p7QkgQkjmVG7MhjVnixuxFQ08CoWWx48bO
O88TiSYLDJ23b9ebx2o1dFyVRz4nyTnv2LFjzvUInVM7CUk7WS93YntCSBCSQjakMUvcmL1opYEf
O27svPMISey8/eV5rFZDx5UvxszMTOY5V2LV2qpC0k7Wy53YnhAShKSwTWnIEjeWPCsN/KJWvP55
5xGSIuctqrVa9QdKQ5av7S4kadexVa2XO7E9ISQISSH70Jglbr0CvxIr3noLSbVWq0W8wztNSFrZ
erkT2xNCgpAUsiGNWeLWK/Bjxy1inVsrISlqtepbqcoRT/3PCa9fv0ZIctZ3M1svd2J7QkgQkkI2
pDFL3Fjgh6xLQ4EfO27svH1C55FXSGJWq+4A7fT0tB00DQ22qzwISb76bmbr5U5sTwgJQlLYpjRk
iRsL/JB1aewpIXTcPOftErNQzSMkImS1miQcdSMokSkR+ftRY9X56hVLnXPszrlThCRW381svdyJ
7QkhQUigSVBy7O7unpdkPp9CAh2VhLgICAnUEt3tafA2eZdfd9GhQVyEBBASQEigjPHxcfu+vroW
9J/tJ06csIKCkABCAggJ0JBJIkAMICRAQyaJADEACAkgJED8AUICCAkQf4CQAA2ZJALEAEISplNt
a2nItTl2J8YPVs/QEUJSZF1/FluCiYZc5NidaHvcCmVGSKChQlI0OAgmhCT0904QklYoM0IChYQk
Zqv54cMHOxePJojTPEOyNn3w4EEpMHxLz9D6yTaaaC6xSt27d2/ZXEmx7WO2pyELUYKguYSknW2P
s86nkjLH4jrrmhB/0DAhidlqbt682c4GmswUqkamgM0KjjzrJ+6AWn7//n1z6NCh3NuHbE9jFqIE
QWs8kbS67XHR84ntP48lr39NiD9oqJBUYqsZc3GLre8+gSj45TyXd/uQ7WnMQpQgaA0haXXb46Ln
E9t/JZa8xB80VEjy2GrqsVkeEAMDA7aRxKZYL7q+fw6h7UO2pzELUYKgNcdIWs32uOj55HHTLGrJ
S/zBvAqJX+G3bt2yxj4jIyN2okE9OocaWdH1/YYc2z4RmjTbU0SjM4Wk2WyPi55PbP+VWPISf9BQ
IYnZamoA0rXl9C1j/f3mWX9qaqrssd/14Yht7+LbnsYsRAmC9hSSZrM9Lno+sf1XYslL/EFDhSRm
q6k3SZK3piQyanQhu8/Y+vq9t7fXfP361R5TA/3uYHts+5DtacxClCBoPiFpR9vj2PkULXMllrzE
HzRUSETIVvP58+d2YE+NUUlcA90hu8/Y+vpdx9CxtI1ExR0ojG0fsz2NWYgiJM117Ha1PQ6dT9Ey
x+IaIYGmEBJASEgi/59G2B4Tf4CQAA25jZLIfNgeE3+AkAANuY2SyHzYHhN/gJAADZkkAsQAQgI0
ZJIIEAOAkABCAsQfICSAkADxBwgJ0JBJIkAMICRAQyaJADEAbSAksXMkEBESIP4AISHQEBIg/qDd
hKQa69o8trq+BagmqktsdrX+xMRE2foxm1X3d022F7MnzbJPpSE3x7Fj8VeNhW7R+IvFe+xcASHp
WCGpxro2j62ubwEqw6rE4VDTUmhiRnf9mM2q+7tELGvdmH0qDbk5jh2Kv2otdIvGXyzeQ+cKCElH
C0mtrWt95zbfAlQN199naP2smV9j68bsU2nIzXHsUPxVa6FbNP5i8R46V0BIOlpIqrWurdZWNxZo
ISEJrRuzT6UhN8exQ/FXrYVu0fiLxXvoXAEh6WghScSgEuvaSmx1GyUkebzoacjNceys+KvWQrdo
/OWxas46V0BIOl5IEopa1xa14RUyFgp1bdVKSGL2qTTk5jt2WvxVY6FbNP6KWDX75woISUcLSTXW
tXlsdX3UDaYuAvH06dM5g+21EpKYfSoNuTmOHYu/aix0i8ZfLN5D5woISUcLSTXWtXlsdX3kPtff
32+30XE1CF4PIREh+1QacnMcOxZ/1VjoFo2/WLzHzhUQErq22hzsU/mHREBIACEpBPapCAkQf4CQ
VAX2qQgJEH+AkABCAsQfICRAQyaJADGAkAANmSQCxAAgJICQAEICCAkgJED8AUICCAkQf4CQAA2Z
JALEAEICNGSSCBADgJAAQgLEHyAkgJAA8QcICdCQSSJADCAkQEMmiQAxAAgJICRA/EH965CKpBFz
DkDdQ9VCQoXSiDkXoM6haiFJKpZP53yaMbHwIf6gxYWEOyMA4g8AIaEhA/EHgJDQkIH4A0BIaMgA
xB8gJDRkAOIPACGhIQPxB4CQ0JCB+ANASGjIAMQfICQ0ZADiDwAhoSED8QeAkNCQgfgDQEhoyADE
HyAkNGQA4g8AIaEhA/EHgJDQkIH4A0BIaMhA/HERACGhIQMQf4CQ0JABiD8AhISGDMQfAEJCQwbi
DwAhac2GzIfPfH4AEBLgjhoAEBIAhAQAEBJASAAAIQGEBAAQEkBIAAAhAUBIAAAhAYQEABASQEgA
ACEBhAQAEBIAhAQAEBJASAAAIYHmExDmjAIAWj4gJACAkEBziAkAICQACAkAICSAkAAAQgIICQAg
JNBpYgIACAkAQgIA7S8keHvz4YMPPCAk3PUC0GYAIaFBACAmAC0kJDQEANoQICQ0AgDaECAkNAIA
hAQAIQFASAAQEgCgDQFCQiMAoA0BQkIj6DzevHnDRWjR60AbAoQk0AhOnTplli5dahYvXmz6+/vN
zMxMaZl+//e//20WLVpUWv7ly5fS8h8/fpiDBw/a5StWrDDHjx833759I0n8H48fPzYLFy40W7Zs
sd91nVqtPO6+arXfRl0HhAQQkgY0guHhYXP16lXz588f+xkaGjK7d+8uLe/p6TF3794tLdfvvb29
peWHDx82Fy9eLC2/cuWK6evrI0n8HxKRJ0+eNDwZ1UtIOjkpIySAkGQ0grVr15qfP3/OSX5pv6f9
TXeWEpAE/a6nm9B5vHz50qxcudJs3bq19Pfz58+bZcuWmSVLltinGpdfv37Zpx49Ea1fv95MTEzM
eaLSdlouEfz06VPweDrHI0eO2PPs6uoyd+7cKbs+yVPEggULzKZNm8yzZ88yy/Phwwezf/9+e2xt
o/N78OBB6dh55nAKlT3rernEypNW9/7yW7du2SdKncPRo0fN7Oxs9IkkVC9Frkue61CkThASQEjm
sRF8//7dNuaBgYE5TyQJ9+7dM7t27coUEiWXULeFzkOJStt8/vzZ/u369evm5s2b9m+/f/+2iVBP
OQlnz561xxWPHj0yGzZsKC27dOlS2ROV9qXkFjre5cuXzYULF+zf1E23c+fOsuvjPkWMjY1Zsc1i
8+bNZnR0tHR8nYuSftZ197/Hyp52/j6x8uQREnW9SYC1D8XAsWPHokISqpei1yV2HYrUCUICCMk8
NYIDBw7YO0F9Xr9+Xfr71NSUWb58eenuUb/rbwlK2urOUgLQXawSkO4aQ+fhPjEIJTFXjJInpQQl
KH95wsaNG614uUKmO+vQ8XRn727z6tWrsuujhJckyEpwyx8TkljZ087fJ1aePELiPk3oCbW7uzsq
JKF6KXpdYteh2jpBSAAhaWAjUDeRug4S1D2hu/7kzlJjKu4YiAbWJUK6Y1y3bp29W4w9kaR1lfnd
HW7SSeteS0tOaetnHc/vGnLXUxmSu/Rz585Fr5m6nnR3ric5CVsoifvfY2XPU2+x8uQREj+JZ11D
/8mtVtcldh2K1glCAgjJPDYCdSvExkDU753F27dvbT99kfMIPcHEElbaslgSjW2TJEF11+zZs8ec
PHky8/gaW9Cd+cjIiBkfH7fdT0WEJFb2SoQkzzUoco0qEZKi1yV2HYrUCUICCEmDG4G6DNzXef2u
IV80JCTq/sri/v37ZWMsec5DT0Aan8lCTzpZXSja1u/acp+I0o63ffv2sm0kflnXZ3JyMphANMDt
nvvHjx8LCUms7HmSV6w8/j7SzlHldJ8y3RcmsvYVqpei1yV2HYrUCUICCEmDG4G6stRVkHRdnT59
2n4SNNCru0o9qWi5Bnb1hlCC7jolHkJv6uhuUX30Rc5DXWfJYLE++u6+gqzuEXVtiKdPn84ZbE/G
aPS5du2aTXCh42kQWK85J4PTeqHA7/vXW0JCA7yhO+/Vq1eX3kZSAt+2bVswYUqYNeaRJP5Y2fMk
r1h53IHq6elp213pn6OOqW2TGHC7L0OD7Vn1ErsuRa9DkTpBSAAhaXAjkEBILHQXrycNCYuLBtCT
5fpIRNxXQyUaGuxNxkhiA6JZ53HmzBl7F6tjKNG5byjpePpHSB1Dfe2+UCWv/+qjwf/3799Hj6ex
Hj156XVTvTHkrqcuFB1H3S06ZpLA0nj+/LkdFNZ6SnYqf0hI9CZSci3zlD1v8gqVJ0m8Ko/qSOXx
z1FJf9WqVfYJ9cSJE2X/VJpVnlC9xK5L0etQpE4QEkBIaARAbHCdACGhEQAJkusEgJBAx9CK817R
hgAhoREAICQACAkAQgKAkAAAbQgQEhoBAG0IEBIaAQBCAoCQACAkAAgJjR2A2AKEhEZAYwdiCxCS
BjeCSqxvtY0mctTcTjK6koOiJtnTPEm+R7lIs8L98eOHNU9y5+0SmsTP9UMJnUfMYhYAIQGEpEFC
UtT6VtscOnTILnv48KFN5IcPH7bf/ZlZQ1a4g4ODdrmLZheWeOQ5j5jFLABCAghJg4SkqPWtv42+
u14S7rFCVriy7NVTSXIs/VyzZk1p37HziFnMAiAkgJA0SEh8itq/hr7HrHB37dplnzqEfDU0fXje
84hZzAIgJICQzJOQFLV/DX2P2cDKOnX9+vX2d42NyJY173nkscwFQEgAIZkHISlq/xr6HrPCFXLT
03iHurWKnEcRy1wAhAQQkgYKSVH719D3mBWu0AC63rpyB9LznEfMYhYAIQGEZJ6ERBSxf419D1nh
iq9fv9rjSAyKnIcIWcwCICSAkNAIAGhDgJDQCAAQEgCEBABoQ4CQ0AgAaEOAkNAIAGhDgJDQCAAQ
EgCEBAAhAUBIAIA2BAgJjQCANgQICY0AACEBQEgAEBIAhAQAaEOAkNAIAGhDgJDQCABoQ4CQ0AgA
EBIAhAQAaEOAkNAQAGg7gJDQIABoM4CQNHXD4MOHT74PAEIC3PkCAEICCAkAICQACAkAICSAkAAA
QgIICQAgJICQAABCAoCQAABCAggJACAkgJAAAEICCAkAICQACAkAICSAkAAAQgIICQAgJICQAABC
AggJACAkAAgJACAkgJAAAEICCAkAICSAkAAAQgKAkAAAQgIICQAgJICQAABCAggJACAkAAgJACAk
gJAAAEICCAkAICSAkAAAQgKAkAAAQgIICQAgJICQAABCAggJACAkgJAAAEICUJGA+B8AQEgAEBIA
QEhgfsQEABASAIQEABASQEgAACEBhAQAEBLoNDEBAIQEACEBAISkGRIqn875AHFP3CMk3JUDdc41
gBrUOVFAYwLqnrJDVXVPJNCYgBigzFBVDBANNCggBigzICQ0KCAGKDMgJDQoIAYoMyAkXEwgBigz
ICRAgwJigDIDQkKDAmKAMgNC0iYN6tSpU2bp0qVm8eLFpr+/38zMzJSW6fd///vfZtGiRaXlX758
KS3/9u2b2b9/v122ZMkSc+DAgbLlJBzK2Ixl/vnzpxkcHLQxq9hWXCuWE75//577v6Xv3bvXste2
0+IeIalTwAwPD5urV6+aP3/+2M/Q0JDZvXt3aXlPT4+5e/duabl+7+3tLS0/f/68OXfuXGn57du3
zZkzZ2hQlLGpy3zs2DFz7dq1UtzqZkpikvDo0aOy71lMT0/b9oKQICQd3aDWrl1r785cFi5cmPp7
2t8kKm/fvi19//37t9m7d2/wPF6+fGlWrlxptm7dWiZIy5Yts3eIx48fL9vm169f5uDBg/apZ/36
9WZiYmLOE5W203I16k+fPgWPp8Rx5MgR+xTW1dVl7ty5U3Z9Hj9+bMu4YMECs2nTJvPs2TOEpM3K
vHz5chsHbtzqySRBN1RXrlyJ7n/Pnj3m3bt30WtL3CMkHZNE9DivwB4YGJjzROI+xu/atav0XUHp
Nsjkb6HzOHr0qN3m8+fP9m/Xr183N2/etH9Tg1aAX7x4sbTN2bNn7XGTO8UNGzaUll26dKnsiUr7
UuMLHe/y5cvmwoUL9m/qhtu5c2fZ9VFjevLkif19bGzMii1C0t5lVtJW0k3o6+uzN0lK8opnJW0f
iY1iL89xiHuEpCMalMY2dHejz+vXr0t/n5qasndvSR+xftff8j6xpJ2He+cktmzZMkeM3CBWA/KX
J2zcuNEmATchrFixIng83aG527x69ars+iihJA2Yrq3OKLO6ZJW4E1atWmX/ltzJ37hxo2z5P//8
U9bFm0dIiHuEpGMalO689FiboIF03f0kdz4aU9HdWoIeg4sKSdr6/qCmu9/Q/mLHzzqei8rlrqe7
MX1XQ9f4D0LS3mX++vWrvZHSU0EWihGJi/jx44dNyu5LKXmEhLhHSDomiagxuQGnfmP3rki/q082
1I0V69rK0yjyClPasrLAydGg0tZT/7K6E9QHfvLkSYSkTcuseP/7779zvWmYxOmhQ4fM/fv3Cx2H
uEdI2rpB6XHWbUT+I7IrGomQqPsrQQHnDtbPzs6WvfWV5zz0BKTxmSzWrVuX+Yivbf1HfHfQNO14
27dvL9tGLwtkXZ/Jycm2ScAIydwnEb0C/PHjxznL1Ab05OHGlQa8k30WNREj7hGStm5Q6spyX989
ffq0/SRowG5kZMTeuWm5Buz05keCBueTATx9tG7osTjtPNR15u5D310xUt+0HrvF06dP5ww66u2a
ZFu90qkGGDre6OioHShNBh31QoG7nvavN1iEBh9Dd4YISWuW+cWLF/alEbd7yuXEiRM2tpO40iC4
YqvSa0vcIyRt3aAkEBIL3c3oScN/O0VPGMlyfSQi+luC3ghRQCbL9+3bV/aPXXnPQ/97oi4x7UPj
MsmbJsk56J1+BbYGGTVI6Ith8qKA3lx5//599Hga69Fdp97K0Rsv7np6vNdx1PWgYyaNCyFpnzJ3
d3cHnygUc4cPH7bxqBdMlPCrubbEPUJCEgFigDIDQgI0KEBIACEBGhQQA5QZEBIaFBADlBkQEhoU
EAOUGRASkggQA5QZEBKgQQExQJkBIaFBATFQfZmK/kc5ICRAEgFiYI6QZP1jIXEPCAlJhHLX4VqE
5opqx0+rxNp8b4+QAEFGuXkimecnEoQEIenYJBKy1wxZfVZiHRpbrn3KMW716tWl+X4Sx7Y828es
RIkBxkjyxJK8STRJottGEvvoWJsIHdf9W55YJdYRkpZJIiF7zZDVZyXWobHl2qcmrkuc3fwZSGPb
x6xEiQHe2soTS4rnbdu22WWaOFFtInEFjbWJvEISi1ViHSFpqQYVstcMWX1WYh0aW562T/e8Y9vH
rESJAYQkbywpkStZK3kfO3Ysd5vIKySxWCXWEZKWalAhe816WOaGlscaX1FrUt9KlBhASPLGUpLM
NeW6DLCKtok8sRyKVWIdIWm5JJJlr1lUSGLWobHlscZXiTUpjQshqSQWhbx19ATSCCEh1hGStkki
vr1myOqzEuvQ2PJY44ttX8RKlBjo7DLHYkmOgxqjkOOn27WVt034x5Wdr/u3WKwS6whJSzWokL1m
yOqzEuvQ2PKYkMS2j1mJEgMISZ5Y0mD7jh07ypL6u3fvCrUJ9yWW6elp+xKJuzwWq8Q6QtJSDSpk
rxmy+qzEOjS2PCYkefYfshIlBhCSPLGkmHdf/9XvWl6kTSQ3ZWpXeopRu/LPJRarxDpCQhIBYoAy
A0JCgwJigDIDQgI0KEBIgLhHSGhQQAxQZkBIaFBADFBmQEhoUEAMUGZASLiYQAxQZkBIgAYFxABl
BoSEBgXEAGUGhIQGBcQAZQaEhAYFxABlBoQEaFBADFBmQEhoUEAMUGZASGhQQAxQZkBIaFBADFBm
QEiABgXEAGUGhIRGBdQ9ZYc61T2RQKMC6pxrAFXVOVFQ4wvMp3M+QNwT9wgJcFcKALXIAVwCQEgA
ACEBhAQAEBJASAAAIQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQAEBJASAAA
IQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQAEBJASAAAIQGEBAAQEkBIAAAh
AUBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQAEBJASAAAIQGEBAAQEkBIAAAhAUBIAAAhAYQEABAS
QEgAACEBhAQAEBIAhAQAEBJASAAAIQGEBAAQEkBIAAAhAYIIIQFASAAQEgBASAAhgXmrfz6d80FI
ACEB6h5qXudEAZBMgHqHquqeSAASClDnUFUMEA1AUgHqHBASIKkAdQ4ICZBUgDoHhAQIKKDOASEB
IKkAdQ4ICZBUgDqP8+bNm6baT733iZAASQVaqs5nZ2fNunXrUpfduXPHrFmzxixatMhs27bNTE5O
Zu7n8ePHZuHChWbLli3Fk1vkHHX8WlCr/YT2mbeNNbItIiSAkEDd6vz379+mr68vdZ1//vnHbN++
3Xz8+NH8+fPHjI6Omg0bNmTuSyLy5MmTypJbJC5rFbf1iP9K94mQAEICbVHnu3fvNtPT06nrDAwM
mOHh4dzH8Od4Sp2eI0M8QueYNX/U+fPnzbJly8ySJUvM8ePHS38/cOCAefr0admT0t69e3PNQ/Xh
wwezf/9+s3jxYiuM69evNw8ePCg7l5cvX5qVK1earVu3Rsv969cvc/DgQbs/7WtiYiKzzFnlcZ/2
FixYYDZt2mSePXuGkABCAs1R5+Pj45nrrF69ulD//5ypOGokJGnLr1+/bm7evGmflPRUpS64ixcv
2mWfP3+23XBapm67tWvXmqmpqVzH2bx5s33y0rb6XL161YqGex5Hjx61y3ScWLnPnj1r7t27Z39/
9OhR2ROdu16oPP7T3tjYmC0TQgIICTRVnaeto+SlpKU7ad1R9/f3m2/fvjWFkGgcRknXxU2uSsyX
L1+2yfjYsWNVxb+eAtztP336lLvcEg7/PNPWi5VHYpYIUrUxQAYAhAQaJiT62+DgoPn+/btNckrO
6u5qBiGRyPndSm7CT5LzihUrzNevXwtdC3Vd6UlCZd24cWP0PEPl1nnmKVOsPBJ0/U1lOnfuHEIC
CAm0hpAsXbrU9vEnSExCbz3VQkiyxjH8ffmikca+ffvsE0ERIbl165bdZmRkxHb7qfuqEUKSpzwS
OHWP7dmzx5w8eRIhAYQEml9INEDtIiFRF1elQqK3v2r1RKIBZz0pZXHt2jU75iBBKNK1JfF09xs6
5zzl1mvVebq2YuVx0SvYRdsxQgIICcyLkKhPXp9k4PnKlSt2EDvvPtwBYr0ZprehKhUSCZjGJpIn
pEuXLpkLFy6Uzk3f9Qaa0FPEjh07ypL0u3fvUvfjoxcMkre03r59a8sbO09/n/5gu7qlhN4kyxps
D5VHaDu9uSV0TUNPOggJICTQNEIiJB4a6FWXloQgSch59pEkPHXb6M5cibBSIdGguc7B7Vo7c+aM
fYJIzi15i0ovBbiv/+p3Lc/aj8vz58/tILfOW8lbQho7T3+f7jp6a0zno/1pvOXVq1eZ+8oqj1C3
lrbXtdS+ElFBSAAhAeocGh4DRAOQVIA6B4QESCpAnQNCAiQVoM4BIQECCqhzQEgASCpAnQNCAiQV
oM4BIQGSClDngJAASQWoc0BIAEgqMO91Xu2x5nt7hASAhgYICRWOkABCAo2s86J2tSKvfWxsplxN
TnjkyBE7v1RXV5d1BSxiPxvbnlhHSAAhgTrXeaV2tXntY2NCIgfDZMbbL1++mJ07dxayn41tDwgJ
ICRQ5zqv1K42r31sTEi2bt1aNp27ZsYtYj8b2x4QEkBIoM51XqldbV7Xv5iQ+PuRaBSxn41tDwgJ
ICRQ5zqv1K62XkLiL4+dX2x7QEgAIYE613mldrV57WNjVrvbt28v65qSI2ER+9nY9oCQAEICda7z
Su1q89rHxqx2R0dHzdDQUGmwvKenp5D9bGx7QEgAIYEG1HkldrV57WNjVrtieHjYjsHoFV8N7hex
n41tT6wjJICQAHUOCAmQVIA6B4QESCpAnQNCAkBSoc6BGEBIgKQC1DkgJEBSAeocEBIgqQB1DggJ
EFCEEXUOCAkASQWoc0BIgKQC1DkgJEBSAeocEBIgqQB1DggJAEkFqHNASICkAtQ5ICRAUgHqHBAS
IKkAdQ4ICQBJBahzQEiApALUOSAkQFIB6hwQEiCpQHvX+ffv3+0y/wMICQBCArnq/NGjR6a/v58L
hJAAICRQWZ0PDQ2ZK1eu5NrHmjVrzNevX+3vHz9+tPv8559/7PeZmRm7POH8+fNm2bJlZsmSJeb4
8eNzzuXly5dm5cqVZuvWrbm2AYQEEBJo0jrv6+szvb29NoEvXbrUnDp1KnMff//9t7l//779/e7d
u2bRokXm+vXrpe8HDx60v+tvN2/eNH/+/DG/f/82d+7cMRcvXiw7l6NHj9rlnz9/zrUNICSAkECT
1vmqVavM7du37e9K4jdu3DBnz55NXffWrVtmcHDQ/v6f//zHDAwM2I84dOiQTf5iy5Ytdl8ua9eu
LTuXT58+lS2PbQMICSAk0CJ1rmQucUljamrKbN682f6+adMmMzk5abq7u+339evX2+4usXDhwjmD
9wsWLAieS2wbQEgAIYEWqvNQAl++fLn58uVLSUBWr15t3r59W/oe2z7rXBANhAQQEmjROl+xYoX5
8eNH6fuvX7/s00UWGlP57//+71KXVtK9lXxPnlb0WnGRc4ltAwgJICTQpHV+4sQJ+7aUurT00QD3
tWvXMvejN7wkPsk6GlNZvHixHShPuHTpkrlw4UJpn/q+e/fu4LnEtgGEBBASaNI6n52dNYcPH7Zv
YKnbSsk8xIsXL8pe+3316pX9/u7du7L1zpw5Y98C0373799fejsrdC6hbQAhAYQEqHNASICkAtQ5
ICQAJBXqHIgBhARIKkCdA0ICJBWgzgEhAZIKUOeAkAABBdQ5ICQAJBWgzgEhAZIKUOeAkABJBajz
zilzPa9lo/ZNBgCSClDnbVpmhAQIVmi5OtffNeGipoPXVO7yBXny5EnZOnJNlP2tJmfURIquKVWe
7dOO6Vvtfvjwwc6vpWNoH5qB+MGDB7mPo4kejxw5Yufq6urqsiZbfplj5RgZGbETUmrOMTk+auJI
7c8/lrvfx48f2+U6J81g/OzZs7JjhuyD85wzQgIICbSEkCiBJ0lVCVOJMUHJ9OrVq6VZeWWJm1jq
5tk+65i+1a4Ms0ZHR0vH0TElNHmPc/ny5dLswfJL2blzZ1mZ85RDLo+y+X348KFN7prMUt/9Y7n7
dUVmbGyszNUxZh8cO2eEBBASaBkh8W1v3XU3btxoPUoS9Lvu2vNun/eYafiuiqHj6MnGPc9kVuJK
y6Hvrj9KWRJ2fpfY3bt3L/X8Y/bBsXNGSAAhgZYRktDf0pwLs+7OiwhJGurukl+8TLKU+LOSd9aT
gd9tVE05Qt/d3/UUou8SjXPnzs3Zf8g+OHbOCAkgJNAWQpLWTZU3wftJNLTNrVu3zIYNG+w4xfj4
uO3yqkZIqi1HXiFJBPDRo0dmz5495uTJk0HxyhKyRrRNhAQQEpgXIdEAst8lJOOpWj+RaEzC7Ur6
+PFjISHZvn172XnKR76achQRkoTJyck5xwzZB8fOGSEBhATaQkg0SC173WSQWha769atq7mQ6G2s
5C0tJdRt27YVEhIN1A8NDZUGrnt6eqoqR14h0VOU3twSaS8qhOyDY+eMkABCAm0hJCJ5bVYfven0
/v37mgvJ8+fP7UC0ErGSswawiwiJGB4etgPoet1Wb0xVU468QqJuLY3nJK8kJ6KSELMPjp0zQgII
CVDn0JQxQDQASQWoc0BIgKQC1DkgJEBSAeocEBIgoIA6B4QEgKQC1DkgJEBSAeocEBIgqQB1DggJ
kFSg8+r8zZs3XByEBAAhgcrr3J1vqhbxQmwhJICQQIfVea1jgdhCSAAhgQ6q87Rp3tNscN1t81ji
JsRsaAEhAYQE2vCJJM0G110njyVuQsiGFhASQEigjYWkqHWub4mbELKhBYQEEBJoYyGJrZPXEjdk
QwsICSAk0KFCUtQSN8uGFhASQEigQ4WkEktc4dvQAkICCAm0SZ3r7SuNiSTe4TEhKWKJG7KhBYQE
EBJokzq/ePGi/afE5B8TY0JSxBI3ZkMLCAkgJECdA0ICBBRQ54CQAJBUgDoHhARIKkCdA0ICJBWg
zgEhAZIKUOeAkACQVIA6B4QESCpAnQNCAiQVoM4BIQGSClDngJAAkFSAOgeEBEgqQJ0DQgIkFaDO
ASEBkgpQ54CQAJBUqHMgBhASIKkAdQ4ICZBUgDoHhARIKkCdA0ICBBRQ54CQAJBUoBZ1furUKbN0
6VKzePFi09/fb2ZmZuoeO9XuZ763R0iApIKQUOf/x/DwsLl69ar58+eP/QwNDZndu3c3fQwiJAgJ
ICTQJHW+du1a8/Pnz7K/LVy4MF8y+p/fb968aVavXm0WLFhgt3vy5Elp+a9fv8zBgwftk8769evN
xMRE5n5Cx5HAHTlyxD41dXV1mTt37szZ5vz582bZsmVmyZIl5vjx42XL8myPkAAgJFCDOv/+/btN
yAMDA7mFZP/+/ebTp0/2u0TEFaGzZ8+ae/fu2d8fPXpkNmzYUJGQXL582Vy4cMEKwpcvX8zOnTvL
ll+/ft0Kmpb//v3bCsXFixdzb4+QACAkUIM6P3DggL2b1+f169e5hSQRkbTlEg4l7zz7CS3funWr
fbpJePXqVdnyLVu2zDmOnrTybo+QACAkUMM618D7pk2bcgtJaHmRLrIi+5Fo+Mv13f2oqy3v9ggJ
AEICNaxzdQ3VSwBquR93uSsaacS2R0gAEBKoos5Xrlxpxw0S1AW0YsWKmgjAunXrKura+vjxY9nf
tm/fXtY19fbt27LleoLS+E4Wse0REgCEBKqoc3VlnTt3rvT67+nTp+2nFkKiwfaxsTH7+9OnTzMH
2923vaanp+0Avrt8dHTUvpacDJb39PSULb906VJpMF0ffXdfYY5tj5AAICRQRZ2rK+vo0aNm0aJF
dqBdwpI7GUWEZHZ21v6Do4Ri48aNdpA7bb3kbS91Uekp5vHjx3P2rf930ZOSXvHVW1r+8jNnztjX
e1UOCdHnz58LbY+QACAkQJ0DQgIkFaDOASEBkgpQ54CQAEkFqHNASABIKkCdA0ICJBWgzgEhAZIK
UOeAkABJBahzQEgASCowT3X+5s2btrl+9SxLo64TQgIICbRcneu/zGt5jvMZt35ZankuRa8TQgII
CXRMnRc9ZjMLST2P3ahyISSAkEBd6jw2X1bMTlfzYiXzZGkW3mfPnpW2cz/iw4cPdh4sWe9qG9nv
PnjwoOxYMspK7Hn37t2bOT+XCNnrppXp1q1bdr4tra/5xTQXWELo3NLKUuRcQtcwbd9Z1xQhAYQE
WlZIQna6blLUTL+uM6G/782bN9uZeJNZeq9evWqnsXfX15TvMzMzdvn9+/fNoUOHUvcXs9dNK5Oc
FFUObaPEf+zYsULnlnWNYucSu4b+vkPXFCEBhARaUkhCdrpKtokveyVx5ppSaX33CUSJWck/bX8x
e920c5mYmCh9//nzp+nu7i50bllli51L7Br6+w5dU4QEEBJoSSEJLdcdc3K3L1+T2L5fvnxpfUoG
Bgbs1PKxY2XducfsddPO2U/2vnNikXMrci5Fr3HomiIkgJBA2wlJkoAfPXpk9uzZY06ePJm5nsYo
ZG41MjJixsfHrWdI7FjuG01F7HXzlNMVkqLnVuRcKrnGWdcUIQGEBJpeSHyb2zxCkjA5ORncVsZT
riVu2rGmpqZK32WP63Y/FbHXTTtnnV/Ct2/f7PkUObesaxA7l0qEJOuaIiSAkEDT1XnM5jaWBHUX
r7eMhD+IrDegNDaQ+KXrraXkTSj5pm/btm3OsXp7e83Xr19tN5Tsc7MG22P2umnnrOWy2k0shfv6
+krLY+fml6XIucSuob/v0DVFSAAhgaar85jNbSwJqgtG4wnJa61JAhR6c0ldU0n31PPnz+0gtNZT
stSAsn8svQGl12i1jUTFHaQuaq/rn7OEYtWqVXYw+8SJE/apJCF2bn5ZipxL7Br6+w5dU4QEEBKg
zil/U1wDrgbQqIA6p/wICdCogDpvJI2azwohAZIKUOeAkACQVIA6B4QESCpAnQNCAiQVoM4BIQGS
ClDngJAAkFSAOgeEBEgqUOc612yz+/btm/N3GT/pv9199J/bT58+pQ20WNtCSAAhgbrVuaYrdydL
FDJo0lxUadtp3a1bt3JRERIg2IE6N+bFixd2TisfTTqoSRyzttM22jbEqVOnrPWsJiXU/vx5szSn
lOa9yhKlmDVvWhk1DbzsdJcvX27u3r1rJ1DUHFi+RXBSrgMHDpQ9XWleK1n8JoQsdDVB45EjR+z+
u7q6rDMiQgIICXRcnctuVl4cPvLkCG2nhO1a1foogcuuNpkRV5MxyovdPR/5pmtZ1mSLMfvbtDJq
tmA9TT18+NAm+MOHD9vvWfa2OrZm+tX+1ZWniRuTp7OYhe7ly5dLs/5qVuGdO3ciJEBSgc6rcyVR
TZtedLtkqvUsNHttMi260O96UnD369vP5iHmgug/9bg+IVmzGkswJAoSCVccYxa6epJyyyibYIQE
EBLouDpXt5GfLPNsp23U3VMk4WfZ5oYI2d/GzjX03V8m0ZDQyQvFPd+Qha7vE6JrgpAAQgIdV+eV
2MRmJdLYsryugAkx+9taConeWtOxXCGJXZtYGRESQEiAJ5LAdhozCD2RyH7W79rK8l/PImZ/Wysh
uXbtmh0L8cd9Yha627dvLyujuvsQEkBIoOPqXOMc6tsvut3r16+DYyQabL9y5UppoFzJ2v2flDwx
GLO/rYWQ6Clnx44dZeLx7t27UhlCFrp6EWBoaKg02N7T04OQAEkFOq/OdQeuweai2924cSP41pZI
Xv/VR29svX//vlAMxuxvayEk/f39Za//6ne9cpwQs/MdHh62Yyt6RVjXESEBhAQ6rs4nJibK7rLz
olddNRAOrRkDZABASKCmda43lt68eZN7X+pm0jaAkAABBdS5Rf+s99dff+Xel9Zt9bm2EBIAhASo
c0BIgKQC1DkgJEBSAeocEBIgoIA6B4QEgKQC1DkgJEBSAeo8RpFXlAEhAZIKdEidFzkvd66uRpTJ
tyD++fOnGRwctP+pr3PRf8V/+/attLzZLYgREkBIoOOFpNFl8C2INSWM5gxL5t7SFDASk4RmtyBG
SAAhgbrUuf6u6do1X5TutOVaKKdAl5hlbmj7tONmzcIbstb1fUHS9h07T83wq4kgNT28b73rk2ZB
LPted6ZkzYDsPyXlsSBGSAAhgbYTEt15K+kqScqj3J2MMY9lbmj7IkISs9YNTcKY5zwlUom4+Na7
PlkWxC6aQt63/o1ZECMkgJBAWwqJJm5M0DhAd3d36Xsey9zQ9kWEJA3XXCokJJVY+4aOHbMgFrdv
37bujS4xC2KEBBASaEsh8Y2t3Dv1PJa5oe2LCknIWjckJJVY+4baQczwS06KBw4csN1bLjELYoQE
EBJoSyEJJeBKLHMrFZKYtW5ISCo5z1A7CNnsSjz+/vtva2aVRqjLDCEBhATaUkgmJydL3/U6q4yc
EvJY5oa294/r2+W6v8esdUNCUom1byVPJHoS0SvAOrcskeGJBBAS6Dgh0RtOurtW4jx9+rTp6+sr
Lc9jmRva3n07anp62g54Z4lDzFpXyV3jHIlg+IPtRa19Y2MkvgWx3sbatWuXmZmZydwuZkGMkABC
Am0pJEreq1atsm8gnThxouyf7ETMMje0ffJ2lLqKlNgfP36cKSQxa92LFy/ap4zkSSPr9d+81r6h
dpBmQayXCPzXkP195LEgRkgAIYG2ExJiaS7taEGMkABCAghJg2k3C2KEBBASqEud+/+ZXZRqt29m
2s2CGCEBhASoc0BIgKQC1DkgJEBSAeocEBIAkgp1DggJAEkFqHNASICkAtQ5ICRAUgHqHBASIKCA
OgeEBICkAtQ5ICRAUgHqHBASIKkAdQ4ICZBUgDoHhASApALUOSAkQFIB6hwQEiCpAHUOCAmQVIA6
rydFTKM4P4QESCrQ5HU+OztrPdV95L++f/9+s3jxYuuFfuDAAfPly5eaxFazm2L559fq7QYhAYQE
6lbnv3//Nn19fanrnD9/3pw7d878+fPHfm7fvm3OnDnTEXHYbu0EIQEaCNStznfv3m2mp6dT1+nt
7bVe5K7o7N27N1+y+p/fb968aVavXm0WLFhgFi5caO1rk2XuxxWuZcuW2aef48ePz9n3y5cvzcqV
K603end3t32Scvn165fZtGlT7v0VOT//+pw6dcruV09ruoafPn3KtW/x+PFj+zct0/k+e/YMIQGE
BFq3zsfHxzPXWbp0qX0S8f+WV0jULZYkWCVSJc+sc7p+/bpNvjqeBOvOnTvm4sWLZesfPXrULv/8
+bMZHBw0ly5dKtvH5cuXrXjk3V+R83O/67hXr14tPanpWAcPHsy9b1dYxsbGzNq1axESQEig9es8
bR03+YX+liUk7l162nIXPWX4ouUmWH9/U1NT9qkk2UY/16xZU1qn6P5i5+d+37hxo336cZ+EVqxY
kXvfeqq6d+/evMUAGQAQEmiYkKjrpRohKbJc+/W7lNzjp+1v165d9qlDjI6O2qeAavaXV0hi1yW2
bz2F6LvETmNQCAkgJNC2QpLWjVWka6vI8rTkHDu/R48emfXr19vfNdaQdNNVur+8QpImpkXKLjTe
o/Pfs2ePOXnyJEICCAm0p5Aoyf38+bP0XYPbGliuh5BICL5//164DBrQ1tiIurWq3V9eIdG+/a4t
93XhPEKSMDk52ZA2iZAAQgLzIiQauL5w4UJpUHlkZCTYFVNESPS2k8YRkoSsAWz3WPruilZWGTSA
3tXVVTaQXun+QufnD7ZfuXKltO9r166V/R9ObN8bNmywb24JfyAeIQGEBNpKSPR2VE9Pj73b1mff
vn32nxRrISRK/Ml+E/Q/Kuo609803qHjx8rw9etXu37aP0oW3V/o/LJe/9VHb2y9f/8+977VraUB
++TV4ERUEBJASIA6h5aIAaIBSCpAnQNCAiQVoM4BIQGSClDngJAAAQXUOSAkACQVoM4BIQGSClDn
gJAASQWoc0BIgKQC1HlR2s2OFiEBQEigwXVerV1uYvCkWXABIQGSCnRgnVe7X985EBASQEigBes8
Zhmbta8su9y8+8+zfciSVpMpao4r7VdTyU9MTBQq161bt6wZldaR86Jv2xuz6U3jx48fNbEATiyF
/+u//sts3rx5znHk+Kjj6HgICSAkMK91nscyNpiQIrFUyf6znlh8S9qzZ8+WXAbl66EZdYscV91p
EhctV2I/duxYaXnMpjdELSyAXUthTZrpe7pr+8OHD/NEAggJzH+d57GMrUZIKtm/S8iSVsLhW+kW
Oa77BCPPFd3hJ8RsekPU2gI4Mb9y2bp1q3n9+jVCAggJzH+dV2sZG4ulSvbvErKkDXl45Dmun8zd
5TGb3hi1tgCWeZcESrx69coKSTUxQAYAhARqVufVWsbm6ZqqZnuRZUkbEpJKjutuU0Q00qi1BfDQ
0JDtMhPqortx4wZCAggJNEedF7WM/fjxYyEhqMSSNgvfklaOhFldW3mOq/0lyKzL9aKP2fTmoZYW
wDLt0ksDMzMzdpDeH8xHSAAhgXmr85hlrDvYPT09bbtoQna0Rfcfi8WQJa0G29X1JZ4+fTpnsD12
XL3JpQSt5adPnzZ9fX1l24dsevNQSwvg5Enkr7/+sgPx1cYAGQAQEqhpnYcsY5Pkre4YJWIl9Zhd
bpH9x2IxZEmru/L+/n77d62jsYMix33w4IFZtWqVHdA/ceLEHAvhSmx/XWppASz0coCWVTqbAEIC
CAlQ5x1+PSQ26i6rRZmJBiCpAHXeYddDXWB6ivHfXENIgEYE1Pk8Ue0cYY1GY1G9vb0VDbIjJEBS
Aeocah4DRAOQVIA6B4QESCpAnQNCAiQVoM4BIQECCqhzQEgASCrQQnWONS9CAiQV6KA6r0ectNpr
t7Vkvm2FERJASKAthKSTY2++bYUREqAxQ13qPGRlq2008aGm5UjmuvITYczONrGMlX9GHmvdau1z
g8nTO59Y+UXIEjeNamyFERJASKAl6zxkZatt9u3bV0qG/uy7eexsXcvYPLFXrX1uTEj88wmVv6jd
brW2wggJICTQknUesrL1LV/9/eSxsw1tn0a19rkxIfHPJ1T+ona71doKIySAkEBL1nnIyjaWmKu1
6c16QsqiHrbAMSvfIna71doKIySAkEDL1nmWlW0sMVdr01tUSOplC5xV/qJ2u7WwFUZIACGBlq5z
38o2lpgrsdGNnUe19rkuRW2B/fIXtdutpa0wQgIICbRMnYesbGNCUImNbsyatxr73JgtcNr5hMpf
1G63WlthhAQQEmjJOg9Z2eZ5oihqoxuz5q3GPjdmC5x2PqHyi5AlbhrV2AojJICQAHUOLRMDRAOQ
VIA6B4QESCpAnQNCAiQVoM4BIQECCqhzQEgASCpAnQNCAiQVoM4BIQGSClDngJAASQWo81qCrS5C
AiQV6NA6r1V8+P+93qi403HkHRJMpP/z+8+fP615VtbcXvq7ln/9+jV1uaZykV9LGpqa3i+v/jNe
074gJICQAELS5HGm48oBUdOthIREaEqTkZGR1P2Mjo4GXRE19fzU1NScv2ueL83J5Zdf6ybOjAgJ
ICTQNnWuu+4jR47Y+aS6urrsnby77ocPH+ydtCZb1FxUukN/8OCBnUNq8+bNc/YnJ8Hu7u5Ua1k/
kSuBy/hp+fLl5u7du3bSQ51HmqVvEctb7fvGjRtBf5Xkd82dlVaORCg0g3AaL168ML29vanLNB39
u3fvUq+5ttG2CAkgJNA2dX758uXSDLdfvnwxO3fuLFtXSVZ35smMtrKSlaug6OnpmeNxLmvaw4cP
px7TT+SHDh2ywvPw4UMrINpO3/1ZeIta3ibH2bZtW6anu/u7jusLl7qgBgYGMo9x7Ngxc+vWrTl/
Hxoastco65pLPLUtQgIICbRNnaurxZ3SXbPtxuIjMXxKzKD8/b1+/TqXkPhJ3vX+cNctanmbbPv8
+XNz4MCBqJCoy2nXrl1l+5BIvn37NvMYEil/+T///FP2lJJ2HbWNtkVIACGBtqlz39VPCdtfV1Ot
yydEd+iact1dvnr16tI4gUTIHQOICUno/HwnxiKWt+62EhIJSuz4GjSXsZWQEGZ1WyWoq88Vtx8/
ftiyz8zMBK+5tlH3HEICCAm0rZD466r7RuZP6pIZHx+3YwrucnXlDA4O2t/lv6GxiVoLSVHLW3db
DXwnTwCh40tskq6sv//+e06XXdZTWYK66e7fv1/xNUdIACGBlq3z7du3l3VtqevFXVdjF26Xk29f
q3EV3Z3rTlyD4e6bUrUSkqKWt/6+NOgugYuZXOlaaCA8z5tV/hOJ/8Tkv2iQoDEenkgAIYG2qnMN
pOupIhls19iA33Wlt7QSkdHdvb8vPYn89ddf5ujRo3OSrWurW6mQFLW89fclcdM4S0xI9EShsRf9
D0gMXQffvTHPNVe3GWMkgJBA29X58PCwfQ1XTxR6Q8pdV10+Sq7qjlEXV9o/2k1MTNi/+f/J7tvq
ViokoojlbVpZ/deas65HbGwkQW9e6VoVveZ6MvLf2mrkP2oiJICQQFPWuZK6nlw6CYln6KkoC71e
rZcXXP7zn/8gJEBSgc6tc3U16WnB/+e/TkDdZUXmE1PXoLbx0RtxCAmQVKBj61zjIOoO8qcj6QT0
T4waG8qL1mWuLSCpAHUObREDRAOQVIA6B4QESCpAnQNCAiQVoM4BIQECCqhzQEgASCrQInWe51VZ
7HkREiCpQJvVeS2dFX3r3TzrtLs9r+YQC83PVUt7XoQEEBJo+jqPHSPPOXSaPa88Xfr7+zPXr6U9
L0ICCAnUpc71d7kPaooTTY3u29z628nyVnNeyR5XToB+or1y5UrqvkIz4rrbd5o9rybM1DULUSt7
XoQEEBKom5Co+yRxK/Rtbt3tJDgnT54szRS8Y8eOOYlW3TZ59pX3PNvdnrevr88KhQRP5dHTjk+t
7HkREkBIoG5C4ibOUPKUX4frAOjb8hbZV6VC0m72vKtWrTK3b9+2v+t89VTkz71VK3tehAQQEqib
kAQTjvO7PxDu2/IW2VelQpJ33Vaw501DyyUu/t9qYYaFkABCAvMuJDF/9yL7yhoz6SR73iLr1cKe
FyEBhATmXUiUXDU2kqC78GZ9ImkFe16hFwd+/PhR+i43Sb0+7FIre16EBBASmHch8QfbZexUREh8
692sZNtJ9rwnTpywb5cl56kXAq5du1a2Tq3seRESQEhg3oVE6HVVvWHU1dVl34xyx01i+/Ktd9Po
NHteCZbeANM56pVmiZ9Prex5ERJASKDp6lxJsLu7m4ubk/m250VIACGBea9z9efrP7GT/83Q/zyo
qwvyM5/2vAgJICQw73U+Pj5uB5WTbhj170tQID/zac+LkABCAtQ5ICRAUgHqHBASIKkAdQ4ICQBJ
hToHhASApALUOSAkQFIB6hwQEiCpAHVOmebw+PFjO8li2v9/ICTQFg0vj1MdICRQOWlujQgJICTQ
tkKiyREPHjxoJ0vUrLOaxsNF/72umWe1XNN7+MZSea1vta7cAbWu9nf06NEyf/QPHz7Y+bB0HG2r
c3nw4EHZ9pomZOXKlaWZdt0yJU8BmoJdM//6U7rHyhGyG04ja3/N3L4QEqiLmABCoqk2kplrNf3J
hg0bSsskCvJlT2am1YSDEh13n3mtb7WuunqUcLUvzXjrTkQoD/TR0dHSsXRciYa7vcRHy5LJF32v
lCT5j42Nlbkh5ilHyG7YJ8/+mj0GaP2AkEDNhETCkeXat3HjxrIp3/W7nijcfea1vtXv7tPOz58/
oxM+ugZPMRtfiU7WVO5FyxETgzz7Q0gAIYGOEZLQnXfMqa/ItO763Rcs/9jqutITklwHlayLeJ3o
KSR56pEpVTXliIlBJftDSAAhgY4UkrRllfqDpB3f3b/GT/R0pDEXTQ6p7qsiQpIIkbrn9uzZUzYr
cdFyxMSgkv0hJNAxSQU6r87XrVuX2bWlQWu/CydkZBUTksnJydL3b9++2TGVBP3udot9/Pix4mSv
4/i2u0XKEWsjlewPIQGEBNq2ztWVpG4hoenK/cH2K1eulAaVZQEr4alUSPR2kyx6ta/Tp0+bvr6+
0nK9MZW8pSUPDlnLFhESnbfe3BL+YHnRcsTaSCX7Q0g6pJuHT/t/EJK56BXc/v5+m3g1LuF7iiev
ueqjN5Pev39fsZBIKFatWmUHxuVloqeShOfPn9s3rXQeEgUNnBcREnVr6fyT13cTUamkHHnEoOj+
EBLuyoE6p+xc+7aKAWqDoAbqHiEBhISABmKgs8rsDkYDQkKDAmKAMgNCwsUEYoAyA0ICNCggBigz
ICQ0KCAGKDMgJDQoIAYoMyAkNKjW482bN021n3rvkxho/TK3QlwgJFB1g9K01oODg/Y/VfWqov7b
1/3PW3Hnzh2zZs0au1xTOLhzB/kUtdssMulbrV6lrMcrmf4+8yawRiY6hKTx16LSuKiEeljd6nzV
/mPtVnlEplxZ85fp71r+9etXhKQdG5RMdjRnTjJ/jqZAkJgk/PPPP2b79u12MjktlwmPOy+RT1G7
zSJCUqtGWI/GXOk+EZL2FpJGXvN6WN3q/OXM6Lo6ZrVb5Q7NYpyG8sbx48d5ImnXBiWrUPcuQi5v
7l2UPBKGh4dzH8Of4yk2n09eIcmaP0qOc8uWLbNPVG6gHjhwwE7G596t7d27N9c8VEXtT2PlDtm6
+ueQVR73jjPLVhUhqVxIQpa0ofoLxUqe9lArK9ysuI7t37fxTdvvjRs35nidpLVbTYEvx8c09JSk
m1GEpE0blI8ajWv1qSAu0s8bm9CuUiFJWy6rTzU0CaEEUI/gFy9eLAW1uuG0THdTmhhvamoq13Gq
tT/1v4dsXd31QuXx7zh9W1WEpHIhiVnIhuovT6xUetyiVrj+sfLs34/jrH2qLfkilPa7LId9sdMN
nW5ImyEGEJIGCcnt27dtw3GTl5KW7rR0V5M2hjJfQqK7HL9P1k2uajiXL1+2ydj1ya4koRaxP/W/
h2xd3fVi5QnZqiIklQtJzEI2VH95YqXS4xa1wvWXVbL/rH1qlmI95cfarW7Wdu3aVbaPnp4eO0U+
QtIhQqKBMAWL7obd7TQYL/Od5K4mdHfRSCGRyPmP9L4dqJKzGo87yJfnWlRjf+p/z3sXGStPyFYV
IalcSGIWsqH6KxorRY5bdJp3f1ktrHHddZQbJCixdrtv377SCzmvX782vb29TRMDCEmdhUTi8fff
f1sDHhc5uLl3NRKT0FtPtRCSrP7ePA3FR0GtO8oiQlIL+9NKhCRPebJsVRGSyoUkZiEbqr+isVLk
uNUKSS2scd11pqenbRdXbD8Sm+RmUzml6FgeQtKiQqIkq6eOtMEwDVC7SEjUxVWpkISsRIs+kWjA
2bUp9dHbaBpzUCMv0rVVC/tT93vI1tW3Rg2Vx8W3VUVIKheSmIVsqP6Kxko9rXDT2ke11rj+OnoS
1uB7rD3oTc8XL15kDuIjJG3WoFTZ6tOcmZlJXa4+eX2SATtZbSZ3JXnvipLBN93RaPCwUiGRgKlP
N2kcGky8cOFC6dz0XW+mCN0Z7tixo6xRvXv3LnU/PpXYn/r79Afbs2xd/cHXrPKIkK0qQlK5kMQs
ZEP1F4uVUFzU2go3bbC9Wmtcfx29uKKu1Vh7uH//vh3fq2ZMDyFpoQbV3d0dtWdVMGqgV3czEoIk
Iec5TpLw1G2jIFYirFRINGiuc3Dvqs6cOWPvCpNzS94+0UsB7uu/+l3Ls/bjP5oXtT/19+muE7J1
9feVVZ6kWytkq4qQVCYkImQhG6q/WKyE4iJ23GqFpJL959mn3ibM027ne2wEIWlw1xYQA5QZOiEG
iAYaFBADlBkQEhoUEAOUGRASGhQQA5QZEBIuJhADlBkQEqBBATFAmQEhoUEBMUCZASGhQQExQJkB
IaFBATFAmfNSjXUutrsICQ2qTcteD3tSYqD5y1zkWrjrVmOd20jbXW4cERICq4Flr4c9KTHQvmWu
Zn/YKiMkbdugYrayIXvXmPVrpbax1exXk9MdOXLEzlfV1dU1Z14g/5rUw54UIWmtJ5KYpW3I3sDd
T7PY7ibra4680Pqx42nWbHn5yI777t27dhJItau0fYXaJELSAQ0qZhUasncNLavGNraa/coRMZlB
V94qO3fuLDxjarX2pAhJ6wlJyNI277TwzWa7Ky+erPXzHO/QoUO2jT18+NAKiGx09d3fV6xNIiQd
+ojvGiyF7F1Dy6qxja1mv3pKcKeH10ytjbYnRUhaT0hClrZ5hSTWlhptuxtav+jx9N31XSliEY2Q
dIiQhKxCQ/auoWXV2MZWs1//Lk0B3mh7UoSk9YQk7/KYkDSr7W61x4s5PcYsrxGSNm9QMavQpHFk
2btmLavWNrbS/cbsRWPLamFPipB0ppA0s+1utccrKoLNGgMISZ0aVMwq1CVk7+ovq5VtbNH9yuLT
fWSXa12j7UkRksaWqWhCrZeQNLPtbrXHi5173raOkLSpkMSsQkP2rqFl1djGVrNfDXYODQ2VBtt7
enoabk+KkDReSLLewKu1kISsc5vZdrfa48VeFAi1SYSkA4QkZhUasneNWb9WahtbzX7F8PCwHTjU
64h6o6TR9qTNHgNZybddP7UUkpB1brPb7lZzvNj3WJtESNpcSIAY6MQnEujMuCcaSCJADGQKCXEP
CAlJBIgBygwICQ0KiAHKDAgJDQqIAcoMCAnQoIAYIO4BIaFBATFAmQEhoUEBMUCZASGhQTUV2JQS
A5SZ9oiQtGiDqvSfu4psl2deI9+mFEiqnVjm+SxPNe0xdt6a8Vv+KT6zs7NlU7ck6L/nnz59ipC0
opA04ti18NgGhAQhaa7ziK0vy4ipqamyv8kkq6+vL3VbrZvXoRQhaVDFh2wyQ08W2k7z68iKU25r
oScLTVan+Xw0cd3evXut4VTeJxJ/+gs50fko6Lq7u82PHz+obIQkWGbFie50XTSRomaxzdsmfLvl
kD10bN6rmLW0v101Frqx89RU+JqnTtvLCdS9TiHL4Zhldyj2Xrx4YXp7e+f8Xec+PT2dua220bYI
SRMkkZhNZlaS1zbyCUlm2d2xY0dQEDS9+8zMjF3//v371sYzr5D4v2tGX7+x6XxkBQoISazMg4OD
doZaF1k0SzzytgnfbjlkD53HGyRr27TtqrHQjZ2nngy0b22r63Hs2LFcN5VFbYZddAwJmI88XULb
yvfFPT+EZB6TSMwmMyt4EmFI8C1t/d/dJxAdT8etVEgSwysX3Rm+fv2aikZIomVWt4ieSpK41881
a9aUknOeNuHb2IbsoWNCEto2bbtqLHRj5zkxMVH6/vPnT3ud8ghJGiGbYRdNt69p94vGbTJVP0LS
BEkkZpOZd/Dbt7SNBV2WrWfefejRPulTlUjl7S8lBiiz2LVrl33qELqTVrdMJW0iIWQPHROS0LZF
RSlmoRs7T19A87TThCI2wy7qDvOPm6cOtY264BCSJmhQMZvMrGCIeaPHgijLjS3vPmRepS4KoUf3
GzduUMkISe4y66lW/fhCYwVJN0rRNuEn0jR76DzeICHb6SJCksdqush55hWSojbDleag0PkhJPPY
oGI2mVnBoEdKjY0kqFspJALuGxl63M7zyBwKRB1bdzLqXtOgqD94CghJrMx6qtXYiLq1Km0Tafj2
0P76ldpZ5xGSmIVu7Dz1t4Rv377Zl2nytMeiNsO1eCLR+BVPJE3SoGI2mXkH27VNSAT0hsXXr1/t
+jpe0cF236Y0eRL566+/7MAnICRFy6wB9K6urrKB9KJtIiFkD+0OcOstJHWj5bWzLiokMQvd0LG0
H5VT7Vnbnj592r5+m6c9xmyGY2Mk7hhq3jrUzStjJE3UoEI2mbHuJT0NqDHq7ZBQd5WWa12tI1Fx
BwzzCIlvUyo0MKh1+K93hKSSMuvGRvHkPlkXbRNud1GWPXSSsLVMSV3L8tpZFxUSEbLQDR1L+5EY
rFq1yg7Knzhxwj6V5GmPMZvh2Ftbyg9F61Dd2by11WZJRF1LbndVI1Dj1p0QICSUuXWvlW4I3Se+
vOzcudMKI0LSwkGiVwo1YJe8a6+7oNAgYa3RcXXXGHvLBRASaP5rpbfIivQsqPvM/RcChKRFg0Rv
ZuiVWz3a6j/b9RgsQWkU6qNVFxmD7CRVylwb5nM+O3X/abwzL1qXubZoUEAMUGZoeAwQDTQoIAYo
MyAkNCggBigzICQ0KCAGKDMgJFxMIAYoMyAkQIMCYoAyA0JCgwJigDIDQkKDAmKAMgNCQoMCYoAy
A0ICNCggBigzICQ0KCAGKDMgJDQoIAYoMyAkNCggBigzICRAowLqnrJDSt0TCTQqoM65BlBVnRMF
Nb7AfDrnA8Q9cY+QAHelAFCLHMAlAIQEABASQEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBI
AAAhAYQEABASAIQEABASQEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBIAAAhAYQEABASAIQE
ABASQEgAACEBhAQAEBJASAAAIQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQA
EBJASAAAIQGEBAAQEgCEBAAQEkBIAAAhgaYTEP8DAAgJAEICAAgJzI+YAABCAoCQAABCAggJACAk
gJAAAEICnSYmAICQACAkAICQNENC5dM5HwBASLgrB+ocACEhoQB1D4CQkEiAGABASEgiQAwAICRA
EgFiAAAhIYkAMQCAkJBEgBgAQEhIIkAMACAk0FJJ5M2bN1QEQgKAkLRrEpmdnTXr1q2b8/dv376Z
/fv3m8WLF5slS5aYAwcOmC9fvlR0DosWLappOUiMCAkAQtIkSeT379+mr68vdZ3z58+bc+fOmT9/
/tjP7du3zZkzZ+YtkZEMuXYACEkTJpHdu3eb6enp1HV6e3vN27dvy0Rn7969mft6/PixWbhwoVmw
YIHZtGmTefbsWen4/vxPacdz/ybhOnLkiFm6dKnp6uoyd+7cCT6RSPSWLVtmn5yOHz+e67yIAQCE
BGqQRMbHxzPXURJXQvf/loWS9ZMnT+zvY2NjZu3atZnnEBOSy5cvmwsXLtjjqztt586dmUJy/fp1
c/PmTbuuxE6ic/HixVznRQwAICRQoySSto4ScJ6/JaxcudLcu3cv1/5jQrJ161bz69ev0vdXr15l
CsmWLVvmCJ4rFqHzIgYAEBKoo5CoK6iIkOhuX/tRYtfYSjVC4h9HQpElJFrX7z5zzz10XsQAAEIC
dRSStG6sUNeWePnypXn06JHZs2ePOXnyZM2ExF/u/p4meHnPixgAQEigjkKipPvz58/Sd70mrMH5
PExOTgYHx/3vHz9+LPvb9u3by7q2NOiftT8NoH///r2i8yIGABASqKOQ6E2oZMBbn5GRkWDX0IYN
G+wbUkKD2+5Thf4X5dOnTyVxcAfA9daY/l/FPYfR0VEzNDRUGmzv6enJFJJLly6Vnae+u4IXOi9i
AAAhgToKyefPn20C1z8T6rNv3z77T4pZqPto48aNtqtJyTpJ3kJvUSX7cRO61tU/Q2pd/xyGh4fN
ihUr7Gu9ejMr9ISj/29Rt5v2L1HSuec5L2IAACEBkggQAwAICUkEiAEAhIQkAsQAAEJCEgFiAAAh
AZIIEAMACAlJBIgBAISEJALEAABCQhIBYgAAIQGSCBADAAhJPZNIrZJLtfup5/YkUK4DAELSAkmk
mYUEuEYACEmDnkj0u1wGV69eXZqTKplUUWiyxYMHD9rJF9evX28mJiYy9xM6TsxCV4Rsc/NsX2kZ
ERIAhASqFBJNdqgZeoU/S+7Zs2dLLoPy9dCMupUIScxCN2abG9u+mjIiJAAICVQpJEmCTVsu4fDt
bCsRkpiFbsw2N7Z9NWVESAAQEqhSSELLQ3fu1ezHt9CN2ebGtq/m3BASAIQEWlBI/OUx29zY9ggJ
QgKAkDSpkMh8qpKuraIWujHb3Nj2CAlCAoCQNKmQaLB9bGzM/v706dPMwfZqLXRjtrmx7REShAQA
IWlSIZmdnTX9/f1WKGRbq0HutPWqtdAVIdvcPNsjJAgJAEJCEgFiAAAhIYkAMQCAkJBEgBgAQEiA
JALEAABCQhIBYgAAISGJADEAgJCQRIAYAEBISCJADAAgJNAGSeTNmzd1XR8QEgCEpE2SSNZ/les/
1ovgr09SREgAEJIOFJJqzockiJAAICRNnEROnTpl57VauXKluXXrVqG5qT58+GDnwpL9rubXkgXv
gwcPgk8kvtdIbD9p6+vnjx8/THd3t50DzEUzA2sG4YSQbS8xAICQQJVJRLa1yUy6mhhR7oNFhGTz
5s12Nt5kpt6rV69aQQoJSdp+i+zH/T44OGhnB/bLJPEQMdteYgAAIYEqk4hsbd07+omJiapny3WN
qfIKSZH9uN+npqbsU0nik6Kfa9asKdnpxmx7iQEAhASqTCIx29o8QvLy5UvrVTIwMGCnl88jHmn7
zbsf//uuXbvsU4fQU426yNzyhWx7iQEAhARqLCR5Er77N42pyOBqZGTEjI+P2+6xSoSkyH78748e
PbJjKkJjI9o+7amGGKAZAUICdUgiO3bsMN++fSt9921rY7a5GqR3bXH95XmFpMh+0r6vXr3ajo2o
W8slZttLDAAgJFBlErl//759ayvLtjZmm6sEnrxdJRHatm1bLvHQ21kax0i812P78df3y6MB9K6u
rjkD6THbXmIAACGBGiQRvdmkN6RWrVplk3kR29znz5/bwWuto66pe/fu5RISJXz9k2Hyj4ax/fjr
++X5+vWrXSYx9InZ9hIDAAgJ1DiJkHCIAQCEBBASoF4BEJL5SyJF58EChAQAISGJADEAgJAASQSI
AQCEhCQCxAAAQkISAWIAACEhiQAxAICQwHwnEaxxiQEAhIQkUhWNtMYlQXKdABCSNkwisUkWASEB
QEjaJIlo7qxkLi3NlPvs2TPz/v1761joI4dBmUjJ4lb7kweIJlvUtu7kjlnWuFeuXEldPyFkiZt2
nmllC61HDNCMACGBOiQRN6GPjY2V3AM1C7CfhCUchw8fLu1PEyAmToTJ5I6hJ5J9+/Zlrh+zxM06
T/9YofWIAZoRICRQhySiWX81066PzKL27NlT9jf5ub9+/bq0v0QU0o6RJiSh9WOWuFnn6e8ntB4x
QDMChATqkER0165lSuTnzp0rW6ZuKHmii1evXlkhCe2viBFV2pNEyBI3dJ7ufkLrEQM0I0BIoE5J
RF7pyRPIyZMnS38fGhoyg4OD9veDBw+aGzdu1E1I8ljiZp1nmod82nrEAM0IEBKocxKZnJwsW08m
UXImnJmZsYPgs7OzdROSIpa4/nlmlc1fjxjgWgBCAnVIInIj1JtOwh8AT55E/vrrL3P06NFCwhCz
xvX/FrPEDZ2nu59YeYgBAIQEapxE1A20cePG0iu5SRJOmJiYsNv6/6keE4aYNW7a30KWuKHzdPcT
Kw8xAICQQIOTiJK5Bt0BIQFASEgihbdRF5OeEnj7CSEBQEigoiSicY7e3t6yQXZASAAQEpIIEAMA
CAmQRIAYAEBISCJADAAgJCQRIAYAEBKSCBADAAgJkESAGABASEgiQAwAICQkESAGABASkggQAwAI
CZBEgBgAQEhIIkAMACAkJBEgBgAQEpIIEAMACAmQSIC6B0BISChAnQMgJM2XWPh0zgcAEBLgzhwA
EBJASAAAIQGEBAAQEkBIAAAhAUBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQAEBJASAAAIQGEBAAQ
EkBIAAAhAUBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQAEBJASAAAIQGEBAAQEkBIAAAhAUBIABAS
AIQEABASQEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBIAAAhAYQEABASAIQEABASQEgAACEB
hAQAEBJoSwHxPwCAkAAgJACAkMD8iAkAICQACAkAICSAkAAAQgIICQAgJNBpYgIACAkAQgIACEkz
JFQ+nfMBAISEu3KgzgEQEhIKUPcACAmJBIgBAISEJALEAABCAiQRIAYAEBKSCBADAAgJSQSIAQCE
hCQCxAAAQgJNlUTevHnDhUZIABCSTkwi3759M93d3aXf16xZU9ExFi1aVNPzrFfiq9V+q91Po7dH
SAAhgbolnQcPHpiBgQH7+/37983BgwfnLUG3UrJDSAAQEoTk/zh37py5fv26/f3UqVPm7t27mes+
fvzYLFy40CxYsMBs2rTJPHv2rLR/f36ntGO6f/vz5485cuSIWbp0qenq6jJ37twJPpGcP3/eLFu2
zCxZssQcP34813nleeq5efOmWb16td1W+3jy5Elp+a9fv6ywLl682Kxfv95MTEzkfnoqUtZY+fJs
j5AAICQNF5JKJvtzE+3Y2JhZu3Zt5jFiyfXy5cvmwoULNkl++fLF7Ny5MzM5S+iU8LXu79+/bSK9
ePFirvOKCcn+/fvNp0+f7HftQ/tKOHv2rLl37579/dGjR2bDhg0VCUmsrLHyxbZHSAAQknl9Ilm+
fLm98xarVq0ys7OzmeuuXLmylFhjx4gl161bt5aOK169epWZnLds2WKTqIsrFqHziglJIiJpyyUc
/nErEZJYWWPli22PkAAgJPMmJK9fvzY7duywvyuhJr9nobt97UuJT11i1QiJe+efdN9kJWet6z8x
qSsqz3lVIwD+OdZqP35ZY+WLbY+QACAk8yIklfpYvHz50nbz7Nmzx5w8ebJmQhJKzm5SLXpezSgk
RcsX2x4hAUBI5u2JRAPJt27dsr8fOnQoONDuMzk5GUym/vePHz+W/W379u1l3TVv377N3J8G0L9/
/17ReVUjAOvWrauoa6toWWPli22PkAAgJPMmJPv27TNPnz6d83sWGjPQG1LCH5jWm03qHksSnjsA
Pj09bQe13fMYHR01Q0NDpQHknp6ezOR86dKl0mCzPvq+e/fuXOdVjZBosF3dZkLXJmuwvdqyxsoX
2x4hAUBI5k1I9Dppkvj16ql715vVfbRx48bSq7JJ8hZ6y0j/lJj8Y2KS0LWu7uy1rn8ew8PDZsWK
FfbYenMplOTPnDljz1f7V6L+/PlzrvOqRkj04kF/f7/dp/avQe609aota6x8ebZHSAAQknkREiAG
ABASIIkAMQCAkJBEgBgAQEhIIkAMACAkJBEgBgAQEiCJADEAgJCQRIAYAEBISCJADAAgJCSRZidk
7VvU9rcTbIIREkBIoC5JpJWTi2/t65alqO1vaF8ICQBCAh2YGJk+BCEBQEjm4YkkZjubhqx5NT+U
jKU0i3CReaw+fPhg55TSZI86lqxs5R+f53xC1r5py0LHytrXjx8/THd39xyjL81Hptl6E0IWuQgJ
AELScUISsp31kf1rMiOtJhiUi18RIdm8ebOd1TaZ8fbq1atWkPKeT2jaen9ZnmOl7WtwcNDOxOuX
W+IhYha5CAkAQtJxQhKynfWRG6F7tz4xMVFISNJwDZ5i51NESPIcK21fU1NT9qkk8STRzzVr1pTO
K2aRi5AAICQdJyRFkk8Rq9ysv2n6d3l+DAwM2Gnai2xfVEiKHMv9vmvXLvvUIfRUo6ck9xqELHIR
EgCEBCEpICRF96cxFRlFjYyMmPHxcds9Vi8hKXos97vsezWmIjQ2ou3TnmpaNQYAEBKYNyHZsWOH
+fbtW+l7yCpX+PazGqR37WX95bUUkqLH8r9rwF9jI+rWciliAYyQACAkCInH/fv37VtbWfavMftZ
JefkzSmJ0LZt2wqdj2/tG1oWO1ZoX0ID6F1dXXMG0mMWuQgJAEKCkESSj95a0ttPq1atsom6iP3s
8+fP7cC01lG307179wqdj2/tG1oWO1ZoX+Lr1692mQTTJ2aRi5AAICRtLSQkK2IAACEBhASoGwCE
pH2SSNE5rgAhAUBISCJADAAgJCQRIAYAEBIgiQAxAICQkESAGABASEgiQAwAICQkkVrQCda1xAAA
QkISqSONtK4lQXKdABCSNkwisUkQASEBQEjaJIlo/qtkPizNZPvs2TPz/v176yjoIwdAmTzJgrYS
G9wrV64EbXxDlrVp55lWttB6xADNCBASqEMScRP62NhYyd1PM/n6SVjCcfjw4dL+itrg7tu3L3P9
mGVt1nn6xwqtRwzQjAAhgTokEc3cq5lwfWTmtGfPnrK/yZP99evXpf0VtcENrR+zrM06T38/ofWI
AZoRICRQhySiu3YtUyI/d+5c2TJ1Q8mzXLx69coKSWh/RYyi0p4kQpa1ofN09xNajxigGQFCAnVK
IvIyT55ATp48Wfr70NCQGRwctL8fPHjQ3Lhxo25CkseyNus803zg09YjBmhGgJBAnZPI5ORk2Xoy
cZJz4MzMjB0En52drZuQFLGs9c8zq2z+esQA1wIQEqhDEpFboN50Ev4AePIk8tdff5mjR48WEoaY
da3/t5hlbeg83f3EykMMACAkUOMkom6gjRs3ll7JTZJwwsTEhN3W/0/1amxws/YRsqwNnae7n1h5
iAEAhAQanESUzDXoDggJAEJCEim8jbqY9JTA208ICQBCAhUlEY1z9Pb2lg2yA0ICgJCQRIAYAEBI
gCQCxAAAQkISAWIAACEhiQAxAICQkESAGABASKCZkwiWu8QAAELSAUlEM+bKK6Qe+Ja77Zpg8+5D
/7H/9OlThAQAIWkvIdGU68l08Z2YvBp5jrrO7nT8CAkAQtLyQvLixQv7T4f+uiMjI2bFihVm+fLl
5u7du3YSRc2DVcQiN81y98OHD/auXP/sqH2tX7/ePHjwIHjusW1Ctr95t89jL1wru19db113hAQA
IWkLITl27Ji5devWnHUPHTpkk+jDhw+tgMhiV9+LWuT6x1WyHh0dLc3ye/XqVetqGCK2Tcz2N8/2
ImYvXCu7X4m0rjtCAoCQtIWQbNu2zbx9+3bOuq4trr67XiFFLHLzJK88plahbWI2vnm2FzF74VrZ
/ep667ojJAAISVsIibp7fCGImVIVschNO66mej979qwZGBiwU77nSXChbfJMUZ93+5C9cK3sfnW9
1Q2IkAAgJG0hJGlPA0WEJPY04W+rbjSZT6l7Z3x83E5Tn6yTNqYS2yaPkBTZPmQvnAhSLex+58Nw
CyEBhASa8okkZpHrb6vxFnf9jx8/RhNcbJuYkBTZPmQv7FKN3a/GkngiAUBI2kZI1FevLpxKhSRm
ketb7qrrKHljKhkriCW42DYxISm6fZa9cK3sfjXmwhgJAELSNkKit4f05lWlQiJCFrm+5e7z58/t
YLySqxKuBqVjCS62TUxIim6fZS9cK7tfdZfx1hYAQtI2QqKk6T5BQP3thXfu3GnFBiEBQEjaQkiE
3i5iTqz/pd72wupa0/VuthgAQEigqiSifnyNCUD97YV1nZlrCwAhaTshAWIAACEBkggQAwAICUkE
iAEAhIQkAsQAAEJCEgFiAAAhAZIIEAMACAlJBIgBAISEJALEAABCQhIBYgAAIQGSCBADAAgJSQSI
AQCEhCQCxAAAQkISAWIAACEhkQB1D4CQAAkFqHMAhGTeEwufzvkAwP/y/wCGP1r6dTU7MAAAAABJ
RU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-29 10:22:50 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARsAAAKBCAIAAADoWpjOAAAd20lEQVR42u3dsY4kRfLH8ZaQEMYa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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<APPENDIX ID="APP-01" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<TITLE MODIFIED="2014-06-10 18:29:53 +0100" MODIFIED_BY="Angela A Gunn">NMD Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<P>#1 MeSH DESCRIPTOR Musculoskeletal Diseases Explode All [REFERENCE] [STANDARD]<BR/>#2 MeSH DESCRIPTOR Nervous System Diseases Explode All [REFERENCE] [STANDARD]<BR/>#3 "central nervous" or neuromuscular or muscular or motor or musculo* or musculoskeletal* or bone* or "chest wall" [REFERENCE] [STANDARD]<BR/>#4 #1 or #2 or #3 [REFERENCE] [STANDARD]<BR/>#5 Hypoventilat* or ((gas or oxygen* or "carbon dioxide") and tension*) [REFERENCE] [STANDARD]<BR/>#6 (respirat* or breath* or ventilat*) NEAR10 (insufficienc* or failur* or deficienc* or disorder* or difficult* or depress*) [REFERENCE] [STANDARD]<BR/>#7 #5 or #6 [REFERENCE] [STANDARD]<BR/>#8 MeSH DESCRIPTOR Ventilators, Mechanical Explode All [REFERENCE] [STANDARD]<BR/>#9 MeSH DESCRIPTOR Respiration, Artificial Explode All [REFERENCE] [STANDARD]<BR/>#10 ventilat* or NIPPV or ((positiv* or negativ* or inspirator*) NEAR10 pressur*) [REFERENCE] [STANDARD]<BR/>#11 #8 or #9 or #10 [REFERENCE] [STANDARD]<BR/>#12 #4 and #7 and #11 [REFERENCE] [STANDARD]<BR/>#13 (#4 and #7 and #11) AND (INREGISTER) [REFERENCE] [STANDARD]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-10 18:30:14 +0100" MODIFIED_BY="Angela A Gunn" NO="2">
<TITLE MODIFIED="2013-06-11 14:36:09 +0100" MODIFIED_BY="Angela A Gunn">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-10 18:14:06 +0100" MODIFIED_BY="Angela A Gunn">
<P>#1 MeSH descriptor: [Musculoskeletal Diseases] explode all trees</P>
<P>#2 MeSH descriptor: [Nervous System Diseases] explode all trees</P>
<P>#3 "central nervous system" or neuromuscular* or muscul* or motor or musculoskeletal or bone* or chest wall</P>
<P>#4 #1 or #2 or #3</P>
<P>#5 (Hypoventilat* or ((oxygen* or carbon dioxid*) and tensio*))</P>
<P>#6 ((respirat* or breath* or ventilat*) near/10 (insufficienc* or failur* or deficienc* or disorder* or difficult* or depress*))</P>
<P>#7 #5 or #6</P>
<P>#8 MeSH descriptor: [Ventilators, Mechanical] explode all trees</P>
<P>#9 MeSH descriptor: [Respiration, Artificial] this term only</P>
<P>#10 ventilat* or NIPPV or ((positiv* or negativ* or inspirator*) and pressur*)</P>
<P>#11 #8 or #9 or #10</P>
<P>#12 #4 and #7 and #11</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="3">
<TITLE MODIFIED="2013-06-11 14:27:32 +0100" MODIFIED_BY="[Empty name]">MEDLINE (OvidSP) Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 10:23:56 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Database: Ovid MEDLINE(R) &lt;1946 to May Week 4 2014&gt;</P>
<P>Search strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<P>1 randomized controlled trial.pt. (374960)</P>
<P>2 controlled clinical trial.pt. (88427)</P>
<P>3 randomized.ab. (273382)</P>
<P>4 placebo.ab. (146420)</P>
<P>5 drug therapy.fs. (1704068)</P>
<P>6 randomly.ab. (193925)</P>
<P>7 trial.ab. (283482)</P>
<P>8 groups.ab. (1246094)</P>
<P>9 or/1-8 (3198880)</P>
<P>10 exp animals/ not humans.sh. (3947165)</P>
<P>11 9 not 10 (2722297)</P>
<P>12 exp musculoskeletal diseases/ or exp nervous system diseases/ (2679148)</P>
<P>13 (central nervous$ or neuromuscular$ or muscul$ or motor or skelet$ or musculoskeletal$ or bone$ or chest wall$).mp. (1487938)</P>
<P>14 12 or 13 (3617875)</P>
<P>15 (Hypoventilat$ or ((gas$2 or oxygen$ or carbon dioxid$) adj10 tension$)).mp. (19652)</P>
<P>16 ((respirat$ or breath$ or ventilat$) adj10 (insufficienc$ or failur$ or deficienc$ or disorder$ or difficult$ or depress$)).mp. (79973)</P>
<P>17 15 or 16 (97242)</P>
<P>18 exp Ventilators, Mechanical/ or Respiration, Artificial/ (44530)</P>
<P>19 (ventilat$ or ((positiv$ or negativ$ or inspirator$) and pressur$) or NIPPV).mp. (213803)</P>
<P>20 18 or 19 (225419)</P>
<P>21 11 and 14 and 17 and 20 (1592)</P>
<P>22 remove duplicates from 21 (1568)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-07-17 12:52:31 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-07-17 12:52:15 +0100" MODIFIED_BY="[Empty name]">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-17 12:52:31 +0100" MODIFIED_BY="[Empty name]">
<P>Database: EMBASE &lt;1980 to 2014 Week 23&gt;</P>
<P>Search strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<P>1 crossover-procedure.sh. (39104)</P>
<P>2 double-blind procedure.sh. (113517)</P>
<P>3 single-blind procedure.sh. (18341)</P>
<P>4 randomized controlled trial.sh. (343012)</P>
<P>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1030618)</P>
<P>6 trial.ti. (157233)</P>
<P>7 or/1-6 (1161845)</P>
<P>8 (animal/ or nonhuman/ or animal experiment/) and human/ (1263730)</P>
<P>9 animal/ or nonanimal/ or animal experiment/ (3217383)</P>
<P>10 9 not 8 (2697085)</P>
<P>11 7 not 10 (1066806)</P>
<P>12 limit 11 to embase (882304)</P>
<P>13 exp Motor Dysfunction/ (495826)</P>
<P>14 exp musculoskeletal disease/ or exp central nervous system disease/ or exp neuromuscular disease/ or exp neuropathy/ or exp radiculopathy/ (3197454)</P>
<P>15 (central nervous$ or neuromuscular$ or motor or muscular or muscul$ skelet$ or musculoskeletal$ or bone$ or chest wall$ or nocturnal hypoventilation).mp. (1921421)</P>
<P>16 or/13-15 (4373364)</P>
<P>17 exp Hypoventilation/ (5545)</P>
<P>18 ((gas$2 or oxygen$ or carbon dioxid$) adj10 tension$).mp. (49894)</P>
<P>19 ((respirat$ or breath$) adj10 (insufficienc$ or failur$ or deficienc$ or disorder$ or difficult$)).mp. (106507)</P>
<P>20 sleep apnoea.mp. (6018)</P>
<P>21 or/17-20 (159898)</P>
<P>22 exp artificial ventilation/ (118120)</P>
<P>23 (ventilat$ or NIPPV or ((positiv$ or negativ$ or inspirator$) adj10 pressur$)).mp. (243294)</P>
<P>24 22 or 23 (248409)</P>
<P>25 16 and 21 and 24 (12441)</P>
<P>26 12 and 25 (700)</P>
<P>27 remove duplicates from 26 (698)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;# studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;26 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;380 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;389 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;769 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;254 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;16 full-text articles excluded:&lt;/p&gt;&lt;p&gt;5 were non-randomised trials&lt;/p&gt;&lt;p&gt;3 included unstable patients (1) or a mixed population (2)&lt;/p&gt;&lt;p&gt;10 interventions out of scope: very short course of daytime NIV (4), night-time NIV (5), comparison of location for NIV initiation home versus hospital (1)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>